Novel fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof

Abstract

The present disclosure relates to fatty acid amide hydrolase (FAAH) modulators, inhibitors, or FAAH modulators and inhibitors and methods and uses thereof. The FAAH modulators, inhibitors, or FAAH modulators and inhibitors may be compounds having Formula I, II, III or IV. Pharmaceutical compositions comprising the FAAH modulators, inhibitors, or FAAH modulators and inhibitors are also provided.

Description

[0001] NOVEL FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF FIELD OF INVENTION The present disclosure relates to novel compounds that are fatty acid amide hydrolase (FAAH) inhibitors or modulators, compositions comprising the compounds and uses of the compounds and compositions. In particular, the novel compounds are useful for treating diseases, disorders or conditions that benefit from inhibition or modulation of FAAH. The novel compounds include prodrugs, pharmaceutically acceptable salts and pharmacologically active metabolites thereof. BACKGROUND Fatty acid amide hydrolase (FAAH) is a member of the serine hydrolase family of enzymes capable of modulating the endocannabinoid system (eCB). It is an integral membrane protein that is expressed in high levels in several brain regions, especially in the neurons of the hippocampus, cerebellum, neocortex and olfactory bulb. FAAH is primarily responsible for catalyzing the inactivation of endocannabinoid anandamide (AEA) via hydrolysis to arachidonic acid and ethanolamine. It is also able to hydrolyze a variety of other important bioactive fatty acid amides, including 2-arachidonoylglycerol, N-palmitoylethanolamide, N- oleoylethanolamide and oleamide (Fowler et al., 2001 [1]; Labar & Michaux, 2007 [2]; and Bisogno et al., 2002 [3]). The cannabinoid system and its functions can be modulated by cannabinoid receptor antagonists / agonists and by inhibition of the endocannabinoid synthesizing / degrading enzymes, including FAAH. Genetic or pharmacological inhibition of FAAH leads to elevated levels of AEA providing increased stimulation of the cannabinoid CB1 and CB2 receptors and producing beneficial physiological effects related to the activation of the cannabinoid receptors (Ahn et al., 2009 [4]). In addition, increasing the concentration of endocannabinoids, rather than administering exogenous agonistic agents of the receptors, may reduce psychotropic cannabinoid-like adverse effects. Therefore, modulators of the FAAH enzyme constitute a therapeutic strategy for the treatment of pain, anxiety, post-traumatic stress disorder, inflammation, and other disorders involving the endocannabinoid system (Fernández-Ruiz et al., 2015 [5]; Schmidt. et al., 2012 [6]; and Fazio et al., 2021 [7]). 63336124\1 Inhibition of FAAH by small-molecule inhibitors has been reported to provide beneficial pharmacological effects in animal models and humans (Jayamanne et al., 2006 [8]; Ahn et al, 2009 [9]; Paulus et al., 2021

[0010] ; and Lodola et al., 2015

[0011] ). In addition to AEA, inhibition of FAAH also affects the endogenous levels of several other bioactive amides, ester lipids and their associated pathways, including, but not limited to, transient receptor potential family of calcium channels, non-cannabinoid receptors (such as GPR118) and nuclear receptors (such as Peroxisome Proliferator-Activated Receptors alpha or gamma), and could lead to beneficial outcomes in pain, inflammation and anxiety disorder (McDougall et al., 2017,

[0012] ; Schmidt et al., 2021

[0013] ; and Saghatelian et al., 2006

[0014] ). Chemical series of heteroaryl-substituted ureas have been reported in various publications as FAAH modulators. Certain piperazinyl and piperidinyl compounds as FAAH modulators are described in Intl. Patent Appl. No. WO 2006 / 074025, Intl. Patent Appl. Ser. No. PCT / US2009 / 065757, Intl. Patent Appl. Ser. No. PCT / US2009 / 065752, U.S. Appl. Publ. No. US 2009 / 0062294, and U.S. provisional Appl. Ser. No.61 / 263,477. Various ureas are reported as small-molecule FAAH modulators in US Patent Publication Nos. US 2006 / 173184 and US 2007 / 0004741, in Intl. Patent Appl. Nos. WO 2008 / 023720, WO 2008 / 047229, and WO 2008 / 024139. Certain aryl-substituted heterocyclic urea derivatives are described in U.S. provisional Appl. No. 61 / 184,606. Certain piperazine-1-carboxamide and piperidine-1- carboxamide derivatives are described in Intl. Patent Appl. No. WO 2008 / 023720. Certain piperazine derivatives are described in Intl. Patent Appl. No. WO 99 / 42107. Certain N- aralkylpiperazines are described in Intl. Patent Appl. No. WO 98 / 37077. However, there remains a need for potent FAAH inhibitor or modulators with improved properties. SUMMARY OF THE INVENTION This disclosure relates to novel molecules of formula (I-IV), their prodrug forms, pharmaceutically acceptable salts thereof, or combination thereof, process for their preparation, methods, composition and formulation in a delivery system for the prevention and / or treatment of diseases or medical conditions benefited by the inhibition of FAAH enzyme. The composition and / or formulation include disclosed compounds as at least one active ingredient. Furthermore, molecules, pharmaceutical composition and formulation may be combined with one or more therapeutic agents or compounds to prevent and / or treat diseases or medical conditions. 63336124\1

[0002] This disclosure is also directed to a method of testing the inhibition of FAAH and MAGL enzymes in both in vitro and in vivo systems. Compounds of Formula (I-IV) may act as FAAH modulators, inhibitors, or as modulators and inhibitors. Inhibition of FAAH will slow the normal degradation of endogenous endocannabinoid ligand anandamide (AEA) and thereby allow the accumulation of AEA. The higher level of AEA induces increased stimulation of cannabinoid receptors CB1 and CB2 and produce diverse physiological effects related to the activation the cannabinoid receptors. The compounds of Formula (I-IV), compositions and formulations may be used in methods for the treatment or prevention of disease states, disorders, and conditions mediated by FAAH activity, such as, but not limited to pain, inflammatory disorder, anxiety and mood disorder, cardiovascular diseases, metabolic disorder, neurodegenerative disorders, cancer, or epilepsy. In one aspect the disclosure, provides a compound of Formula I: 63336124\1 a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically active metabolite thereof; wherein W may be NH, N(CH3), or none, wherein when W may be none R3may be directly attached to C(O) by a single bond; X may be CH or N; Y may be CH or N; Z may be CH or N; wherein X, Y and Z cannot all be CH or N; R1 may be independently -C(O)OR4, -C(O)NHOH, -C(O)NHNH2, CF3, CHO, CN or heteroaryl; wherein R4may be independently C1-C5alkyl; R2 may be independently hydrogen, halogen, alkyl, alkoxy, thioalkyl, haloalkoxy, wherein R2 may be linked via any position on the phenyl ring; R3may be independently C5-C20alkyl, C3-C8cycloalkyl, C4-C8heterocycloalkyl, C6-12fused heterocycloakyl, C6-12 spirocycloalkyl, or aryl, wherein R3 may be unsubstituted or substituted at a carbon ring member with halogen or alkyl group. In one embodiment R1may be monocycles: 2-pyrrolyl, 2-furanyl, 2-thienyl, 2-oxazolyl, 5- isoxazolyl, 2-thiazolyl, 1,3,4-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-thiadiazolyl, 1,2,4-triazolyl, or 1,2,3,4-tetrazolyl. In another embodiment R2 may be H, OH, OCH3, SCH3, F, OCF3, CN, or N(CH3)2. Furthermore, R2may be independently OH, OCH3, SCH3, or N(CH3)2. It is further provided a compound of Formula I: wherein W may be NH; X may be N; Y may be CH; Z may be CH; R1may be oxadiazole, oxazole, thiazole, pyrazole or imidazole; R2may be halogen, hydroxy, C1-C4alkoxy, cyano, or fluoroalkyl; and R3 may be C1-C8 alkyl or C3-C8 cycloalkyl. It is also provided a compound of Formula I: wherein W may be NH; X may be N; Y may be CH; 63336124\1 Z may be CH; R1 may be oxadiazole; R2 may be halogen, hydroxy, C1-C4 alkoxy, cyano, or fluoroalkyl; and R3 may be C1-C8 alkyl or C3-C8 cycloalkyl. In some embodiments, the compound of Formula I may have the formula of any one of the compounds of Example 1- Example 268. In some embodiments, the compound of Formula I may have the formula of any one of the compounds of Examples 4, 9, 10, 24, 47, 51, 64, 72, 73, 87, 105, 109, 115, 128, 129, 130, 131, 132, 134, 137, 156, 157, 160, 165, 167, 174, 194, 195, 207, 213, 219, 226, 256 and 263. In another aspect it is provided a compound having Formula II: a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically active metabolite thereof; wherein R1may be independently -C(O)OR4, -C(O)NHOH, -C(O)NHNH2, CF3, CHO, CN; wherein R4may be independently C1-C5alkyl; R3 may be independently C5-C18 alkyl, C3-C8 cycloalkyl, C6-12 fused heterocycloakyl, or aryl. In some embodiments R1may be oxadiazole, oxazole, thiazole, pyrazole or imidazole; and R3may be C1-C8alkyl or C3-C8cycloalkyl. In another embodiment R1 may be oxadiazole; and R3 may be C1-C8 alkyl or C3-C8 cycloalkyl. In some embodiments, the compound of Formula II may have the formula of any one of the compounds of Examples 1-34. In some embodiments, the compound of Formula II may have the formula of any one of the compounds of Examples 1-5, 8-12, 14-18, 26, 27, 30-32, and 34. In another embodiments, the compound of Formula II may have the formula of any one of the compounds of Examples 4, 9, 10 and 24. In another aspect the disclosure, provides a compound of Formula III: 63336124\1 a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically active metabolite thereof; wherein W may be NH, N(CH3), or none, wherein when W may be none R3may be directly attached to C(O) by a single bond; A may be O, S, or NH; B may be CH or N; C may be CH or N; D may be CH or N; R2 may be independently hydrogen, halogen, alkyl, alkoxy, thioalkyl, or haloalkoxy; wherein R2may be linked via any position on the phenyl ring; R3 may be independently C5-C20 alkyl, C3-C8 cycloalkyl, C4-C8 heterocycloalkyl, C6-12 fused heterocycloakyl, C6-12 spirocycloalkyl, aryl, wherein R3 may be unsubstituted or substituted at a carbon ring member with halogen or alkyl group. In one embodiment, R2may be H, OH, OCH3, SCH3, F, OCF3, CN or N(CH3)2. In another embodiment it is provided a compound of Formula III: wherein A may be O; B may be CH; C may be N; D may be N; R2may be halogen, hydroxy, C1-C4alkoxy, cyano, or fluoroalkyl; and R3 may be C1-C8 alkyl or C3-C8 cycloalkyl. In yet another embodiment it is provided a compound of Formula III, wherein A may be S; B may be CH; C may be N; D may be N; R2may be halogen, hydroxy, C1-C4alkoxy, cyano, or fluoroalkyl; and R3may be C1-C8alkyl or C3-C8cycloalkyl. 63336124\1 In a further embodiment it is provided a compound of Formula III, wherein A may be O; B may be CH; C may be CH; D may be N; R2may be halogen, hydroxy, C1-C4alkoxy, cyano, or fluoroalkyl; and R3may be C1-C8alkyl or C3-C8cycloalkyl. In a further embodiment it is provided a compound of Formula III, wherein A may be O; B may be CH; C may be N; D may be CH; R2may be halogen, hydroxy, C1-C4alkoxy, cyano, or fluoroalkyl; and R3may be C1-C8alkyl or and C3-C8cycloalkyl. In some embodiments, the compound of Formula III may have the formula of any one of the compounds of Examples 35-255. In other embodiments, the compound of Formula III may have the formula of any one of the compounds of Examples 35, 40, 41, 47, 48, 50-53, 59, 60, 62-65, 72-74, 78, 80, 81, 83, 85-88, 105-110, 115-117, 119-121, 127, 128, 130-139, 147, 149, 156, 157, 159-161, 163-167, 169, 174, 179, 180, 186,192-195,204-208, 212-214, 218, 219, 220, 222, 229, 226, 232, and 238. Furthermore, in some embodiments, the compound of Formula III may have the formula of any one of the compounds of Examples 47, 51, 64, 72, 73, 87, 105,109, 115, 128, 129, 130- 134, 137,156, 157, 160, 165, 167, 174, 194, 195, 207, 213, 219, and 226. In another aspect the disclosure, provides a compound of Formula IV: a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically active metabolite thereof; wherein 63336124\1 X may be CH or N; Y may be CH or N; Z may be CH or N; wherein X, Y and Z cannot all be CH or N; R2 may be H, OH, or OCH3; R3may be independently C5-C20alkyl, or C3-C8cycloalkyl; wherein R3may be unsubstituted or substituted at a carbon ring member with halogen or alkyl group. In a further embodiment it is provided a compound of Formula IV, wherein X may be N; Y may be CH; Z may be CH; R2 may be halogen, hydroxy, C1-C4 alkoxy, cyano, or fluoroalkyl; and R3may be C1-C8alkyl or C3-C8cycloalkyl. In another embodiment it is provided a compound of Formula IV, wherein X may be N; Y may be CH; Z may be CH; R2may be hydroxy or C1-C4alkoxy; and R3may be C1-C8alkyl or C3-C8cycloalkyl. In a further embodiment it is provided a compound of Formula IV, wherein X may be N; Y may be CH; Z may be CH; R2 may be C1-C4 alkoxy; and R3 may be C1-C8 alkyl or C3-C8 cycloalkyl. In other embodiments, the compound of Formula IV may have the formula of any one of the compounds of Examples 256-268. In yet other embodiments, the compound of Formula IV may have the formula of any one of the compounds of Examples 256, 257, 262-264, and 266-268. In a further embodiments, the compound of Formula III may have the formula of any one of the compounds of Examples 256 or 263. In the compound of Formula I, II, III or IV, X, Y and Z cannot all be CH or N. For example, X and Y may be N and Z may be CH; X and Y may be CH and Z may be N; X and Z may be 63336124\1 N and Y may be CH; X and Z may be CH and Y may be N; Y and Z may be N and X may be CH; Y and Z may be CH and X may be N. The disclosure further provided pharmaceutical composition comprising at least one compound as described herewith. Accordingly, the pharmaceutical composition may comprise one or more than one compound of Formula I, II, III, IV, or a combination thereof. a compound. The pharmaceutical composition may further comprise one or more pharmaceutically acceptable excipients or adjuvants. The pharmaceutical composition may comprise an effective amount of at least one compound as described herewith, wherein the effective amount may be between about 0.0001 to about 1,000 mg. The pharmaceutical composition may further comprise one or more additional therapeutic agent. The one or more additional therapeutic agent may be selected from the group consisting of non-steroidal anti-inflammatory drugs (NSAIDs), anti-anxiety agents, antidepressants, antiepileptic drugs, anti-Alzheimer's agents, antipsychotic drugs, antihemorrhagic agents, benzodiazepines, acetylcholinesterase inhibitors, alpha- adrenoreceptor antagonists, alpha-adrenergic receptor agonists, β-blockers, angiotensin- converting enzymes inhibitors (ACEI), serotonin (5-HT) reuptake inhibitors, serotonin and noradrenaline reuptake inhibitors (SNRIs), antirheumatic drug, and anticancer medications. Compounds having formula I, II, III, or IV as described herewith or the pharmaceutical composition comprising a compound having formula I, II, III, or IV as described herewith may be used in inhibiting or modulating the activity of fatty acid amide hydrolase (FAAH). Furtthermore, compounds having formula I, II, III, or IV as described herewith or the pharmaceutical composition comprising a compound having formula I, II, III, or IV as described herewith may be used to in treating a disease, disorder or condition which benefits from the inhibition or modulation of fatty acid amide hydrolase (FAAH) activity. The disease, disorder or condition may be selected from the group consisting of pain, inflammation, anxiety, mood disorders, metabolic diseases, cardiovascular diseases, autoimmune diseases, central nervous system (CNS) diseases, liver diseases, respiratory diseases, and kidney diseases. In a further aspect a method of treating a disease, disorder or condition which benefits from the inhibition or modulation of fatty acid amide hydrolase (FAAH) activity by administering to a subject in need thereof a compounds having formula I, II, III, or IV as described herewith or the pharmaceutical composition comprising a compound having formula I, II, III, or IV as described are provided. 63336124\1 The disease, disorder or condition may be selected from the group consisting of pain (including but not limited to acute pain, chronic pain, nociceptive pain, and non-nociceptive pain), inflammatory diseases (including but not limited to inflammatory bowel disease, neuroinflammation, neuropathy), anxiety and mood disorder, sleep disorder, eating disorders, obesity, cardiovascular diseases (including but not limited to hypertension, coronary heart disease, ischemia, congestive heart failure, atherosclerosis, myocardial infarction, and peripheral vascular disease), dyslipidemia (including but not limited to hyperlipidemia, hypoalphalipoproteinemia, hypertriglyceridemia, hypercholesterolemia, and low high-density lipoprotein (HDL)), diabetes (type 1 and type 2), allergic airway disease (including but not limited to cough, asthma, and chronic obstructive diseases), cerebrovascular disorders (including stroke, cerebral vasospasm, and learning and memory disorders), drug or alcohol withdrawal, addiction, liver diseases (including but not limited to non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and hepatitis), cancer, chemotherapy- induced nausea and vomiting (CINV), neurodegenerative disease (including but not limited to Alzheimer and Parkinson diseases), central nervous system (CNS) disorders (including but not limited to depression, post-traumatic stress disorder, schizophrenia, seizures, and cognitive disorders), autoimmune diseases (including but not limited to psoriasis, rheumatoid arthritis, Crohn's disease, systemic lupus erythematosis, Sjogren's syndrome, Huntington's chorea, and multiple sclerosis), skin disorders (including but not limited to itching, eczema, pruritis, dermatitis, impaired wound healing), gastrointestinal disorders (including but not limited to nausea, gastrointestinal motility disorder, and paralytic ileus), eye diseases (including but not limited to cataract, and glaucoma). This summary of the disclosure does not necessarily describe all features of the invention. DETAILED DESCRIPTION Features of the invention will become more apparent from the following description which includes a description of example embodiments of the invention. The present disclosure provided fatty acid amide hydrolase (FAAH) modulators, inhibitors, or FAAH modulators and inhibitors. The FAAH modulators, inhibitors, or FAAH modulators and inhibitors may contain a basic amine charge center. Without wishing to be bound by theory, it is believed that the basic amine charge center bestows beneficial 63336124\1 pharmacological and chemical properties to the FAAH modulators, inhibitors, or FAAH modulators and inhibitors described herewith. The FAAH modulators, inhibitors, or FAAH modulators and inhibitors disclosed herewith have improved characteristic, such as improved FAAH inhibitor activity, increased solubility, increased plasma stability, increased oral bioavailability or a combination thereof when compared to known reference compounds such as for example URB597 or JNJ-42165279. Furthermore the FAAH modulators, inhibitors, or FAAH modulators and inhibitors disclosed herewith may exhibit less cross reactivity to other enzymes of the endocannabinoid system such for example monoacylglycerol lipase (MAGL). The FAAH modulators, inhibitors, or FAAH modulators and inhibitors may be compounds having Formula I, II, III or IV (also referred to as Formula I-IV). Furthermore, the FAAH modulators, inhibitors, or modulators and inhibitors may also be pharmaceutical derivatives of the compounds of Formula I, II, III or IV. In an embodiment the FAAH modulators, inhibitors, or FAAH modulators and inhibitors may be compounds having Formula (I) with a basic charge site. In another embodiment the FAAH modulators, inhibitors, or FAAH modulators and inhibitors may be compounds having 63336124\1 Formula (II) with a basic nitrogen center comprising for example a pyridine ring. Without wishing to be bound by theory, it was found that the compounds comprising a basic charge site or a basic nitrogen center, as described herewith, have greater solubility compared to compounds that lack a basic nitrogen center or a basic charge site. It was further found that the compounds comprising a basic charge site or a basic nitrogen center, as described herewith may have greater metabolic stability, greater oral bioavailability, or greater metabolic stability and greater oral bioavailability, compared to compounds that lack a basic nitrogen center or a basic charge site. In addition it was found that the compounds exhibit greater ability to penetrate into the central nervous system and / or brain. Accordingly, the current disclosure also provides compounds having Formula (I) with a basic charge site and / or compounds having Formula (II) with a basic nitrogen center, wherein the compounds have greater solubility, greater metabolic stability, greater oral bioavailability, greater penetration into the central nervous system, greater penetration into the brain or a combination thereof compared to compound that lack a basic nitrogen center or a basic charge site. Accordingly, the present disclosure is directed to novel compounds of Formula (I-IV) described herein, pharmaceutical derivatives thereof, or a combination thereof. The compounds of Formula (I-IV) according to the present disclosure have intrinsic FAAH inhibitory properties and improved characteristics as described herewith and are therefore useful in the treatment of diseases or medical conditions which benefit from the inhibition of FAAH activity. The present disclosure relates to compounds of Formula (I) wherein compound has the following formula: a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically active metabolite thereof; wherein W represents NH, N(CH3), or none. When W is none R3 is directly attached to C(O) by a single bond; 63336124\1 X represents CH or N; Y represents CH or N; Z represents CH or N; X, Y and Z cannot all be CH or N; R1 can independently be -C(O)OR4, -C(O)NHOH, -C(O)NHNH2, CF3, CHO, CN or heteroaryl; heteroaryl rings include, but are not limited to the following monocycles: 2-pyrrolyl, 2-furanyl, 2-thienyl, 2-oxazolyl, 5-isoxazolyl, 2-thiazolyl, 1,3,4-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4- thiadiazolyl, 1,2,4-triazolyl, 1,2,3,4-tetrazolyl; R4 can independently be C1-C5 alkyl; R2 can independently be hydrogen, halogen, alkyl, alkoxy, thioalkyl, haloalkoxy. The R2 groups can be linked via any position on the phenyl ring. Examples of R2include H, OH, OCH3, SCH3, F, OCF3, CN, N(CH3)2; R3 can independently be C5-C20 alkyl, C3-C8 cycloalkyl, C4-C8 heterocycloalkyl, C6-12 fused heterocycloakyl, C6-12 spirocycloalkyl, or aryl. R3 may be unsubstituted or substituted at a carbon ring member with halogen or alkyl group. In one embodiment R2 may independently be OH, OCH3, SCH3, or N(CH3)2. In another embodiment the compound may have Formula (I), wherein W represents NH; X represents N; Y represents CH; Z represents CH; R1may be oxadiazole, oxazole, thiazole, pyrazole or imidazole; R2 may be halogen, hydroxy, C1-C4 alkoxy, cyano, or fluoroalkyl; and R3 may be C1-C8 alkyl or C3-C8 cycloalkyl. In another embodiment the compound may have Formula (I), wherein W represents NH; X represents N; Y represents CH; Z represents CH; R1 may be oxadiazole; R2 may be halogen, hydroxy, C1-C4 alkoxy, cyano, or fluoroalkyl; and R3may be C1-C8alkyl or C3-C8cycloalkyl. In one embodiment the compound may have the formula of any one of the compounds of Example 1- Example 268. In an embodiment the FAAH modulators, inhibitors, or FAAH 63336124\1 modulators and inhibitors may comprise any one of the compounds of Example 1- Example 268 or combinations thereof. In a preferred embodiment the compound may have the formula of any one of the compounds of Examples 4, 9, 10, 24, 47, 51, 64, 72, 73, 87, 105, 109, 115, 128, 130, 131, 132, 134, 137, 156, 157, 160, 165, 167, 174, 194, 195, 207, 213, 219, 226, 256 and 263. The FAAH modulators, inhibitors, or FAAH modulators and inhibitors disclosed herewith may exhibit improved stability in human plasma (also refered to as improved plasma stability), improved aqueous solubility, or a combination thereof. For example, the compounds of Examples 83, 146, 158, 172, 194, 191, 225, and 231 showed improved plasma stability, improved aqueous solubility, or improved plasma stability and aqueous solubility compared to reference compound URB597 (see Table 5). Accordingly, it is also provided compounds of Formula (I), (II), (III) or (IV) which exhibit improved plasma stability, improved aqueous solubility, or improved plasma stability and aqueous solubility. For example, in one embodiment the compounds may be compounds of Examples 83, 146, 158, 172, 194, 191, 225, and 231 which exhibit improved plasma stability, improved aqueous solubility, or improved plasma stability and aqueous solubility. The FAAH modulators, inhibitors, or FAAH modulators and inhibitors disclosed herewith may exhibit improved bioavailability. For example compounds of Example 158 and Example 172 exhibit >50% oral bioavailability in rat (see Examples 272 and 273). Accordingly, it is also provided compounds of Formula (I), (II), (III) or (IV) which exhibit improved bioavailability. For example, in one embodiment the compounds may be compounds of Examples 158 or Example 172. The FAAH modulators, inhibitors, or FAAH modulators and inhibitors disclosed herewith may exhibit improved brain penetration compared to the reference compounds. For example the compound of Example 172 exhibits an improved brain penetration (Brain / Plasma ratio >0.15) (see Example 273). Accordingly, it is also provided compounds of Form,ula (I), (II), (III) or (IV) which exhibit improved brain penetration. For example, in one embodiment the compounds may be a compound of Example 172. Another embodiment provides a compound of Formula (II) 63336124\1 a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically active metabolite thereof; wherein R1can independently be -C(O)OR4, -C(O)NHOH, -C(O)NHNH2, CF3, CHO, CN; R4can independently be C1-C5 alkyl; R3 can independently be C5-C18 alkyl, C3-C8 cycloalkyl, C6-12 fused heterocycloakyl, or aryl. In another embodiment the compound may have Formula (II), wherein R1may be oxadiazole, oxazole, thiazole, pyrazole or imidazole; and R3 may be C1-C8 alkyl or C3-C8 cycloalkyl. In another embodiment the compound may have Formula (II), wherein R1may be oxadiazole; and R3 may be C1-C8 alkyl or C3-C8 cycloalkyl. Examples of certain useful compounds of Formula II include: Example 1: ethyl 5-(3-((pentylcarbamoyl)oxy)phenyl)nicotinate Example 2: ethyl 5-(3-((heptylcarbamoyl)oxy)phenyl)nicotinate Example 3: ethyl 5-(3-((octylcarbamoyl)oxy)phenyl)nicotinate Example 4: ethyl 5-(3-((tetradecylcarbamoyl)oxy)phenyl)nicotinate Example 5: ethyl 5-(3-((cyclopentylcarbamoyl)oxy)phenyl)nicotinate Example 6: ethyl 5-(3-((cyclohexylcarbamoyl)oxy)phenyl)nicotinate Example 7: ethyl 5-(3-(((4-fluorophenyl)carbamoyl)oxy)phenyl)nicotinate Example 8: methyl 5-(3-((pentylcarbamoyl)oxy)phenyl)nicotinate Example 9: methyl 5-(3-((heptylcarbamoyl)oxy)phenyl)nicotinate Example 10: methyl 5-(3-((octylcarbamoyl)oxy)phenyl)nicotinate Example 11: methyl 5-(3-((cyclopentylcarbamoyl)oxy)phenyl)nicotinate Example 12: methyl 5-(3-((cyclohexylcarbamoyl)oxy)phenyl)nicotinate Example 13: methyl 5-(3-((((1s,3s)-adamantan-1-yl)carbamoyl)oxy)phenyl)nicotinate Example 14: 3-(5-formylpyridin-3-yl)phenyl pentylcarbamate Example 15: 3-(5-formylpyridin-3-yl)phenyl heptylcarbamate 63336124\1 Example 16: 3-(5-formylpyridin-3-yl)phenyl octylcarbamate Example 17: 3-(5-formylpyridin-3-yl)phenyl (cyclohexylmethyl)carbamate Example 18: 3-(5-formylpyridin-3-yl)phenyl cyclopentylcarbamate Example 19: 3-(5-formylpyridin-3-yl)phenyl cyclohexylcarbamate Example 20: 3-(5-formylpyridin-3-yl)phenyl cyclohepylcarbamate Example 21: 3-(5-formylpyridin-3-yl)phenyl ((1s,3s)-adamantan-1-yl)carbamate Example 22: 3-(5-(hydroxycarbamoyl)pyridin-3-yl)phenyl heptylcarbamate Example 23: 3-(5-(hydroxycarbamoyl)pyridin-3-yl)phenyl octylcarbamate Example 24: 3-(5-(hydroxycarbamoyl)pyridin-3-yl)phenyl tetradecylcarbamate Example 25: 3-(5-(hydrazinecarbonyl)pyridin-3-yl)phenyl octylcarbamate Example 26: 3-(5-cyanopyridin-3-yl)phenyl heptylcarbamate Example 27: 3-(5-cyanopyridin-3-yl)phenyl octylcarbamate Example 28: 3-(5-cyanopyridin-3-yl)phenyl cyclohexylcarbamate Example 29: 3-(5-cyanopyridin-3-yl)phenyl cyclohptylcarbamate Example 30: 3-(5-(trifluoromethyl)pyridin-3-yl)phenyl octylcarbamate Example 31: 3-(5-(trifluoromethyl)pyridin-3-yl)phenyl (cyclohexylmethyl)carbamate Example 32: 3-(5-(trifluoromethyl)pyridin-3-yl)phenyl cyclopentylcarbamate Example 33: 3-(5-(trifluoromethyl)pyridin-3-yl)phenyl cyclohexylcarbamate Example 34: 3-(5-(trifluoromethyl)pyridin-3-yl)phenyl cycloheptylcarbamate Accordingly, in one embodiment the FAAH modulator, inhibitor, or FAAH inhibitor and modulators may be any one of the compounds of Examples 1-34. In a preferred embodiment the FAAH modulator, inhibitor, or FAAH modulator and inhibitor may be any one of the compound of Examples 1, 2, 3, 4, 5, 8-12, 14, 15, 16, 17, 18, 26, 27, 30-32, or 34. In another embodiment, the FAAH modulator, inhibitor, or FAAH modulator and inhibitor may be any one of the compound of Examples 14, or 15. Furthermore, in another embodiment, the FAAH modulator, inhibitor, or FAAH modulator and inhibitor may be any one of the compounds of Examples 4, 9, 10, or 24. 63336124\1 Another embodiment provides a compound of Formula (III) a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically active metabolite thereof; wherein W is NH, N(CH3), or none, wherein when W is none R3 is directly attached to C(O) by a single bond; A represents O, S, or NH; B represents CH or N; C represents CH or N; D represents CH or N; R2 can independently be hydrogen, halogen, alkyl, alkoxy, thioalkyl, or haloalkoxy. The R2 groups can be linked via any position on the phenyl ring. Examples of R2include H, OH, OCH3, SCH3, F, OCF3, CN, N(CH3)2; R3 can independently be C5-C20 alkyl, C3-C8 cycloalkyl, C4-C8 heterocycloalkyl, C6-12 fused heterocycloakyl, C6-12 spirocycloalkyl, aryl. R3 may be unsubstituted or substituted at a carbon ring member with halogen or alkyl group. In another embodiment the compound may have Formula (III), wherein A may be O; B may be CH; C may be N; D may be N; R2may be halogen, hydroxy, C1-C4alkoxy, cyano, or fluoroalkyl; and R3may be C1-C8alkyl or C3-C8cycloalkyl. In another embodiment the compound may have Formula (III), wherein A may be S; B may be CH; C may be N; D may be N; R2may be halogen, hydroxy, C1-C4alkoxy, cyano, or fluoroalkyl; and 63336124\1 R3 may be C1-C8 alkyl or C3-C8 cycloalkyl. In another embodiment the compound may have Formula (III), wherein A may be O; B may be CH; C may be CH; D may be N; R2may be halogen, hydroxy, C1-C4alkoxy, cyano, or fluoroalkyl; and R3 may be C1-C8 alkyl or C3-C8 cycloalkyl. In another embodiment the compound may have Formula (III), wherein A may be O; B may be CH; C may be N; D may be CH; R2 may be halogen, hydroxy, C1-C4 alkoxy, cyano, or fluoroalkyl; and R3 may be C1-C8 alkyl or and C3-C8 cycloalkyl. Examples of certain useful compounds of Formula III include: Example 35: 3-(5-(1H-pyrrol-2-yl)pyridin-3-yl)phenyl octylcarbamate Example 36: 3-(5-(1H-pyrrol-2-yl)pyridin-3-yl)phenyl (cyclohexylmethyl)carbamate Example 37: 3-(5-(1H-pyrrol-2-yl)pyridin-3-yl)phenyl benzylcarbamate Example 38: 3-(5-(1H-pyrrol-2-yl)pyridin-3-yl)phenyl cyclopentylcarbamate Example 39: 3-(5-(1H-pyrrol-2-yl)pyridin-3-yl)phenyl cyclohexylcarbamate Example 40: 3-(5-(1H-pyrrol-2-yl)pyridin-3-yl)phenyl cycloheptylcarbamate Example 41: 3-(5-(1H-pyrrol-2-yl)pyridin-3-yl)-4-methoxyphenyl octylcarbamate Example 42: 3-(5-(1H-pyrrol-2-yl)pyridin-3-yl)-4-methoxyphenyl (cyclohexylmethyl)carbamate Example 43: 3-(5-(1H-pyrrol-2-yl)pyridin-3-yl)-4-methoxyphenyl benzylcarbamate Example 44: 3-(5-(1H-pyrrol-2-yl)pyridin-3-yl)-4-methoxyphenyl cyclopentylcarbamate Example 45: 3-(5-(1H-pyrrol-2-yl)pyridin-3-yl)-4-methoxyphenyl cyclohexylcarbamate Example 46: 3-(5-(1H-pyrrol-2-yl)pyridin-3-yl)-4-methoxyphenyl cycloheptylcarbamate Example 47: 3-(5-(furan-2-yl)pyridin-3-yl)phenyl octylcarbamate 63336124\1 Example 48: 3-(5-(furan-2-yl)pyridin-3-yl)phenyl (cyclohexylmethyl)carbamate Example 49: 3-(5-(furan-2-yl)pyridin-3-yl)phenyl benzylcarbamate Example 50: 3-(5-(furan-2-yl)pyridin-3-yl)phenyl cyclopentylcarbamate Example 51: 3-(5-(furan-2-yl)pyridin-3-yl)phenyl cyclohexylcarbamate Example 52: 3-(5-(furan-2-yl)pyridin-3-yl)phenyl cycloheptylcarbamate Example 53: 3-(5-(furan-2-yl)pyridin-3-yl)-4-methoxyphenyl octylcarbamatess Example 54: 3-(5-(furan-2-yl)pyridin-3-yl)-4-methoxyphenyl (cyclohexylmethyl)carbamate Example 55: 3-(5-(furan-2-yl)pyridin-3-yl)-4-methoxyphenyl benzylcarbamate Example 56: 3-(5-(furan-2-yl)pyridin-3-yl)-4-methoxyphenyl cyclopentylcarbamate Example 57: 3-(5-(furan-2-yl)pyridin-3-yl)-4-methoxyphenyl cyclohexylcarbamate Example 58: 3-(5-(furan-2-yl)pyridin-3-yl)-4-methoxyphenyl cycloheptylcarbamate Example 59: 3-(5-(thiophen-2-yl)pyridin-3-yl)phenyl octylcarbamate Example 60: 3-(5-(thiophen-2-yl)pyridin-3-yl)phenyl (cyclohexylmethyl)carbamate Example 61: 3-(5-(thiophen-2-yl)pyridin-3-yl)phenyl benzylcarbamate Example 62: 3-(5-(thiophen-2-yl)pyridin-3-yl)phenyl cyclopentylcarbamate Example 63: 3-(5-(thiophen-2-yl)pyridin-3-yl)phenyl cyclohexylcarbamate Example 64: 3-(5-(thiophen-2-yl)pyridin-3-yl)phenyl cycloheptylcarbamate Example 65: 4-methoxy-3-(5-(thiophen-2-yl)pyridin-3-yl)phenyl octylcarbamate Example 66: 4-methoxy-3-(5-(thiophen-2-yl)pyridin-3-yl)phenyl (cyclohexylmethyl)carbamate Example 67: 4-methoxy-3-(5-(thiophen-2-yl)pyridin-3-yl)phenyl benzylcarbamate Example 68: 4-methoxy-3-(5-(thiophen-2-yl)pyridin-3-yl)phenyl cyclopentylcarbamate Example 69: 4-methoxy-3-(5-(thiophen-2-yl)pyridin-3-yl)phenyl cyclohexylcarbamate Example 70: 4-methoxy-3-(5-(thiophen-2-yl)pyridin-3-yl)phenyl cycloheptylcarbamate Example 71: 3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl pentylcarbamate Example 72: 3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl heptylcarbamate Example 73: 3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl octylcarbamate 63336124\1 Example 74: 3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl (cyclohexylmethyl)carbamate Example 75: 3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl cyclopentylcarbamate Example 76: 3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl cyclohexylcarbamate Example 77: 3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl ((1s,3s)-adamantan-1-yl)carbamate Example 78: 4-methoxy-3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl octylcarbamate Example 79: 4-methoxy-3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl (cyclohexylmethyl)carbamate Example 80: 4-methoxy-3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl cyclopentylcarbamate Example 81: 4-methoxy-3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl cyclohexylcarbamate Example 82: 4-methoxy-3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl (4-methylcyclohexyl)carbamate Example 83: 4-methoxy-3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl cycloheptylcarbamate Example 84: 2-methoxy-5-(5-(oxazol-2-yl)pyridin-3-yl)phenyl octylcarbamate Example 85: 4-fluoro-3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl cyclopentylcarbamate Example 86: 4-fluoro-3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl (4-methylcyclohexyl)carbamate Example 87: 4-fluoro-3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl cycloheptylcarbamate Example 88: 3-(5-(oxazol-2-yl)pyridin-3-yl)-4-(trifluoromethoxy)phenyl octylcarbamate Example 89: 3-(5-(oxazol-2-yl)pyridin-3-yl)-4-(trifluoromethoxy)phenyl cyclohexylcarbamate Example 90: 3-(5-(oxazol-2-yl)pyridin-3-yl)-4-(trifluoromethoxy)phenyl(4- methylcyclohexyl)carbamate Example 91: 3-(5-(oxazol-2-yl)pyridin-3-yl)-4-(trifluoromethoxy)phenyl cycloheptylcarbamate Example 92: 2-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenyl octylcarbamate Example 93: 2-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenyl (cyclohexylmethyl)carbamate Example 94: 2-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenyl benzylcarbamate Example 95: 2-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenyl cyclohexylcarbamate Example 96: 3-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenyl (4- methylcyclohexyl)carbamate 63336124\1 Example 97: 2-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenyl cycloheptylcarbamate Example 98: 2-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenyl cyclooctylcarbamate Example 99: 3-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenyl (cyclohexylmethyl)carbamate Example 100 3-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenyl benzylcarbamate Example 101: 3-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenyl cyclohexylcarbamate Example 102: 3-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenyl (4- methylcyclohexyl)carbamate Example 103: 3-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenyl cycloheptylcarbamate Example 104: 3-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenyl cyclooctylcarbamate Example 105: 3-(5-(isoxazol-5-yl)pyridin-3-yl)phenyl octylcarbamate Example 106: 3-(5-(isoxazol-5-yl)pyridin-3-yl)phenyl cyclopentylcarbamate Example 107: 3-(5-(isoxazol-5-yl)pyridin-3-yl)phenyl cyclohexylcarbamate Example 108: 3-(5-(isoxazol-5-yl)pyridin-3-yl)phenyl cycloheptylcarbamate Example 109: 3-(5-(isoxazol-5-yl)pyridin-3-yl)-4-methoxyphenyl octylcarbamate Example 110: 3-(5-(isoxazol-5-yl)pyridin-3-yl)-4-methoxyphenyl (cyclohexylmethyl)carbamate Example 111: 3-(5-(isoxazol-5-yl)pyridin-3-yl)-4-methoxyphenyl benzylcarbamate Example 112: 3-(5-(isoxazol-5-yl)pyridin-3-yl)-4-methoxyphenyl cyclopentylcarbamate Example 113: 3-(5-(isoxazol-5-yl)pyridin-3-yl)-4-methoxyphenyl cyclohexylcarbamate Example 114: 3-(5-(isoxazol-5-yl)pyridin-3-yl)-4-methoxyphenyl cycloheptylcarbamate Example 115: 3-(5-(thiazol-2-yl)pyridin-3-yl)phenyl octylcarbamate Example 116: 3-(5-(thiazol-2-yl)pyridin-3-yl)phenyl (cyclohexylmethyl)carbamate Example 117: 3-(5-(thiazol-2-yl)pyridin-3-yl)phenyl benzylcarbamate Example 118: 3-(5-(thiazol-2-yl)pyridin-3-yl)phenyl cyclopentylcarbamate Example 119: 3-(5-(thiazol-2-yl)pyridin-3-yl)phenyl cyclohexylcarbamate Example 120: 3-(5-(thiazol-2-yl)pyridin-3-yl)phenyl cycloheptylcarbamate Example 121: 4-methoxy-3-(5-(thiazol-2-yl)pyridin-3-yl)phenyl octylcarbamate 63336124\1 Example 122: 4-methoxy-3-(5-(thiazol-2-yl)pyridin-3-yl)phenyl (cyclohexylmethyl)carbamate Example 123: 4-methoxy-3-(5-(thiazol-2-yl)pyridin-3-yl)phenyl benzylcarbamate Example 124: 4-methoxy-3-(5-(thiazol-2-yl)pyridin-3-yl)phenyl cyclopentylcarbamate Example 125: 4-methoxy-3-(5-(thiazol-2-yl)pyridin-3-yl)phenyl cyclohexylcarbamate Example 126: 4-methoxy-3-(5-(thiazol-2-yl)pyridin-3-yl)phenyl cycloheptylcarbamate Example 127: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl pentylcarbamate Example 128: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl hexylcarbamate Example 129: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl heptylcarbamate Example 130: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl octylcarbamate Example 131: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl dodecylcarbamate Example 132: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl tetradecylcarbamate Example 133: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl octadecylcarbamate Example 134: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl (cyclohexylmethyl)carbamate Example 135: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl benzylcarbamate Example 136: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl (3-phenylpropyl)carbamate Example 137: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl (cyclohexylmethyl)carbamate Example 138: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl cyclopentylcarbamate Example 139: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl cyclohexylcarbamate Example 140: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl naphthalen-1-ylcarbamate Example 141: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl piperidine-1-carboxylate Example 142: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl cyclohexyl(methyl)carbamate Example 143: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl 2-methylpiperidine-1- carboxylate Example 144: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl cycloheptyl(methyl)carbamate Example 145: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl azocane-1-carboxylate 63336124\1 Example146: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl 2-azaspiro[3.3]heptane-2- carboxylate Example 147: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl spiro[3.3]heptan-2-ylcarbamate Example 148: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl 3-azabicyclo[3.1.0]hexane-3- carboxylate Example 149: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl hexahydrocyclopenta[c]pyrrole- 2(1H)-carboxylate Example 150: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl 8-azabicyclo[3.2.1]octane-8- carboxylate Example 151: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl morpholine-4-carboxylate Example 152: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl 2-oxa-6-azaspiro[3.3]heptane-6- carboxylate Example 153: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl 2-oxa-7-azaspiro[3.5]nonane-7- carboxylate Example 154: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl heptyl(methyl)carbamate Example 155: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl dibutylcarbamate Example 156: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-hydroxyphenyl heptylcarbamate Example 157: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-hydroxyphenyl octylcarbamate Example 158: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-hydroxyphenyl cyclohexylcarbamate Example 159 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-hydroxyphenyl (4- methylcyclohexyl)carbamate Example 160: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-5-hydroxyphenyl heptylcarbamate Example 161: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-5-hydroxyphenyl (cyclohexylmethyl)carbamate Example 162: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-5-hydroxyphenyl benzylcarbamate Example 163: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-5-hydroxyphenyl cyclopentylcarbamate Example 164: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-5-hydroxyphenyl cyclohexylcarbamate 63336124\1 Example 165: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-5-hydroxyphenyl cycloheptylcarbamate Example 166: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-methoxyphenyl heptylcarbamate Example 167: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-methoxyphenyl octylcarbamate Example 168: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-methoxyphenyl (cyclohexylmethyl)carbamate Example 169: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-methoxyphenyl cyclopentylcarbamate Example 170: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-methoxyphenyl cyclohexylcarbamate Example 171: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-methoxyphenyl (4- methylcyclohexyl)carbamate Example 172: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-methoxyphenyl cycloheptylcarbamate Example 173: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-methoxyphenyl cyclooctylcarbamate Example 174: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-5-methoxyphenyl octylcarbamate Example 175: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-5-methoxyphenyl (cyclohexylmethyl)carbamate Example 176: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-5-methoxyphenyl benzylcarbamate Example 177: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-5-methoxyphenyl cyclopentylcarbamate Example 178: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-5-methoxyphenyl cyclohexylcarbamate Example 179: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-5-methoxyphenyl cycloheptylcarbamate Example 180: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-(dimethylamino)phenyl octylcarbamate Example 181: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-(dimethylamino)phenyl (cyclohexylmethyl)carbamate Example 182: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-(dimethylamino)phenyl benzylcarbamate 63336124\1 Example 183: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-(dimethylamino)phenyl cyclopentylcarbamate Example 184: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-(dimethylamino)phenyl cyclohexylcarbamate Example 185: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-(dimethylamino)phenyl cycloheptylcarbamate Example 186: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-(methylthio)phenyl octylcarbamate Example 187: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-(methylthio)phenyl (cyclohexylmethyl)carbamate Example 188: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-(methylthio)phenyl benzylcarbamate Example 189: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-(methylthio)phenyl cyclopentylcarbamate Example 190: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-(methylthio)phenyl cyclohexylcarbamate Example 191: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-(methylthio)phenyl cycloheptylcarbamate Example 192: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-fluorophenyl cyclohexylcarbamate Example 193: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-fluorophenyl (4- methylcyclohexyl)carbamate Example 194: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-fluorophenyl cycloheptylcarbamate Example 195: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-5-fluorophenyl heptyl carbamate Example 196: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-5-fluorophenyl benzylcarbamate Example 197: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-5-fluorophenyl cyclohexylcarbamate Example 198: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-5-fluorophenyl cycloheptylcarbamate Example 199: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-(trifluoromethoxy)phenyl octylcarbamate Example 200: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-(trifluoromethoxy)phenyl cyclohexylcarbamate 63336124\1 Example 201: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-(trifluoromethoxy)phenyl (4- methylcyclohexyl)carbamate Example 202: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-(trifluoromethoxy)phenyl cycloheptylcarbamate Example 203: 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)-4-(trifluoromethoxy)phenyl phenylcarbamate Example 204: 3-(5-(1,2,4-oxadiazol-5-yl)pyridin-3-yl)phenyl (cyclohexylmethyl)carbamate Example 205: 3-(5-(1,2,4-oxadiazol-5-yl)pyridin-3-yl)phenyl cyclohexylcarbamate Example 206: 3-(5-(1,2,4-oxadiazol-5-yl)pyridin-3-yl)phenyl cycloheptylcarbamate Example 207: 3-(5-(1,3,4-thiadiazol-2-yl)pyridin-3-yl)phenyl octylcarbamate Example 208: 3-(5-(1,3,4-thiadiazol-2-yl)pyridin-3-yl)phenyl (cyclohexylmethyl)carbamate Example 209: 3-(5-(1,3,4-thiadiazol-2-yl)pyridin-3-yl)phenyl benzylcarbamate Example 210: 3-(5-(1,3,4-thiadiazol-2-yl)pyridin-3-yl)phenyl cyclopentylcarbamate Example 211: 3-(5-(1,3,4-thiadiazol-2-yl)pyridin-3-yl)phenyl cyclohexylcarbamate Example 212: 3-(5-(1,3,4-thiadiazol-2-yl)pyridin-3-yl)phenyl cycloheptylcarbamate Example 213: 3-(5-(1,3,4-thiadiazol-2-yl)pyridin-3-yl)-4-methoxyphenyl octylcarbamate Example 214: 3-(5-(1,3,4-thiadiazol-2-yl)pyridin-3-yl)-4-methoxyphenyl (cyclohexylmethyl)carbamate Example 215: 3-(5-(1,3,4-thiadiazol-2-yl)pyridin-3-yl)-4-methoxyphenyl benzylcarbamate Example 216: 3-(5-(1,3,4-thiadiazol-2-yl)pyridin-3-yl)-4-methoxyphenyl cyclopentylcarbamate Example 217: 3-(5-(1,3,4-thiadiazol-2-yl)pyridin-3-yl)-4-methoxyphenyl cyclohexylcarbamate Example 218: 3-(5-(1,3,4-thiadiazol-2-yl)pyridin-3-yl)-4-methoxyphenyl cycloheptylcarbamate Example 219: 3-(5-(1H-1,2,4-triazol-5-yl)pyridin-3-yl)phenyl octyl carbamate Example 220: -(5-(1H-1,2,4-triazol-5-yl)pyridin-3-yl)phenyl (cyclohexylmethyl)carbamate Example 221: 3-(5-(1H-1,2,4-triazol-5-yl)pyridin-3-yl)phenyl benzylcarbamate 63336124\1 Example 222: 3-(5-(1H-1,2,4-triazol-5-yl)pyridin-3-yl)phenyl (naphthalen-2- ylmethyl)carbamate Example 223: 3-(5-(1H-1,2,4-triazol-5-yl)pyridin-3-yl)phenyl cyclopentylcarbamate Example 224:3-(5-(1H-1,2,4-triazol-5-yl)pyridin-3-yl)phenyl cyclohexylcarbamate Example 225: 3-(5-(1H-1,2,4-triazol-5-yl)pyridin-3-yl)phenyl cycloheptyl carbamate Example 226: 3-(5-(1H-1,2,4-triazol-5-yl)pyridin-3-yl)-4-hydroxyphenyl octylcarbamate Example 227: 3-(5-(1H-1,2,4-triazol-5-yl)pyridin-3-yl)-4-hydroxyphenyl (cyclohexylmethyl)carbamate Example 228: 3-(5-(1H-1,2,4-triazol-5-yl)pyridin-3-yl)-4-hydroxyphenyl benzylcarbamate Example 229: 3-(5-(1H-1,2,4-triazol-5-yl)pyridin-3-yl)-4-hydroxyphenyl cyclopentylcarbamate Example 230: 3-(5-(1H-1,2,4-triazol-5-yl)pyridin-3-yl)-4-hydroxyphenyl cyclohexylcarbamate Example 231: 3-(5-(1H-1,2,4-triazol-5-yl)pyridin-3-yl)-4-hydroxyphenyl cycloheptylcarbamate Example 232: 3-(5-(1H-1,2,4-triazol-5-yl)pyridin-3-yl)-4-methoxyphenyl octylcarbamate Example 233: 3-(5-(1H-1,2,4-triazol-5-yl)pyridin-3-yl)-4-methoxyphenyl (cyclohexylmethyl)carbamate Example 234: 3-(5-(1H-1,2,4-triazol-5-yl)pyridin-3-yl)-4-methoxyphenyl benzylcarbamate Example 235: 3-(5-(1H-1,2,4-triazol-5-yl)pyridin-3-yl)-4-methoxyphenyl cyclopentylcarbamate Example 236: 3-(5-(1H-1,2,4-triazol-5-yl)pyridin-3-yl)-4-methoxyphenyl cyclohexylcarbamate Example 237: 3-(5-(1H-1,2,4-triazol-5-yl)pyridin-3-yl)-4-methoxyphenyl cycloheptylcarbamate Example 238: 3-(5-(1H-tetrazol-5-yl)pyridin-3-yl)phenyl octylcarbamate Example 239: 3-(5-(1H-tetrazol-5-yl)pyridin-3-yl)phenyl (cyclohexylmethyl)carbamate Example 240: 3-(5-(1H-tetrazol-5-yl)pyridin-3-yl)phenyl benzylcarbamate 63336124\1 Example 241: 3-(5-(1H-tetrazol-5-yl)pyridin-3-yl)phenyl cyclopentylcarbamate Example 242: 3-(5-(1H-tetrazol-5-yl)pyridin-3-yl)phenyl cyclohexylcarbamate Example 243: 3-(5-(1H-tetrazol-5-yl)pyridin-3-yl)phenyl cycloheptylcarbamate Example 244: 3-(5-(1H-tetrazol-5-yl)pyridin-3-yl)-4-hydroxyphenyl octylcarbamate Example 245: 3-(5-(1H-tetrazol-5-yl)pyridin-3-yl)-4-hydroxyphenyl (cyclohexylmethyl)carbamate Example 246: 3-(5-(1H-tetrazol-5-yl)pyridin-3-yl)-4-hydroxyphenyl benzylcarbamate Example 247: 3-(5-(1H-tetrazol-5-yl)pyridin-3-yl)-4-hydroxyphenyl cyclopentylcarbamate Example 248: 3-(5-(1H-tetrazol-5-yl)pyridin-3-yl)-4-hydroxyphenyl cyclohexylcarbamate Example 249: 3-(5-(1H-tetrazol-5-yl)pyridin-3-yl)-4-hydroxyphenyl cycloheptylcarbamate Example 250: 3-(5-(1H-tetrazol-5-yl)pyridin-3-yl)-4-methoxyphenyl octylcarbamate Example 251: 3-(5-(1H-tetrazol-5-yl)pyridin-3-yl)-4-methoxyphenyl (cyclohexylmethyl)carbamate Example 252: 3-(5-(1H-tetrazol-5-yl)pyridin-3-yl)-4-methoxyphenyl benzylcarbamate Example 253: 3-(5-(1H-tetrazol-5-yl)pyridin-3-yl)-4-methoxyphenyl cyclopentylcarbamate Example 254: 3-(5-(1H-tetrazol-5-yl)pyridin-3-yl)-4-methoxyphenyl cyclohexylcarbamate Example 255: 3-(5-(1H-tetrazol-5-yl)pyridin-3-yl)-4-methoxyphenyl cycloheptylcarbamate Accordingly, in one embodiment the FAAH modulator, inhibitor, or FAAH inhibitor and modulators may be any one of the compounds of Examples 35-255. In a preferred embodiment the FAAH modulator, inhibitor, or FAAH modulator and inhibitor may be any one the compound of Examples 35, 40, 41, 47, 48, 50-53, 59, 60, 62-65, 72-74, 78, 80, 81, 83, 85-88, 105-110, 115-117, 119-121, 127, 128, 129, 130-139, 147, 149, 156, 157, 159-161, 163-167, 169, 174, 179, 180, 186, 192-195, 204-208, 212-214, 219, 220, 222, 226, 232, or 238. In another preferred embodiment, the FAAH modulator, inhibitor, or FAAH modulator and inhibitor may be any one of the compound of Examples 127, 128, 129, 136, 138, 139, 163, 164, or 179. Furthermore, in another preferred embodiment, the FAAH modulator, inhibitor, or FAAH modulator and inhibitor may be any one of the compounds of Examples 47, 51, 64, 72, 73, 87, 105, 109, 115, 128, 129, 130-134, 137,156, 157, 160, 165, 167, 174, 194, 195, 207, 213, 219, or 226. In another preferred embodiment, the FAAH modulator, inhibitor, or FAAH modulator 63336124\1 and inhibitor may be any one of the compounds of Examples 83, 146, 158, 172, 194, 191, 225, and 231. In a further another preferred embodiment, the FAAH modulator, inhibitor, or FAAH modulator and inhibitor the compound of Example 158 or 172. In another preferred embodiment the compound may have the formula of Example 172. Another embodiment provides a compound of Formula (IV) a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically active metabolite thereof; wherein X represents CH or N; Y represents CH or N; Z represents CH or N; X, Y and Z cannot all be CH or N; R2represents H, OH, or OCH3; R3 can independently be C5-C20 alkyl, C3-C8 cycloalkyl. R3 may be unsubstituted or substituted at a carbon ring member with halogen or alkyl group. In another embodiment the compound may have Formula (IV), wherein X may be N; Y may be CH; Z may be CH; R2may be halogen, hydroxy, C1-C4alkoxy, cyano, or fluoroalkyl; and R3 may be C1-C8 alkyl or C3-C8 cycloalkyl. In another embodiment the compound may have Formula (IV), wherein X may be N; Y may be CH; Z may be CH; R2may be hydroxy or C1-C4alkoxy; and R3 may be C1-C8 alkyl or C3-C8 cycloalkyl. In another embodiment the compound may have Formula (IV), wherein 63336124\1 X may be N; Y may be CH; Z may be CH; R2 may be C1-C4 alkoxy; and R3 may be C1-C8 alkyl or C3-C8 cycloalkyl. Examples of certain useful compounds of Formula IV include: Example 256: 3-(4-(1,3,4-oxadiazol-2-yl)pyridin-2-yl)phenyl (2-methylhexyl)carbamate Example 257: 3-(4-(1,3,4-oxadiazol-2-yl)pyridin-2-yl)phenyl (cyclohexylmethyl)carbamate Example 258: 3-(4-(1,3,4-oxadiazol-2-yl)pyridin-2-yl)phenyl benzylcarbamate Example 259: 3-(4-(1,3,4-oxadiazol-2-yl)pyridin-2-yl)phenyl cyclopentylcarbamate Example 260: 3-(4-(1,3,4-oxadiazol-2-yl)pyridin-2-yl)phenyl cyclohexylcarbamate Example 261: 3-(4-(1,3,4-oxadiazol-2-yl)pyridin-2-yl)phenyl (4-methylcyclohexyl)carbamate Example 262: 3-(4-(1,3,4-oxadiazol-2-yl)pyridin-2-yl)phenyl cycloheptylcarbamate Example 263: 3-(6-(1,3,4-oxadiazol-2-yl)pyrazin-2-yl)phenyl octylcarbamate Example 264: 3-(6-(1,3,4-oxadiazol-2-yl)pyrazin-2-yl)phenyl (cyclohexylmethyl)carbamate Example 265: 3-(6-(1,3,4-oxadiazol-2-yl)pyrazin-2-yl)phenyl benzylcarbamate Example 266: 3-(6-(1,3,4-oxadiazol-2-yl)pyrazin-2-yl)phenyl cyclopentylcarbamate Example 267: 3-(6-(1,3,4-oxadiazol-2-yl)pyrazin-2-yl)phenyl cyclohexylcarbamate Example 268: 3-(6-(1,3,4-oxadiazol-2-yl)pyrazin-2-yl)phenyl cycloheptylcarbamate Accordingly, in one embodiment the FAAH modulator, inhibitor, or FAAH inhibitor and modulators may be any one of the compounds of Examples 256-268. In a preferred embodiment the FAAH modulator, inhibitor, or FAAH modulator and inhibitor may be any one the compound of Examples 256, 257, 262, 263, 264, 266, 267 and 268. In a further preferred embodiment, the FAAH modulator, inhibitor, or FAAH modulator and inhibitor may be the compound of Example 256 or 263. The compounds of this disclosure include any and all of possible isomers, regioisomers, stereoisomers, enantiomers, diastereomers, racemates, tautomers, free form (e.g., amorphous, polymorphs), pharmaceutically acceptable salts, polymorphs, hydrates, and solvates thereof. The disclosed compounds can be also used to prepare prodrugs. Formula (I-IV) is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically-labelled compounds are identical to those depicted herein except that one or more atoms are replaced by an atom having atomic mass or mass 63336124\1 number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include, but are not limited to, isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine, and chlorine, such as2H,3H,13C,14C,15N,17O,18O,18F, and36Cl respectively. Isotopically-labeled compounds of the present disclosure can generally be prepared by following methods analogues to those disclosed in the Examples herein by substituting isotopically-labeled reagents for a non-isotopically labeled reagents. Isotopica labeling of the compounds disclosed may be useful in metabolic studies, reaction kinetic studies, compound and / or substrate tissue distribution assays, and detection or imaging techniques. Such applications of isotopically-labeled compounds are well known to person skill in the art and are therefore within the scope of the present invention. Compounds of the invention may be synthesized using the conventional methods and utilizing the commercially available reagents and starting materials and / or from compounds described in the chemical literature. “Commercially available chemicals” are obtained from standard commercial sources. It will be readily understood that numerous alterations may be made to the examples and instructions given herein for the synthesis methods and purification of compounds of Formula I-IV. This disclosure is also directed to a method of inhibition of FAAH enzyme in both in vitro and in vivo systems. The compounds of Formula I-IV may be reversible or irreversible FAAH inhibitor or modulator. Thus, can be used in the treatment of a disease, disorder or condition which benefits from the inhibition or modulation of FAAH activity in a subject. 63336124\1 DEFINITIONS Fatty acid amide hydrolase (FAAH) inhibitor Fatty acid amide hydrolase (FAAH, or FAAH-1), also known as oleamide hydrolase or anandamide amidohydrolase is a member of the serine hydrolase family of enzymes. Broadly, it belongs to the class of endocannabinoid hydrolases. It is the principal enzyme responsible for the hydrolysis of Anandamide to Arachidonic acid and ethanolamine. FAAH is an integral membrane protein widely distributed in mammalian tissues that belongs to a large family of enzymes that share a highly conserved 130 amino acid motif designated the “amidase signature” (AS) sequence. AS enzymes possess an unusual serine-serine-lysine catalytic triad, which functions to promote amide bond hydrolysis in a manner analogous to the serine-histidine- aspartic acid triad more commonly observed in serine hydrolases (Dale et al., 2000

[0015] ; Michele et al., 2005

[0016] ). The compounds of Formula I, II, III or IV, may modulate, inhibit or modulate and inhibit Fatty acid amide hydrolase (FAAH). Accordingly, the compounds of Formula I-IV, may be a FAAH inhibitor, a FAAH modulator or a FAAH inhibitor and modulator. As used herein, the term “modulate”, “modulatory”, “modulation” or “modulating” refers to a change in the activity e.g., of the FAAH enzyme. As used herein, the term "inhibit", “inhibitory”, "inhibition" or "inhibiting" refers to the reduction or suppression of the activity e.g., of the FAAH enzyme or a significant decrease in the baseline activity of a biological activity or process e.g., of the FAAH catalyzed reaction of the FAAH enzyme. FAAH inhibitors or modulators are classified as reversible or irreversible. The main difference is that reversible enzyme inhibition inactivates enzymes through non-covalent interaction. In contrast, an irreversible inhibitor inactivates the enzyme through covalent binding to form a stable complex with the enzyme. As a result, the enzyme is permanently inactivated or, at best, is slowly reactivated. The compounds of Formula I-IV described herein may be an irreversible inhibitor or modulator of the FAAH enzyme through the carbamoylation of the active site of the enzyme and this would not show any subsequent competition for binding by accumulated endogenous substrates. Irreversible binding enables and maintains the essentially complete inhibition of the enzyme. 63336124\1 Compounds The term “alkyl”, as used herein, refers to a saturated linear or branched-chain monovalent hydrocarbon radical. Unless otherwise specified, an alkyl group contains 5-20 carbon atoms. Examples of alkyl groups include, but are not limited to, pentyl, hexyl, heptyl, octyl and the like. The term “cycloalkyl” refers to a saturated or partially saturated, monocyclic or fused or spiro polycyclic, carbocycle having from 3 to 12 ring atoms per ring. Examples of cycloalkyl groups include, but are not limited to, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, etc. The term “heterocycloalkyl” refers to a fully saturated cyclic hydrocarbon group containing one or more heteroatom. The term heterocycloalkyl includes fused, spiro or bridged ring systems. Examples of heterocycloalkyl groups include, but are not limited to, 2- azaspiro[3.3]heptane, 3-azabicyclo[3.1.0]hexane, 3-azabicyclo[3.3.0]octane, 8- azabicyclo[3.2.1]octane, 2oxa-6-azaspiro[3.3]heptane, 2oxa-7-azaspiro[3.5]nonane, etc. The term “aryl” refers to a carbocyclic ring system wherein at least one ring in the system is aromatic and has a single point of attachment to the rest of the molecule. Unless otherwise specified, an aryl group may be monocyclic, bicyclic or tricyclic. The term “heteroaryl”, as used herein, refers to a ring system in which one or more ring members are an independently selected heteroatom. The term heteroaryl also includes fused, spiro or bridged heterocyclic ring systems. Unless otherwise specified, a heterocycle may be monocyclic, bicyclic or tricyclic. “Fused” bicyclic ring systems comprise two rings which share two adjoining ring atoms. “Spiro” bicyclic ring systems share only one ring atom (usually a quaternary carbon atom). The term “halogen” represents chlorine, fluorine, bromine or iodine. The term “halo” represents chloro, fluoro, bromo or iodo. Pharmaceutically acceptable derivative 63336124\1 The term “pharmaceutically acceptable derivative” includes, but is not limited to, a pharmaceutically acceptable salt or prodrug, which after being administered to a patient in need thereof, can directly or indirectly provide the compound of the disclosure or a metabolite or residue thereof. Therefore, "the compound of the disclosure" mentioned herein is also intended to cover various derivative forms of the compound. Pharmaceutically acceptable salt The term “pharmaceutically acceptable salt” as used herein encompasses any and all pharmaceutically acceptable salt forms. Those compounds of the disclosure that are basic in nature are capable of forming acid salts with various pharmacologically accepted anions. The chemical acids which are used as reagents to prepare acid salts of this disclosure include both inorganic and organic acids. In some embodiments, these salts are prepared in situ during the final isolation and purification of the compounds of the disclosure, or by separately reacting a purified compound in its free form with a suitable acid or base, and isolating the salt thus formed. A reference for the preparation and selection of pharmaceutical salts of the compounds described herein is P. H. Stahl & C. G. Wermuth “Handbook of Pharmaceutical Salts”, Verlag Helvetica Chimica Acta, Zurich, 2002 (Stahl & Wermuth 2002

[0017] ). In some embodiments, the pharmaceutically acceptable salts of the compounds described herein are pharmaceutically acceptable acid addition salts. “Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Also included are salts that are formed with organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. and include, for example, acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, and the like. Prodrugs In some embodiments, the compounds described herein may exist in prodrug form. The disclosure provides for methods of treating diseases by administering such prodrugs. The 63336124\1 disclosure further provides for methods of treating diseases by administering such prodrugs as pharmaceutical compositions. Metabolites In some embodiments, the compounds of Formula (I) described herein are susceptible to various metabolic reactions. Therefore, in some embodiments, incorporation of appropriate substituents into the structure will reduce, minimize, or eliminate a metabolic pathway. In specific embodiments, the appropriate substituent to decrease or eliminate the susceptibility of an aromatic ring to metabolic reactions is, by way of example only, a halogen, or an alkyl group. Combinations Also contemplated herein are combination therapies, for example, co-administering disclosed compounds of Formula I-IV and an additional therapeutic agent, as part of a specific treatment regimen intended to provide the beneficial effect from the co-action of these therapeutic agents. The disclosed inhibitory compounds can be combined with one or more agents targeting the endogenous cannabinoid system. Such agents include, but not limited to, MAGL inhibitors, CB1 cannabinoid receptor agonists, CB2 cannabinoid receptor agonists, and phytocannabinoids. The disclosed inhibitory compounds can be combined with one or more additional therapeutic agent may be selected from the group consisting of, but are not limited to, non- steroidal anti-inflammatory drugs (NSAIDs), anti-anxiety agents, antidepressants, antiepileptic drugs, anti-Alzheimer's agents, antipsychotic drugs, antihemorrhagic agents, benzodiazepines, acetylcholinesterase inhibitors, alpha-adrenoreceptor antagonists, alpha-adrenergic receptor agonists, β-blockers, angiotensin-converting enzymes inhibitors (ACEI), serotonin (5-HT) reuptake inhibitors, serotonin and noradrenaline reuptake inhibitors (SNRIs), antirheumatic drug, and anticancer medications. The effective amount of the compound of Formula I-IV or the synergistic additional molecule may be between about 0.0001 to about 1,000 mg. The beneficial effect of the combination includes, but is not limited to, pharmacokinetic or pharmacodynamic co-action resulting from the combination of therapeutic agents. Administration of these therapeutic agents in combination typically is carried out over a defined 63336124\1 time period (usually days, weeks, months or years depending upon the combination selected). Combination therapy is intended to embrace administration of multiple therapeutic agents in a sequential manner, that is, wherein each therapeutic agent is administered at a different time, as well as administration of these therapeutic agents, or at least two of the therapeutic agents, in a substantially simultaneous manner. Therapeutic Uses As discussed above, the compounds according to the present disclosure have intrinsic FAAH inhibition properties. Without wishing to be bound by theory, it is believed that the compounds of Formula (I- IV) described herein may offer an improved therapeutic outcome to subjects with FAAH-related diseases, disorders and conditions. The terms “FAAH-related diseases, disorder or conditions” and “disease, disorder or condition benefitting from FAAH inhibition” refers to any disease state, disorder or condition in a subject that has a symptom that is caused directly or indirectly by the FAAH enzyme and where a positive therapeutic outcome by inhibition of the FAAH enzyme is expected. FAAH inhibitors can find potential applications in the treatment of various diseases including but not limited to pain, inflammation, anxiety and mood disorders, metabolic diseases, cardiovascular diseases, autoimmune diseases, central nervous system (CNS) diseases, liver diseases, respiratory diseases, and kidney diseases. The compounds of Formula (I-IV) described herein may be used to treat a variety of medical conditions including but not limited to pain (including but not limited to acute pain, chronic pain, nociceptive pain, and non-nociceptive pain), inflammatory diseases (including but not limited to inflammatory bowel disease, neuroinflammation, neuropathy), anxiety and mood disorder, sleep disorder, eating disorders, obesity, cardiovascular diseases (including but not limited to hypertension, coronary heart disease, ischemia, congestive heart failure, atherosclerosis, myocardial infarction, and peripheral vascular disease), dyslipidemia (including but not limited to hyperlipidemia, hypoalphalipoproteinemia, hypertriglyceridemia, hypercholesterolemia, and low high-density lipoprotein (HDL)), diabetes (type 1 and type 2), allergic airway disease (including but not limited to cough, asthma, and chronic obstructive diseases), cerebrovascular disorders (including stroke, cerebral vasospasm, and learning and 63336124\1 memory disorders), drug or alcohol withdrawal, addiction, liver diseases (including but not limited to non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and hepatitis), cancer, chemotherapy-induced nausea and vomiting (CINV), neurodegenerative disease (including but not limited to Alzheimer and Parkinson diseases), CNS disorders (including but not limited to depression, post-traumatic stress disorder, schizophrenia, seizures, and cognitive disorders), autoimmune diseases (including but not limited to psoriasis, rheumatoid arthritis, Crohn's disease, systemic lupus erythematosis, Sjogren's syndrome, Huntington's chorea, and multiple sclerosis), skin disorders (including but not limited to itching, eczema, pruritis, dermatitis, impaired wound healing), gastrointestinal disorders (including but not limited to nausea, gastrointestinal motility disorder, and paralytic ileus), eye diseases (including but not limited to cataract, and glaucoma). Compositions The disclosure is directed to a pharmaceutical formulation comprising at least one compound of Formula IIV. Dosage formulation can be any of a number of dosage forms known in the art. These dosage forms include, but not limited to, tablets, capsules, pills, syrups, solutions, suspensions, emulsions, injection, inhalation, powders, granules, creams, ointments, gels, patches, and solid lipid nanoparticles. The compositions may be formulated such that they are suitable for oral, parenteral (including but not limited to, intramuscular, subcutaneous, intravenous, intrathecal, intraperitoneal), ophthalmic, topical, transdermal, buccal, sublingual, intranasal, intraocular, rectal, and vaginal. The compounds of Formula I-IV described herein can be administered to a human patient by itself, or in compositions where they are mixed with suitable excipients and / or adjuvants. The compositions described herein may be pharmaceutical compositions and may include one or more pharmaceutically acceptable excipient or adjuvant. The term “excipient” refers to any substance, not itself a therapeutic agent, used as a carrier or vehicle for delivery of a therapeutic agent to a subject or combined with a therapeutic agent (e.g., to create a pharmaceutical composition) to improve its handling or storage properties or to permit or facilitate the formation of a dose unit of the composition. Pharmaceutically 63336124\1 acceptable excipients include, by way of illustration and not limitation, diluents, solvents, disintegrants, binders, glidant, lubricants, (physiologically acceptable) surfactant agents, suspending agents, film forming agents, preservatives, sweetening agent, coloring agent, flavoring agents, emulsifying / wetting agent, buffering agents, binders, disintegrants, taste enhancers, thickening agents, penetration enhancers, wetting agents, lubricants, protectives, adsorbents, demulcents, emollients, antioxidants, moisturizers, carriers, buffering agents, solubilizing agents, penetration agents, soothing agents, suspension agents, coating assistants, substances added to mask or counteract a disagreeable odor, fragrances, or taste, substances added to improve appearance or texture of the composition, and combinations thereof. Dosages The compounds of Formula I-IV or the composition comprising the compounds of Formula I-IV may be administered in a dose once a day or multiple times a day. The daily dose may be between 0.0001 to about 2,000 mg or any amount therebetween. The dose may vary according to factors such as the disease state, age, sex and weight of the subject, and the ability of the compound to elicit a desired response in the subject. Dosage regimens may be adjusted to provide the optimal therapeutic response. 63336124\1 EXAMPLES Scheme I: Synthesis of FAAH inhibitors Reagents and conditions: a) Pd(PPh3)4, aq K2CO3, 1,4-dioxane, 90oC, 4-12 h or Pd(dppf)Cl2, KOAc, 1,4-Dioxane, 90oC, 4-12; b) R3-NCO, triethylamine (TEA), acetonitrile (ACN), 75 oC, 2-15 h; c) HCl in methanol, room temperature (RT), 2 h. Synthesis of ethyl 5-(3-hydroxyphenyl)nicotinate To a stirred solution of ethyl 5-bromonicotinate (0.78 g, 3.62 mmol) in 1,4-dioxane (15 mL) was added (3-hydroxyphenyl)boronic acid (0.50 g, 3.62 mmol) and 0.4M Na2CO3(15 mL) at RT. The reaction mixture was degassed for 15 minutes then Pd(PPh3)4 (0.02 g, 0.018 mmol) was added. The reaction mixture was heated at 80 °C for 4 h under nitrogen atmosphere. The reaction was monitored by thin-layer chromatography (TLC). after completion, the reaction mixture was cooled to RT then evaporated under reduced pressure. The residue was dissolved in water (15 mL) and pH was adjusted to 2-3 by using 2N HCl. The precipitated solid was filtered, washed with water, and then dried under high vacuum to afford the crude acid (450 mg). To a suspension of acid compound in ethanol (15 mL) was added concentrated H2SO4(4- 5 drops) at RT then the reaction mixture was heated at 90 °C for 5 h under Nitrogen atmosphere. 63336124\1 The reaction progress was monitored by TLC. After reaction completion, the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The residue was dissolved in ethyl acetate, washed with NaHCO3followed by brine. The organic solvent was dried over sodium sulfate then evaporated under reduced pressure. The residue was purified by column chromatography on silica gel eluting with hexane / EtOAc (gradient 10-70% EtOAc) to yield the target compound (400 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.71 (s, 1H), 9.07 (s, 2H), 8.39 (s, 1H), 7.34 (t, J = 8.1 Hz, 1H), 7.20 (d, J = 8.1 Hz, 1H), 7.12 (s, 1H), 6.87 (dd, J = 8.0 Hz, 1H), 4.39 (q, J = 16 Hz, 2H), 1.37 (t, J = 8.0 Hz, 3H). Synthesis of ethyl 5-(3-((pentylcarbamoyl)oxy)phenyl)nicotinate (Example-1) To a solution of ethyl 5-(3-hydroxyphenyl) nicotinate (0.08 g, 0.32 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.13 mL, 0.98 mmol) and n-pentyl isocyanate (0.03 g, 0.32 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated to 75 °C for 3 h under a nitrogen atmosphere. An additional amount of n-pentyl isocyanate (0.01 g, 0.11 mmol) was added to the reaction mixture, and the reaction was heated for an additional 12 h. The reaction progress was monitored by TLC. After completion, the reaction mixture was cooled to RT, and the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel, eluting with a hexane / EtOAc gradient (20-25% EtOAc) to yield the target compound (56 mg) as an off white solid.1H NMR (400 MHz, CDCl3) δ 9.14 (s, 1H), 8.93 (s, 1H), 8.54 (s, 1H), 7.27 – 7.54 (m, 2H), 7.18 (d, J = 8.7 Hz, 3H), 5.03 (s, 1H), 4.20 – 4.52 (m, 2H), 3.22 (q, J = 6.8 Hz, 2H), 1.53 (d, J = 6.9 Hz, 2H), 1.20 – 1.49 (m, 7H), 0.76 – 0.92 (m, 3H) Synthesis of ethyl 5-(3-((heptylcarbamoyl)oxy)phenyl)nicotinate (Example-2) To a solution of ethyl 5-(3-hydroxyphenyl) nicotinate (0.08 g, 0.32 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.13 mL, 0.98 mmol) and n-heptyl isocyanate (0.0 g, 0.32 63336124\1 mmol) at RT under a nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated to 75 °C for 3 h under nitrogen atmosphere. An additional amount of n-heptyl isocyanate (0.01 g, 0.11 mmol) was added to the reaction mixture, and the reaction was heated for an additional 12 h. The reaction progress was monitored by TLC. After completion, the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel, eluting with a hexane / EtOAc gradient (20-25% EtOAc) to yield the target compound (57 mg) as an off white solid.1H NMR (400 MHz, dimethyl sufoxide (DMSO)) δ 9.12 (dt, J = 22.0, 1.9 Hz, 2H), 8.47 (q, J = 2.0 Hz, 1H), 7.84 (t, J = 5.7 Hz, 1H), 7.44 – 7.69 (m, 3H), 7.21 (dd, J = 8.1, 2.2 Hz, 1H), 4.22 – 4.46 (m, 2H), 3.07 (q, J = 6.7 Hz, 2H), 1.18 – 1.56 (m, 14H), 0.78 – 1.00 (m, 3H). Synthesis of ethyl 5-(3-((octylcarbamoyl)oxy)phenyl)nicotinate (Example-3) To a solution of ethyl 5-(3-hydroxyphenyl) nicotinate (0.08 g, 0.32 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.13 mL, 0.98 mmol) and n-octyl isocyanate (0.04 g, 0.32 mmol) at RT under a nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated to 75 °C for 3 h under nitrogen atmosphere. An additional amount of n-octyl isocyanate (0.01 g, 0.11 mmol) was added to the reaction mixture, and the reaction was heated for an additional 12 h. The reaction progress was monitored by TLC. After completion, the reaction mixture was cooled to RT, and the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel, eluting with a hexane / EtOAc gradient (20-25% EtOAc) to yield the target compound (58 mg) as an off white solid.1H NMR (400 MHz, CDCl3) δ 9.22 (s, 1H), 8.92 – 9.05 (m, 1H), 8.53 (d, J = 2.1 Hz, 1H), 7.39 – 7.58 (m, 3H), 7.18 – 7.36 (m, 1H), 5.15 (t, J = 5.8 Hz, 1H), 4.48 (q, J = 7.1 Hz, 2H), 3.31 (q, J = 6.7 Hz, 2H), 1.61 (p, J = 7.0 Hz, 3H), 1.22 – 1.52 (m, 12H), 0.90 (t, J = 6.5 Hz, 3H). Synthesis of ethyl 5-(3-((tetradecylcarbamoyl)oxy)phenyl)nicotinate (Example-4) 63336124\1 To a solution of ethyl 5-(3-hydroxyphenyl) nicotinate (0.08 g, 0.32 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.13 mL, 0.98 mmol) and n-tetradecyl isocyanate (0.07 g, 0.32 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated to 75 °C for 3 h under a nitrogen atmosphere. An additional amount of n-tetradecyl isocyanate (0.02 g, 0.11 mmol) was added to the reaction mixture, and the reaction was heated for an additional 12 h. The reaction progress was monitored by TLC. After completion, the reaction mixture was cooled to RT, and the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel, eluting with a hexane / EtOAc gradient (20-25% EtOAc) to yield the target (56 mg) compound as an off white solid.1H NMR (400 MHz, CDCl3) δ 9.22 (s, 1H), 9.01 (d, J = 2.3 Hz, 1H), 8.53 (t, J = 2.0 Hz, 1H), 7.38 – 7.59 (m, 3H), 7.24 (d, J = 7.3 Hz, 1H), 5.14 (t, J = 5.8 Hz, 1H), 4.48 (q, J = 7.2 Hz, 2H), 3.31 (q, J = 6.8 Hz, 2H), 1.61 (p, J = 7.0 Hz, 3H), 1.18 – 1.41 (m, 20H), 0.90 (t, J = 6.7 Hz, 3H). Synthesis of ethyl 5-(3-((cyclopentylcarbamoyl)oxy)phenyl)nicotinate (Example-5) To a solution of ethyl 5-(3-hydroxyphenyl) nicotinate (0.08 g, 0.32 mmol) in anhydrous acetonitrile (2 mL) under a nitrogen atmosphere was added TEA (0.13 mL, 0.98 mmol) and cyclopentyl isocyanate (0.03 g, 0.32 mmol) at RT. The reaction mixture was stirred at RT for 10 minutes and then heated to 75 °C for 3 h under nitrogen atmosphere. An additional amount of cyclopentyl isocyanate (0.01 g, 0.094 mmol) was added to the reaction mixture, and the reaction was heated for an additional 12 h. The progress of the reaction was monitored by TLC. Upon completion, the reaction mixture was cooled to RT and the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel, eluting with a hexane / EtOAc gradient (20-25% EtOAc) to yield the target compound (62 mg) as an off white solid.1H NMR (400 MHz, CDCl3) δ 9.23 (d, J = 2.1 Hz, 1H), 9.01 (d, J = 2.3 Hz, 1H), 8.56 (t, J = 2.1 Hz, 1H), 7.38 – 7.60 (m, 3H), 7.25 (d, J = 7.9 Hz, 1H), 5.09 (d, J = 7.5 Hz, 1H), 4.48 (qd, J = 7.2, 1.5 Hz, 2H), 4.10 (h, J = 7.0 Hz, 1H), 2.07 (dq, J = 12.6, 6.3 Hz, 2H), 1.71 (dt, J = 35.0, 6.2 Hz, 4H), 1.40 – 1.60 (m, 5H). Synthesis of ethyl 5-(3-((cyclohexylcarbamoyl)oxy)phenyl)nicotinate (Example-6) 63336124\1 To a solution of ethyl 5-(3-hydroxyphenyl) nicotinate (0.22 g, 0.90 mmol) in anhydrous acetonitrile (8 mL) was added TEA (0.15 mL, 1.08 mmol) and cyclohexyl isocyanate (0.115 mL, 0.90 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes then heated at 75 °C 3 h under Nitrogen atmosphere. An additional amount of cyclohexyl isocyanate (0.07 g, 0.3 mmol) was added to the reaction mixture and the reaction was heated for an additional 3 h. The reaction progress was monitored by TLC. After reaction completion, the reaction was cooled to RT then evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 10-70% EtOAc) to yield the target compound (88 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.15 (d, J = 4 Hz, 1H), 9.10 (d, J = 4 Hz, 1H), 8.48 (s, 1H), 8.48 (s, 1H), 7.81 (d, J = 8 Hz, 1H), 7.65 (d, J = 8 Hz, 1H), 7.51-7.56 (m, 2H), 7.21 (d, J = 8 Hz, 1H), 4.39 (q, J = 16 Hz, 2H), 3.3 (s, 1H), 1.37 (t, J = 8.0 Hz, 3H), 1.11-1.86 (m, 10H). Synthesis of ethyl 5-(3-(((4-fluorophenyl)carbamoyl)oxy)phenyl)nicotinate (Example-7) To a solution of ethyl 5-(3-hydroxyphenyl) nicotinate (0.08 g, 0.32 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.13 mL, 0.98 mmol) and 4-fluorophneyl isocyanate (0.04 g, 0.32 mmol) at RT under a nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated to 75 °C for 3 h under nitrogen atmosphere. An additional amount of 4-fluorophneyl isocyanate (0.01 g, 0.11 mmol) was added to the reaction mixture, and the reaction was heated for an additional 12 h. The reaction progress was monitored by TLC. Upon completion, the reaction mixture was cooled to RT and the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel, eluting with a hexane / EtOAc gradient (20-25% EtOAc) to yield the target compound (25 mg) as an off white solid.1H NMR (400 MHz, DMSO) δ 1.24 – 1.55 (m, 3H), 4.24 – 4.54 (m, 2H), 6.38 – 6.68 (m, 1H), 6.75 – 6.98 (m, 1H), 7.05 – 7.24 (m, 1H), 7.24 – 7.39 (m, 2H), 7.37 – 7.65 (m, 2H), 7.64 – 7.79 (m, 1H), 8.39 (q, J = 1.8 Hz, 1H), 8.51 (t, J = 2.0 Hz, 1H), 8.70 (s, 63336124\1 1H), 8.98 – 9.19 (m, 1H), 9.72 (d, J = 1.3 Hz, 1H). Synthesis of methyl 5-(3-hydroxyphenyl)nicotinate To a stirred solution of methyl 5-bromonicotinate (0.20 g, 0.45 mmol) in 1,4-dioxane (10 mL) were added 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (0.2 g, 0.45 mmol), KOAc (0.27 g, 2.72 mmol) at RT. The reaction mixture was degassed for 15 minutes then Pd(dppf)Cl2(0.022 g, 0.027 mmol) was added. The reaction mixture was stirred at RT for 30 minutes and then heated at 80 °C overnight under nitrogen atmosphere. The reaction was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The compound was purified by column chromatography on silica gel eluting with hexane / EtOAc (gradient 10-70% EtOAc) to yield the methyl 5-(3- hydroxyphenyl)nicotinate (120 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.71 (s, 1H), 9.07 (dd, J = 8 Hz, 1H), 8.40 (s, 1H), 7.34 (t, J = 8 Hz, 1H), 7.20 (d, J = 8.1 Hz, 1H), 7.12 (s, 1H), 6.87 (dd, J = 8 Hz, 1H), 3.93 (s, 3H). Synthesis of methyl 5-(3-((pentylcarbamoyl)oxy)phenyl)nicotinate (Example-8) To a solution of methyl 5-(3-hydroxyphenyl) nicotinate (0.08 g, 0.34 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.14 mL, 1.0 mmol) and n-pentyl isocyanate (0.03 g, 0.34 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated at 75 °C for 3 h under a nitrogen atmosphere. An additional amount of n-pentyl isocyanate (0.01 g, 0.11 mmol) was added to the reaction mixture, and the reaction was heated for an additional 12 h. The reaction progress was monitored by TLC. After completion, the reaction mixture was cooled to RT and the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel, eluting with a hexane / EtOAc gradient (20-25% EtOAc) to yield the target compound (60 mg) as an off white solid.1H NMR (400 MHz, CDCl3) δ 9.22 (d, J = 1.9 Hz, 1H), 9.01 (d, J = 63336124\1 2.1 Hz, 1H), 8.50 (t, J = 2.1 Hz, 1H), 7.40 – 7.58 (m, 3H), 7.24 (dt, J = 7.7, 1.9 Hz, 1H), 5.13 (s, 1H), 4.01 (d, J = 1.5 Hz, 3H), 3.31 (q, J = 6.6 Hz, 2H), 1.62 (d, J = 14.2 Hz, 2H), 1.39 (q, J = 5.2 Hz, 4H), 0.94 (q, J = 6.8 Hz, 3H). Synthesis of methyl 5-(3-((heptylcarbamoyl)oxy)phenyl)nicotinate (Example-9) To a solution of methyl 5-(3-hydroxyphenyl) nicotinate (0.08 g, 0.34 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.14 mL, 1.0 mmol) and n-heptyl isocyanate (0.04 g, 0.34 mmol) at RT under a nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated to 75 °C for 3 h under nitrogen atmosphere. An additional amount of n-heptyl isocyanate (0.01 g, 0.11 mmol) was added to the reaction mixture, and the reaction was heated for an additional 12 h. The reaction progress was monitored by TLC. After completion, the reaction mixture was cooled to RT and the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel, eluting with a hexane / EtOAc gradient (20-25% EtOAc / hexane) to yield the target compound (65 mg) as an off white solid.1H NMR (400 MHz, CDCl3) δ 9.22 (d, J = 2.0 Hz, 1H), 9.01 (d, J = 2.2 Hz, 1H), 8.50 (t, J = 2.1 Hz, 1H), 7.38 – 7.61 (m, 2H), 7.19 – 7.33 (m, 1H), 5.13 (t, J = 6.1 Hz, 1H), 4.01 (d, J = 1.4 Hz, 3H), 3.22 – 3.37 (m, 2H), 1.62 (p, J = 7.2 Hz, 2H), 1.24 – 1.45 (m, 10H), 0.88 – 0.95 (m, 3H). Synthesis of methyl 5-(3-((octylcarbamoyl)oxy)phenyl)nicotinate (Example-10) To a suspension of methyl 5-(3-hydroxyphenyl)nicotinate (0.08 g, 0.34 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.14 mL, 1.0 mmol) and n-octyl isocyanate (0.05 g, 0.34 mmol) at RT under a nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated to 75 °C for 3 h under a nitrogen atmosphere. An additional amount of n-octyl isocyanate (0.01 g, 0.11 mmol) was added to the reaction mixture, which was then heated for an additional 12 h. The reaction progress was monitored by TLC. Upon completion of the 63336124\1 reaction, the mixture was cooled to RT and then the sol vent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel, eluting with a hexane / EtOAc gradient (20-25% EtOAc) to yield the target compound (59 mg) as an off white solid.1H NMR (400 MHz, CDCl3) δ 9.22 (t, J = 1.7 Hz, 1H), 9.01 (t, J = 1.9 Hz, 1H), 8.50 (t, J = 2.1 Hz, 1H), 7.39 – 7.58 (m, 2H), 7.24 (dt, J = 7.8, 1.9 Hz, 1H), 5.13 (d, J = 6.6 Hz, 1H), 3.31 (q, J = 6.8 Hz, 2H), 3.16 (q, J = 6.6 Hz, 1H), 1.61 (q, J = 7.2 Hz, 2H), 1.21 – 1.45 (m, 13H), 0.91 (td, J = 6.2, 3.3 Hz, 3H). Synthesis of methyl 5-(3-((cyclopentylcarbamoyl)oxy)phenyl)nicotinate (Example-11) To a solution of methyl 5-(3-hydroxyphenyl)nicotinate (0.08 g, 0.34 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.14 mL, 1.0 mmol) and cyclopentyl isocyanate (0.03 g, 0.34 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated at 75 °C for 3 h under a nitrogen atmosphere. An additional amount of cyclopentyl isocyanate (0.01 g, 0.11 mmol) was added to the reaction mixture, and the reaction was heated for an additional 12 h. The reaction progress was monitored by TLC. After completion, the reaction mixture was cooled to RT, and the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel, eluting with a hexane / EtOAc gradient (20-25% EtOAc) to yield the target (52 mg) compound as an off white solid.1H NMR (400 MHz, CDCl3) δ 9.22 (t, J = 1.7 Hz, 1H), 9.01 (d, J = 2.3 Hz, 1H), 8.50 (t, J = 2.2 Hz, 1H), 7.37 – 7.54 (m, 3H), 7.24 (d, J = 7.8 Hz, 1H), 5.09 (d, J = 7.5 Hz, 1H), 4.10 (h, J = 6.9 Hz, 1H), 4.01 (d, J = 1.4 Hz, 3H), 2.07 (dt, J = 13.1, 6.4 Hz, 2H), 1.63 – 1.83 (m, 4H), 1.54 (dq, J = 13.2, 6.4 Hz, 2H). Synthesis of methyl 5-(3-((cyclohexylcarbamoyl)oxy)phenyl)nicotinate (Example-12) To a solution of methyl 5-(3-hydroxyphenyl)nicotinate (0.09 g, 0.39 mmol) in anhydrous acetonitrile (5 mL) was added TEA (0.06 mL, 0.47 mmol) at RT under nitrogen atmosphere. 63336124\1 The reaction mixture was stirred for 10 minutes and then added cyclohexyl isocyanate (0.05 ml, 0.39 mmol). The reaction mixture was heated at 75 °C for 3 h under nitrogen atmosphere. An additional amount of cyclohexyl isocyanate (0.03 g, 0.13 mmol) was added to the reaction mixture was heated for an additional 2 h. The reaction was monitored by TLC, after completion the reaction mixture was concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 10-70% EtOAc) to yield the target compound (60 mg) as an off white solid.1H NMR (400 MHz, DMSO- d6) δ 9.10 (d, J = 4 Hz, 1H), 8.48 (s, 1H), 8.48 (s, 1H), 7.81 (d, J = 8 Hz, 1H), 7.65 (d, J = 8 Hz, 1H), 7.51-7.56 (m, 2H), 7.21 (d, J = 8 Hz, 1H), 3.94 (s, 3H), 3.3 (s, 1H), 1.11-1.86 (m, 10H). Synthesis of methyl 5-(3-((((1s,3s)-adamantan-1-yl)carbamoyl)oxy)phenyl)nicotinate (Example-13) To a solution of methyl 5-(3-hydroxyphenyl)nicotinate (0.08 g, 0.34 mmol) in anhydrous acetonitrile (2 mL) was added triethylamine (TEA) (0.14 mL, 1.0 mmol) and adamantyl isocyanate (0.06 g, 0.34 mmol) at RT under a nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated to 75 °C for 3 h under a nitrogen atmosphere. An additional amount of adamantyl isocyanate (0.01 g, 0.11 mmol) was added to the reaction mixture, and the reaction was then heated for an additional 12 h. The reaction progress was monitored by TLC. Upon completion, the reaction mixture was cooled to RT, and the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel, eluting with a hexane / ethyl acetate gradient (20-25% EtOAc) to yield the target compound (80 mg) as an off white solid.1H NMR (400 MHz, CDCl3) δ 9.22 (d, J = 1.9 Hz, 1H), 9.01 (d, J = 2.1 Hz, 1H), 8.50 (q, J = 1.9 Hz, 1H), 7.40 – 7.54 (m, 3H), 7.23 (d, J = 7.5 Hz, 1H), 4.98 (s, 1H), 4.01 (d, J = 1.4 Hz, 3H), 2.15 (s, 3H), 2.01 – 2.12 (m, 6H), 1.72 (d, J = 6.3 Hz, 6H), 1.63 (s, 2H). Synthesis of 5-(3-hydroxyphenyl)nicotinaldehyde 63336124\1 To a solution of 5-bromonicotinaldehyde (0.25g, 1.34 mmol) in 1,4-dioxane (8 mL) was added (3-hydroxyphenyl)boronic acid (0.18 g, 1.34 mmol) and 0.4M Na2CO3solution (5 mL) at RT. The reaction mixture was degassed for 15 minutes then Pd(PPh3)4 (0.01 g, 0.067 mmol) was added. The reaction mixture was heated to 80 °C for 4h under nitrogen atmosphere. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The crude compound was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 10-60% EtOAc) to yield the 5-(3-hydroxyphenyl)nicotinaldehyde (120 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.72 (s, 1H), 9.14 (s, 1H), 8.96 (s, 1H), 8.37 (s, 1H), 7.34 (t, J = 8.1 Hz, 1H), 7.24 (d, J = 4 Hz, 1H), 7.17 (s, 1H), 6.89 (dd, J = 8.0 Hz, 1H). Synthesis of 3-(5-formylpyridin-3-yl)phenyl pentylcarbamate (Example-14) To a suspension of 5-(3-hydroxyphenyl)nicotinaldehyde (0.08 g, 0.40 mmol) in anhydrous acetonitrile (2 mL), TEA (0.16 mL, 1.2 mmol) and n-pentyl isocyanate (0.05 g, 0.40 mmol) were added at RT under a nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated at 75 °C for 3 h under a nitrogen atmosphere. An additional amount of n-pentyl isocyanate (0.01 g, 0.14 mmol) was added to the reaction mixture, and the reaction was heated for an additional 12 h. The reaction progress was monitored by TLC. After completion, the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel, eluting with a gradient of hexane / EtOAc (10-15% EtOAc) to yield the target compound (53 mg) as an off white solid.1H NMR (400 MHz, CDCl3) δ 10.12 (s, 1H), 8.99 (dd, J = 4.6, 2.1 Hz, 2H), 8.26 (t, J = 2.2 Hz, 1H), 7.32 – 7.50 (m, 3H), 7.16 (ddd, J = 7.9, 2.3, 1.4 Hz, 1H), 5.05 (d, J = 6.0 Hz, 1H), 3.22 (td, J = 7.3, 6.0 Hz, 2H), 1.53 (p, J = 7.3 Hz, 2H), 1.18 – 1.36 (m, 4H), 0.78 – 0.90 (m, 3H). 63336124\1 Synthesis of 3-(5-formylpyridin-3-yl)phenyl heptylcarbamate (Example-15) To a suspension of 5-(3-hydroxyphenyl)nicotinaldehyde (0.08 g, 0.40 mmol) in anhydrous acetonitrile (3 mL) was added TEA (0.16 mL, 1.2 mmol) and n-heptyl isocyanate (0.05 g, 0.40 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated at 75 °C for 3 h under nitrogen atmosphere. An additional amount of n-heptyl isocyanate (0.01 g, 0.14 mmol) was added to the reaction mixture, and the reaction was heated for an additional 12 h. The reaction progress was monitored by TLC. After completion, the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel, eluting with hexane / EtOAc (gradient 10-15% EtOAc) to yield the target compound (59 mg) as an off white solid.1H NMR (400 MHz, CDCl3) δ 10.22 (s, 1H), 9.09 (dd, J = 4.7, 2.1 Hz, 2H), 8.36 (t, J = 2.2 Hz, 1H), 7.37 – 7.75 (m, 3H), 7.26 (dt, J = 7.7, 1.8 Hz, 1H), 5.12 (d, J = 6.0 Hz, 1H), 3.32 (q, J = 6.8 Hz, 2H), 1.64 (q, J = 7.1 Hz, 2H), 1.36 (tdd, J = 19.5, 14.0, 10.5 Hz, 8H), 0.80 – 1.01 (m, 3H). Synthesis of 3-(5-formylpyridin-3-yl)phenyl octylcarbamate (Example-16) To a suspension of 5-(3-hydroxyphenyl)nicotinaldehyde (0.08 g, 0.40 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.16 mL, 1.2 mmol) and n-octyl isocyanate (0.06 g, 0.40 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated at 75 °C for 3 h under nitrogen atmosphere. An additional amount of n-octyl isocyanate (0.02 g, 0.14 mmol) was added to the reaction mixture, and the reaction was heated for an additional 12 h. The reaction progress was monitored by TLC. After completion, the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel, eluting with 63336124\1 hexane / EtOAc (gradient 10-15% EtOAc) to yield the target compound (58 mg) as an off white solid.1H NMR (400 MHz, CDCl3) δ 10.22 (s, 1H), 9.09 (dd, J = 5.0, 2.2 Hz, 2H), 8.37 (d, J = 2.4 Hz, 1H), 7.41 – 7.64 (m, 3H), 7.26 (d, J = 7.8 Hz, 1H), 5.12 (t, J = 5.7 Hz, 1H), 3.32 (q, J = 6.8 Hz, 2H), 1.64 (q, J = 7.1 Hz, 2H), 1.23 – 1.49 (m, 10H), 0.91 (h, J = 3.3 Hz, 3H). Synthesis of 3-(5-formylpyridin-3-yl)phenyl (cyclohexylmethyl)carbamate (Example-17) To a suspension of 5-(3-hydroxyphenyl)nicotinaldehyde (0.08 g, 0.40 mmol) in anhydrous acetonitrile (2 mL), TEA (0.16 mL, 1.2 mmol) and cyclohexanemethyl isocyanate (0.05 g, 0.40 mmol) were added at RT under a nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated to 75 °C for 3 h under a nitrogen atmosphere. An additional amount of cyclohexanemethyl isocyanate (0.015 g, 0.14 mmol) was added to the reaction mixture, and the reaction was heated for an additional 12 h. The reaction progress was monitored by TLC. After completion, the reaction mixture was cooled to RT, and then the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel, eluting with a gradient of hexane / EtOAc (10-15% EtOAc) to yield the target compound (57 mg) as an off white solid.1H NMR (400 MHz, CDCl3) δ 10.19 (s, 1H), 9.05 (d, J = 2.0 Hz, 1H), 8.33 (s, 1H), 5.11 (s, 1H), 3.29 (td, J = 7.3, 6.0 Hz, 2H), 3.14 (td, J = 7.2, 5.5 Hz, 1H), 1.60 (dd, J = 8.4, 5.8 Hz, 1H), 1.26 – 1.44 (m, 11H), 1.44 – 1.55 (m, 1H), 0.90 – 1.12 (m, 3H). Synthesis of 3-(5-formylpyridin-3-yl)phenyl cyclopentylcarbamate (Example-18) To a suspension of 5-(3-hydroxyphenyl)nicotinaldehyde (0.08 g, 0.40 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.16 mL, 1.2 mmol) and cyclopentyl isocyanate (0.04 g, 0.40 mmol) at RT under a nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated at 75 °C for 3 h under a nitrogen atmosphere. An additional amount of cyclopentyl isocyanate (0.01 g, 0.14 mmol) was added to the reaction mixture, and the reaction 63336124\1 was heated for an additional 3 h. The reaction progress was monitored by TLC. Upon completion, the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel, eluting with hexane / EtOAc (gradient 10-15% EtOAc) to yield the target compound (50 mg) as an off white solid.1H NMR (400 MHz, CDCl3) δ 10.22 (s, 1H), 9.09 (dd, J = 5.1, 2.2 Hz, 2H), 8.37 (d, J = 2.5 Hz, 1H), 7.42 – 7.69 (m, 3H), 7.26 (d, J = 8.0 Hz, 1H), 5.08 (d, J = 7.4 Hz, 1H), 3.83 – 4.35 (m, 2H), 1.85 – 2.17 (m, 2H), 1.53 – 1.85 (m, 3H), 1.32 – 1.53 (m, 2H). Synthesis of (5-formylpyridin-3-yl)phenyl cyclohexylcarbamate (Example-19) To a suspension of 5-(3-hydroxyphenyl)nicotinaldehyde (0.08 g, 0.40 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.16 mL, 1.2 mmol) and cyclohexyl isocyanate (0.05 g, 0.40 mmol) at RT under a nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated at 75 °C for 3 h under a nitrogen atmosphere. An additional amount of cyclohexyl isocyanate (0.01 g, 0.14 mmol) was added to the reaction mixture, and the reaction was heated for an additional 12 h. The reaction progress was monitored by TLC. Upon completion, the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel, eluting with hexane / EtOAc (gradient 10-15% EtOAc) to yield the target compound (50 mg) as an off white solid.1H NMR (400 MHz, CDCl3) δ 10.12 (s, 1H), 8.99 (dd, J = 5.4, 2.1 Hz, 2H), 8.26 (t, J = 2.2 Hz, 1H), 7.34 – 7.50 (m, 3H), 7.16 (ddd, J = 7.8, 2.3, 1.3 Hz, 1H), 4.92 (d, J = 8.2 Hz, 1H), 3.51 (ddp, J = 10.5, 7.9, 4.0 Hz, 1H), 1.97 (dd, J = 12.2, 3.7 Hz, 2H), 1.60 – 1.75 (m, 2H), 1.08 – 1.44 (m, 6H). Synthesis of 3-(5-formylpyridin-3-yl)phenyl cyclohepylcarbamate (Example-20) To a suspension of 5-(3-hydroxyphenyl)nicotinaldehyde (0.08 g, 0.40 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.16 mL, 1.2 mmol) and cycloheptyl isocyanate (0.05 g, 63336124\1 0.40 mmol) at RT under a nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated at 75 °C for 3 h under a nitrogen atmosphere. An additional amount of cycloheptyl isocyanate (0.01 g, 0.14 mmol) was added to the reaction mixture, and the reaction was heated for an additional 12 h. The reaction progress was monitored by TLC. Upon completion, the reaction mixture was cooled to RT, and then the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel, eluting with hexane / EtOAc (gradient 10-15% EtOAc) to yield the target compound (53 mg) as an off white solid.1H NMR (400 MHz, CDCl3) δ 10.19 (s, 1H), 9.06 (dd, J = 5.3, 2.1 Hz, 2H), 8.33 (t, J = 2.2 Hz, 1H), 7.37 – 7.67 (m, 3H), 7.14 – 7.30 (m, 1H), 5.04 (d, J = 8.2 Hz, 1H), 3.78 (d, J = 10.3 Hz, 1H), 1.97 – 2.21 (m, 2H), 1.47 – 1.81 (m, 12H). Synthesis of 3-(5-formylpyridin-3-yl)phenyl ((1s,3s)-adamantan-1-yl)carbamate (Example-21) To a suspension of 5-(3-hydroxyphenyl)nicotinaldehyde (0.08 g, 0.40 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.16 mL, 1.2 mmol) and adamantyl isocyanate (0.07 g, 0.40 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated at 75 °C for 3 h under nitrogen atmosphere. An additional amount of adamantyl isocyanate (0.02 g, 0.14 mmol) was added to the reaction mixture, and the reaction was heated for an additional 12 h. The reaction progress was monitored by TLC. After completion, the reaction mixture was cooled to RT, and then the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel, eluting with hexane / EtOAc (gradient 10-15% EtOAc) to yield the target compound (59 mg) as an off white solid.1H NMR (400 MHz, CDCl3) δ 10.22 (s, 1H), 9.09 (dd, J = 5.4, 2.1 Hz, 2H), 8.36 (t, J = 2.2 Hz, 1H), 7.35 – 7.61 (m, 3H), 7.25 (dt, J = 7.9, 1.7 Hz, 1H), 4.98 (s, 1H), 2.06 (s, 4H), 2.11 (d, J = 37.6 Hz, 6H), 1.74 (d, J = 3.1 Hz, 5H). Synthesis of 5-(3-hydroxyphenyl)-N-((tetrahydro-2H-pyran-2-yl)oxy)nicotinamide 63336124\1 To a stirring solution of the 5-(3-hydroxyphenyl)nicotinic acid (1.0 g, 4.65 mmol) in dry N-N- dimethylformamide (DMF) at RT, EDC·HCl (1.06 g, 5.58 mmol) and HOBt (0.91 g, 9.2 mmol) were subsequentially added. After 10 minutes, the o-(tetrahydro-2h-pyran-2-yl)hydroxylamine (0.53 g, 4.6 mmol) was added to the reaction mixture followed by the addition of TEA (1.8 mL, 13.9 mmol). The mixture was stirred under nitrogen atmosphere overnight at RT. The end of the reaction was monitored by TLC. Afterward, the reaction was quenched with saturated NaHCO3 solution, and the mixture was extracted with ethyl acetate (EtOAc). The organic layer was washed with distilled water, 2N HCl solution and saturated NaCl. The organic layer was then dried over anhydrous Na2SO4and the EtOAc evaporated to give the crude peptide which was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 60-80% EtOAc) to yield the 5-(3-hydroxyphenyl)-N-((tetrahydro-2H-pyran-2- yl)oxy)nicotinamide (600 mg) as an off white solid. Synthesis of 3-(5-(((tetrahydro-2H-pyran-2-yl)oxy)carbamoyl)pyridin-3- yl)phenylheptylcarbamate To a suspension of 5-(3-hydroxyphenyl)-N-((tetrahydro-2H-pyran-2-yl)oxy)nicotinamide (0.08 g, 0.25 mmol) in anhydrous acetonitrile (3 mL) was added TEA (0.10 mL, 0.75 mmol) and n- heptyl isocyanate (0.035 g, 0.25 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated at 75 °C for 3 h under nitrogen atmosphere. An additional amount of n-heptyl isocyanate (0.015 g, 0.11 mmol) was added to the reaction mixture and the reaction was heated for an additional 3 h. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 50-60% EtOAc) to yield 3- (5-(((tetrahydro-2H-pyran-2-yl)oxy)carbamoyl)pyridin-3-yl)phenyl heptyllcarbamate (34 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 11.94 (s, 1H), 9.05 (d, J = 2.2 Hz, 1H), 63336124\1 8.92 (d, J = 2.0 Hz, 1H), 8.37 (t, J = 2.1 Hz, 1H), 7.81 (t, J = 5.7 Hz, 1H), 7.64 (dt, J = 7.8, 1.2 Hz, 1H), 7.44 – 7.62 (m, 2H), 7.19 (ddd, J = 8.1, 2.3, 1.0 Hz, 1H), 5.05 (t, J = 2.8 Hz, 1H), 4.07 (q, J = 7.4 Hz, 1H), 3.44 – 3.81 (m, 1H), 3.07 (td, J = 7.1, 5.8 Hz, 2H), 1.40 – 1.64 (m, 6H), 1.10 – 1.38 (m, 9H), 0.51 – 1.10 (m, 3H). Synthesis of 3-(5-(hydroxycarbamoyl)pyridin-3-yl)phenyl heptylcarbamate (Example-22) To a solution of 3-(5-(((tetrahydro-2H-pyran-2-yl)oxy)carbamoyl)pyridin-3-yl)phenyl octylcarbamate (0.03, 0.05 mmol), in hydrogen chloride in methanol (2 mL, 4N HCl in methanol) at RT and the reaction stirred over 2 h. The reaction progress monitored by TLC, after completion the reaction mixture solvent was evaporated under reduced pressure. The desired product was purified via recrystallization using ethanol to yield the target compound (25 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.15 (d, J = 2.2 Hz, 1H), 9.00 (d, J = 1.9 Hz, 1H), 8.61 (t, J = 2.1 Hz, 1H), 7.84 (t, J = 5.7 Hz, 1H), 7.71 (dt, J = 7.8, 1.2 Hz, 1H), 7.49 – 7.66 (m, 2H), 7.22 (dd, J = 8.0, 2.3 Hz, 1H), 3.08 (q, J = 6.6 Hz, 1H), 1.49 (p, J = 7.2 Hz, 2H), 1.28 (q, J = 6.5 Hz, 5H), 0.81 – 0.95 (m, 3H) Synthesis of 3-(5-(((tetrahydro-2H-pyran-2-yl)oxy)carbamoyl)pyridin-3-yl)phenyl octylcarbamate To a suspension of 5-(3-hydroxyphenyl)-N-((tetrahydro-2H-pyran-2-yl)oxy)nicotinamide (0.08 g, 0.25 mmol) in anhydrous acetonitrile (3 mL) was added TEA (0.10 mL, 0.75 mmol) and n- octyl isocyanate (0.038 g, 0.25 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated at 75 °C for 3 h under nitrogen atmosphere. An additional amount of n-octyl isocyanate (0.017 g, 0.11 mmol) was added to the reaction mixture and the reaction was heated for an additional 3 h. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The crude product was purified by flash column 63336124\1 chromatography on silica gel eluting with hexane / EtOAc (gradient 50-60% EtOAc) to yield the 3-(5-(((tetrahydro-2H-pyran-2-yl)oxy)carbamoyl)pyridin-3-yl)phenyl octylcarbamate (30 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 11.93 (s, 1H), 9.05 (d, J = 2.2 Hz, 1H), 8.92 (d, J = 2.0 Hz, 1H), 8.36 (t, J = 2.2 Hz, 1H), 7.81 (t, J = 5.7 Hz, 1H), 7.39 – 7.75 (m, 3H), 7.19 (ddd, J = 8.1, 2.3, 1.0 Hz, 1H), 5.05 (s, 1H), 3.74 – 4.37 (m, 1H), 3.49 – 3.64 (m, 1H), 3.31 (s, 6H), 3.07 (q, J = 6.9 Hz, 2H), 1.75 (s, 4H), 1.42 – 1.67 (m, 6H), 1.16 – 1.40 (m, 14H), 0.86 (td, J = 6.8, 1.9 Hz, 4H). Synthesis of 3-(5-(hydroxycarbamoyl)pyridin-3-yl)phenyl octylcarbamate (Example-23) To a solution of 3-(5-(((tetrahydro-2H-pyran-2-yl)oxy)carbamoyl)pyridin-3-yl)phenyl octylcarbamate (0.03, 0.05 mmol), in hydrogen chloride in methanol (2 mL, 4M HCl in methanol) at RT and the reaction was stirred over 2 h. the reaction progress was monitored by TLC, after completion the reaction mixture solvent was evaporated under reduced pressure. The desired product was purified via recrystallization using ethanol to yield the target compound (15 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.15 (d, J = 2.2 Hz, 1H), 9.00 (d, J = 1.9 Hz, 1H), 8.61 (t, J = 2.1 Hz, 1H), 7.84 (t, J = 5.7 Hz, 1H), 7.71 (dt, J = 8.0, 1.2 Hz, 1H), 7.61 (t, J = 2.0 Hz, 1H), 7.56 (t, J = 7.9 Hz, 1H), 7.17 – 7.35 (m, 1H), 3.08 (q, J = 6.7 Hz, 2H), 1.14 – 1.39 (m, 8H), 1.49 (t, J = 7.0 Hz, 2H), 0.79 – 0.91 (m, 3H). Synthesis of 3-(5-(((tetrahydro-2H-pyran-2-yl)oxy)carbamoyl)pyridin-3-yl)phenyl tetradecylcarbamate To a suspension of 5-(3-hydroxyphenyl)-N-((tetrahydro-2H-pyran-2-yl)oxy)nicotinamide (0.08 g, 0.25 mmol) in anhydrous acetonitrile (3 mL) was added TEA (0.10 mL, 0.75 mmol) and n- tetradecyl isocyanate (0.053 g, 0.25 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated at 75 °C for 3 h under nitrogen atmosphere. An additional amount of n-tetradecyl isocyanate (0.023 g, 0.11 mmol) was added 63336124\1 to the reaction mixture and the reaction was heated for an additional 3 h. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 50-60% EtOAc) to yield the 3-(5-(((tetrahydro-2H-pyran-2-yl)oxy)carbamoyl)pyridin-3-yl)phenyl tetradecylcarbamate (23 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 11.94 (s, 1H), 9.05 (d, J = 2.2 Hz, 1H), 8.92 (d, J = 2.0 Hz, 1H), 8.36 (t, J = 2.2 Hz, 1H), 7.80 (t, J = 5.7 Hz, 1H), 7.64 (dt, J = 7.9, 1.2 Hz, 1H), 7.45 – 7.57 (m, 2H), 7.19 (ddd, J = 8.1, 2.3, 1.0 Hz, 1H), 5.05 (d, J = 3.1 Hz, 1H), 4.05 (d, J = 10.8 Hz, 1H), 3.51 – 3.67 (m, 1H), 3.07 (q, J = 6.6 Hz, 2H), 1.24 (d, J = 6.6 Hz, 26H), 1.40 – 1.66 (m, 5H), 0.70 – 0.94 (m, 3H). Synthesis of 3-(5-(hydroxycarbamoyl)pyridin-3-yl)phenyl tetradecylcarbamate (Example- 24) To a solution of 3-(5-(((tetrahydro-2H-pyran-2-yl)oxy)carbamoyl)pyridin-3-yl)phenyl octylcarbamate (0.03, 0.05 mmol ), in hydrogen chloride in methanol (2 mL, 4N in Methanol) at RT and the reaction was stirred over 2 h. the reaction progress was monitored by TLC, after completion the reaction mixture solvent was evaporated under reduced pressure. The desired product was purified via recrystallization using methanol to yield the target compound (20 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.11 (d, J = 2.2 Hz, 1H), 8.97 (d, J = 2.0 Hz, 1H), 8.52 (t, J = 2.1 Hz, 1H), 7.83 (t, J = 5.7 Hz, 1H), 7.68 (ddd, J = 7.8, 1.8, 1.0 Hz, 1H), 7.51 – 7.60 (m, 2H), 7.21 (ddd, J = 8.1, 2.3, 0.9 Hz, 1H), 3.07 (q, J = 6.8 Hz, 2H), 1.25 (d, J = 6.1 Hz, 15H), 1.30 – 2.07 (m, 3H), 0.44 – 1.06 (m, 3H). Synthesis of 5-(3-hydroxyphenyl)nicotinohydrazide To a solution of ethyl 5-(3-hydroxyphenyl)nicotinate (0.25 g, 1.028 mmol) in ethanol (6 mL) was added hydrazine hydrate (0.61 g, 6.16 mmol) at RT. The reaction mixture was heated at 90 63336124\1 °C for 15 h. The reaction progress was monitored by TLC, after completion the reaction was cooled to RT. The precipitated product was collected by filtrations and washed by ethanol. The filtrate was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with dichloromethane (DCM) / MeOH (gradient 2-5% MeOH) to yield the 5-(3-hydroxyphenyl)nicotinohydrazide (140 mg) as a pale-yellow solid.1H NMR (400 MHz, DMSO-d6) δ 10.06 (s, 1H), 9.67 (s, 1H), 8.94 (m, 2H), 8.35 (m, 1H), 7.32 (m, 1H), 7.20 (d, J = 7.7 Hz, 1H), 6.86 (dd, J = 7.8, 1.7 Hz, 1H), 4.60 (s, 2H), 7.14 (s, 1H) Synthesis of 3-(5-(hydrazinecarbonyl)pyridin-3-yl)phenyl octylcarbamate (Example-25) To a suspension of 3-(5-(oxazol-2-yl)pyridin-3-yl)phenol (0.08 g, 0.33 mmol) in anhydrous acetonitrile (6 mL) was added TEA (0.13 mL, 0.99 mmol) and octyl isocyanate (0.041 g, 0.33 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated at 75 °C for 3 h under nitrogen atmosphere. An additional amount of octyl isocyanate (0.013 g, 0.11 mmol) was added to the reaction mixture and the reaction was heated for an additional 3 h. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 80-100% EtOAc) to yield the target compound (80 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.12 (d, J = 2.2 Hz, 1H), 8.98 (d, J = 2.0 Hz, 1H), 8.55 (t, J = 2.1 Hz, 1H), 7.84 (t, J = 5.7 Hz, 1H), 7.69 (dt, J = 8.0, 1.2 Hz, 1H), 7.50 – 7.63 (m, 2H), 7.22 (ddd, J = 8.1, 2.3, 1.0 Hz, 1H), 3.45 – 2.83 (m, 2H), 1.48 (d, J = 7.2 Hz, 2H), 1.29 (dt, J = 10.1, 5.7 Hz, 12H), 0.53 – 1.02 (m, 3H). 63336124\1 Synthesis of 5-(3-hydroxyphenyl)nicotinonitrile To a solution of 5-bromonicotinonitrile (0.23g, 1.34 mmol) in 1,4-dioxane (8 mL) was added (3-hydroxyphenyl)boronic acid (0.18 g, 1.34 mmol) and 0.4M Na2CO3 solution (5 mL) at RT. The reaction mixture was degassed for 15 minutes then Pd(PPh3)4 (0.01 g, 0.067 mmol) was added. The reaction mixture was heated to 80 °C for 4 h under nitrogen atmosphere. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The crude compound was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 10-60% EtOAc) to yield the 5-(3-hydroxyphenyl)nicotinonitrile (120 mg) as an off white solid.1H-NMR (400 MHz, DMSO-d6) δ 9.72 (s, 1H), 9.14 (s, 1H), 8.96 (s, 1H), 8.37 (s, 1H), 7.34 (t, J = 8.1 Hz, 1H), 7.24 (d, J = 4 Hz, 1H), 6.89 (dd, J = 8.0 Hz, 1H), 7.17 (s, 1H). Synthesis of 3-(5-cyanopyridin-3-yl)phenyl heptylcarbamate (Example-26) To a suspension of 5-(3-hydroxyphenyl)nicotinonitrile (0.1 g, 0.51 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.07 mL, 0.51 mmol) and n-heptyl isocyanate (0.08 g, 0.61 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated at 75 °C for 12 h under nitrogen atmosphere. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 15-25% EtOAc) to yield the target compound (88 mg) as an off white solid.1H NMR (400 MHz, CDCl3) δ 8.95 (d, J = 2.3 Hz, 1H), 8.79 (d, J = 2.0 Hz, 1H), 8.05 (t, J = 2.1 Hz, 1H), 7.44 (t, J = 7.9 Hz, 1H), 7.26 – 7.38 (m, 2H), 7.08 – 7.19 (m, 1H), 5.01 (s, 1H), 3.11 – 3.37 (m, 2H), 1.16 – 1.39 (m, 8H), 1.54 (d, J = 7.1 Hz, 2H), 0.78 – 0.86 (m, 3H). 63336124\1 Synthesis of 3-(5-cyanopyridin-3-yl)phenyl octylcarbamate (Example-27) To a suspension of 5-(3-hydroxyphenyl)nicotinonitrile (0.1 g, 0.51 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.07 mL, 0.51 mmol) and n-octyl isocyanate (0.09 g, 0.61 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated at 75 °C for 3 h under nitrogen atmosphere. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 15-25% EtOAc) to yield the 5-(3-hydroxyphenyl)nicotinonitrile (69 mg) as an off white solid.1H NMR (400 MHz, CDCl3) δ 9.02 (d, J = 2.3 Hz, 1H), 8.86 (d, J = 2.0 Hz, 1H), 8.12 (t, J = 2.1 Hz, 1H), 7.51 (t, J = 7.9 Hz, 1H), 7.29 – 7.46 (m, 2H), 7.03 – 7.34 (m, 2H), 5.07 (d, J = 6.7 Hz, 1H), 3.29 (td, J = 7.3, 6.0 Hz, 2H), 1.14 – 1.39 (m, 10H), 0.63 – 0.99 (m, 3H), 1.58 (s, 2H). Synthesis of 3-(5-cyanopyridin-3-yl)phenyl cyclohexylcarbamate (Example-28) To a suspension of 5-(3-hydroxyphenyl)nicotinonitrile (0.1 g, 0.51 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.07 mL, 0.51 mmol) and cyclohexyl isocyanate (0.07 g, 0.61 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated at 75 °C for 3 h under nitrogen atmosphere. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 15-25% EtOAc) to yield the target compound (77 mg) as an off white solid.1H NMR (400 MHz, CDCl3) δ 8.95 (d, J = 2.3 63336124\1 Hz, 1H), 8.79 (d, J = 2.0 Hz, 1H), 8.05 (t, J = 2.1 Hz, 1H), 7.43 (t, J = 7.9 Hz, 1H), 7.26 – 7.36 (m, 2H), 7.11 – 7.19 (m, 1H), 4.93 (d, J = 8.1 Hz, 1H), 3.51 (pd, J = 6.8, 4.1 Hz, 1H), 1.96 (dq, J = 12.1, 3.7 Hz, 3H), 1.68 (dh, J = 13.6, 4.3 Hz, 2H), 1.09 – 1.39 (m, 5H). Synthesis of 3-(5-cyanopyridin-3-yl)phenyl cycloheptylcarbamate (Example-29) To a suspension of 5-(3-hydroxyphenyl)nicotinonitrile (0.1 g, 0.51 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.07mL, 0.51 mmol) and cycloheptyl isocyanate (0.08 g, 0.61 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated at 75 °C for 3 h under nitrogen atmosphere. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 15-25% EtOAc) to yield the target compound (73 mg) as an off white solid.1H NMR (400 MHz, CDCl3) δ 8.95 (d, J = 2.3 Hz, 1H), 8.79 (d, J = 2.0 Hz, 1H), 8.05 (t, J = 2.1 Hz, 1H), 7.43 (t, J = 7.9 Hz, 1H), 7.29 – 7.38 (m, 2H), 7.09 – 7.18 (m, 1H), 5.00 (d, J = 8.1 Hz, 1H), 4.06 (d, J = 7.8 Hz, 1H), 3.66 (dqd, J = 33.9, 8.0, 3.8 Hz, 1H), 1.76 – 2.05 (m, 3H), 1.43 – 1.55 (m, 8H). Synthesis of 3-(5-(trifluoromethyl)pyridin-3-yl)phenol To a stirred solution of 3-bromo-5-(trifluoromethyl)pyridine (0.10 g, 0.44 mmol) in 1,4-dioxane (6 ml), was added 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (0.12 g, 0.53 mmol), KOAc (0.13 g, 1.32 mmol) at RT under nitrogen atmosphere. The reaction mixture was degassed for 10 minutes then Pd(dppf)Cl2(0.01 g, 0.013 mmol) was added. The reaction was heated at 80 °C for 12 h under nitrogen atmosphere. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT then evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 10-70% EtOAc) to yield the 3-(5-(trifluoromethyl)pyridin-3- 63336124\1 yl)phenol (60 mg) as an off white solid.1H-NMR (400 MHz, DMSO-d6): δ 6.89 (dd, J = 8.0 Hz, 1H), 7.17 (s, 1H), 7.24 (d, J = 4 Hz, 1H), 7.34 (t, J = 8.1 Hz, 1H), 8.37 (s, 1H), 8.96 (s, 1H), 9.14 (s, 1H), 9.72 (s, 1H). Synthesis of 3-(5-(trifluoromethyl)pyridin-3-yl)phenyl octylcarbamate (Example-30) To a solution of 3-(5-(trifluoromethyl)pyridin-3-yl)phenol (0.08 g, 0.33 mmol) in anhydrous acetonitrile (2 mL), add triethylamine (TEA) (0.13 mL, 0.99 mmol) and n-octyl isocyanate (0.05 g, 0.33 mmol) at RT under a nitrogen atmosphere. Stir the reaction mixture at RT for 10 minutes and then heat to 75 °C for 3 h under a nitrogen atmosphere. After 3 h, add an additional amount of n-octyl isocyanate (0.01 g, 0.11 mmol) to the reaction mixture and continue heating for an additional 12 h. Monitor the reaction progress by TLC. Upon completion of the reaction, cool the reaction mixture to RT and evaporate the solvent under reduced pressure. Purify the crude product by flash column chromatography on silica gel, eluting with a hexane / EtOAc gradient (10-15% EtOAc) to yield the target compound (57 mg) as an off white solid.1H NMR (400 MHz, CDCl3) δ 9.05 (d, J = 2.2 Hz, 1H), 8.81 – 8.98 (m, 1H), 8.12 (t, J = 2.3 Hz, 1H), 7.37 – 7.67 (m, 3H), 7.27 (ddd, J = 8.0, 2.4, 1.1 Hz, 1H), 5.11 (t, J = 5.9 Hz, 1H), 1.34 (qd, J = 9.6, 4.8 Hz, 11H), 0.86 – 1.03 (m, 3H), 1.52 – 1.76 (m, 3H). Synthesis of 3-(5-(trifluoromethyl)pyridin-3-yl)phenyl (cyclohexylmethyl)carbamate (Example-31) To a solution of 3-(5-(trifluoromethyl)pyridin-3-yl)phenol (0.08 g, 0.33 mmol) in anhydrous acetonitrile (2 mL), add TEA (0.13 mL, 0.99 mmol) and cyclohexanemethyl isocyanate (0.04 g, 0.33 mmol) at RT under a nitrogen atmosphere. Stir the reaction mixture at RT for 10 minutes and then heat to 75 °C for 3 h under a nitrogen atmosphere. After 3 h, add an additional amount of cyclohexanemethyl isocyanate (0.01 g, 0.11 mmol) to the reaction mixture and continue heating for an additional 12 h. Monitor the reaction progress by TLC. Upon completion of the 63336124\1 reaction, cool the reaction mixture to RT and evaporate the solvent under reduced pressure. Purify the crude product by flash column chromatography on silica gel, eluting with a hexane / EtOAc gradient (10-15% EtOAc) to yield the target compound (50 mg) as an off white solid.1H NMR (400 MHz, CDCl3) δ 9.05 (d, J = 2.2 Hz, 1H), 8.91 (t, J = 1.5 Hz, 1H), 8.12 (t, J = 2.2 Hz, 1H), 7.36 – 7.62 (m, 3H), 7.21 – 7.28 (m, 1H), 5.15 (d, J = 7.3 Hz, 1H), 3.17 (t, J = 6.5 Hz, 2H), 1.69 – 1.90 (m, 5H), 1.15 – 1.42 (m, 4H), 1.02 (qd, J = 12.5, 3.8 Hz, 2H). Synthesis of 3-(5-(trifluoromethyl)pyridin-3-yl)phenyl cyclopentylcarbamate(Example- 32) To a solution of 3-(5-(trifluoromethyl)pyridin-3-yl)phenol (0.08 g, 0.33 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.13 mL, 0.99 mmol) and cyclopentyl isocyanate (0.037 g, 0.33 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated to 75 °C for 3 h under a nitrogen atmosphere. An additional amount of cyclopentyl isocyanate (0.01 g, 0.11 mmol) was added to the reaction mixture, and the reaction was then heated for an additional 12 h. The reaction progress was monitored by TLC. Upon completion, the reaction mixture was cooled to RT, and the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel, eluting with a hexane / ethyl acetate gradient (10-15% EtOAc) to yield the target compound (50 mg) as an off white solid.1H NMR (400 MHz, CDCl3) δ 9.01 (d, J = 2.2 Hz, 1H), 8.87 (dd, J = 2.1, 1.0 Hz, 1H), 8.08 (s, 1H), 7.50 (t, J = 7.9 Hz, 1H), 7.40 – 7.45 (m, 1H), 7.39 (t, J = 2.0 Hz, 1H), 7.23 (ddd, J = 8.1, 2.3, 1.1 Hz, 1H), 5.05 (d, J = 7.5 Hz, 1H), 4.08 (q, J = 6.8 Hz, 1H), 1.95 – 2.36 (m, 3H), 1.60 – 1.87 (m, 3H), 1.45 – 1.58 (m, 2H). Synthesis of 3-(5-(trifluoromethyl)pyridin-3-yl)phenyl cyclohexylcarbamate (Example-33) To a solution of 3-(5-(trifluoromethyl)pyridin-3-yl)phenol (0.08 g, 0.33 mmol) in anhydrous acetonitrile (3 mL) was added TEA (0.13 mL, 0.99 mmol) and cyclohexyl isocyanate (0.04 g, 63336124\1 0.33 mmol) at RT under a nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated to 75 °C for 3 h under nitrogen atmosphere. After 3 h, an additional amount of cyclohexyl isocyanate (0.01 g, 0.11 mmol) was added to the reaction mixture, which was then heated for an additional 12 h. The reaction progress was monitored by TLC. Upon completion of the reaction, the mixture was cooled to RT, and the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel, eluting with a hexane / ethyl acetate gradient (10-15% EtOAc) to yield the target compound (55 mg) as an off white solid.1H NMR (400 MHz, CDCl3) δ 9.01 (d, J = 2.2 Hz, 1H), 8.87 (dd, J = 2.1, 1.0 Hz, 1H), 8.08 (s, 1H), 7.50 (t, J = 7.9 Hz, 1H), 7.31 – 7.47 (m, 2H), 7.21 – 7.30 (m, 1H), 4.99 (d, J = 8.1 Hz, 1H), 3.59 (dq, J = 8.1, 3.4 Hz, 1H), 2.03 (dt, J = 12.1, 4.0 Hz, 2H), 1.75 (dt, J = 13.4, 3.9 Hz, 2H), 1.08 – 1.58 (m, 6H). Synthesis of 3-(5-(trifluoromethyl)pyridin-3-yl)phenyl cycloheptylcarbamate (Example- 34) To a solution of 3-(5-(trifluoromethyl)pyridin-3-yl)phenol (0.08 g, 0.33 mmol) in anhydrous acetonitrile (2 mL) was added triethylamine (TEA) (0.13 mL, 0.99 mmol) and cycloheptyl isocyanate (0.04 g, 0.33 mmol) at RT under a nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated to 75 °C for 3 h under a nitrogen atmosphere. An additional amount of cycloheptyl isocyanate (0.01 g, 0.11 mmol) was added to the reaction mixture, which was then heated for an additional 12 h. The reaction progress was monitored by TLC. Upon completion of the reaction, the mixture was cooled to RT, and the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel, eluting with a hexane / ethyl acetate gradient (10-15% EtOAc) to yield the target compound (55 mg) as an off white solid.1H NMR (400 MHz, CDCl3) δ 8.94 (d, J = 2.2 Hz, 1H), 8.80 (d, J = 2.1 Hz, 1H), 8.01 (d, J = 2.3 Hz, 1H), 7.25 – 7.51 (m, 3H), 7.16 (ddd, J = 8.2, 2.4, 1.2 Hz, 1H), 4.97 (d, J = 8.2 Hz, 1H), 3.71 (td, J = 8.5, 4.3 Hz, 1H), 1.88 – 2.15 (m, 2H), 1.39 – 1.70 (m, 11H). 63336124\1 Scheme II: Reagents and conditions: a) Pd(PPh3)4, Cs2CO3, 1,4-dioxane, 90-100oC, 2 h; b) Pd(PPh3)4, K2CO3, 1,4-dioxane, H2O, 90oC, 5 h; c) R3-NCO, TEA, ACN, 75oC, 2-6 h; e) DCM, TFA, 40 °C, 30 min. Synthesis of tert-butyl 2-(5-bromopyridin-3-yl)-1H-pyrrole-1-carboxylate To a stirred solution of 3,5-dibromopyridine (2 g, 8.44 mmol) in 1,4-dioxane (20 mL) was added (1-(tert-butoxycarbonyl)-1H-pyrrol-2-yl) boronic acid (2.13 g, 10.13 mmol) and Cs2CO3(5.50 g, 16.89 mmol) at RT. The reaction mixture was degassed for 15 minutes then Pd(PPh3)4 (0.68 g, 0.591 mmol) was added. The reaction mixture was stirred at 90 °C for 2 h under nitrogen atmosphere. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The residue was dissolved in ethyl acetate, washed with water followed by brine. The organic layer was dried over sodium sulfate then evaporated under reduced pressure. The residue was purified by automated normal-phase chromatography and eluted with ethyl acetate / petroleum ether to give tert-butyl 2-(5-bromopyridin-3-yl)-1H-pyrrole-1-carboxylate (1.45 g) as an off white solid. MS (ES+APCI) m / z 323.1. 63336124\1 Synthesis of tert-butyl 2-(5-(3-hydroxyphenyl)pyridin-3-yl)-1H-pyrrole-1-carboxylate To a stirred solution of tert-butyl 2-(5-bromopyridin-3-yl)-1H-pyrrole-1-carboxylate (1 g, 3.09 mmol) in 1,4-dioxane (10 mL) and water (1.1 mL) was added (3-hydroxyphenyl)boronic acid (0.512 g, 3.71 mmol) and K2CO3 (1.28 g, 9.28 mmol) at RT. The reaction mixture was degassed for 15 minutes then Pd(PPh3)4(0.179 g, 0.155 mmol) was added. The reaction mixture was stirred at 80 °C for 5 h under nitrogen atmosphere. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The residue was dissolved in ethyl acetate, washed with water followed by brine. The organic layer was dried over sodium sulfate then evaporated under reduced pressure. The residue was purified by automated normal-phase chromatography and eluted with ethyl acetate / petroleum ether to give tert-butyl 2-(5-(3-hydroxyphenyl)pyridin-3-yl)-1H-pyrrole-1- carboxylate (1 g) as an off white solid. MS (ES+APCI) m / z 337.1 (M+1). Synthesis of tert-butyl 2-(5-(3-((octylcarbamoyl)oxy)phenyl)pyridin-3-yl)-1H-pyrrole-1- carboxylate To a stirred solution of tert-butyl 2-(5-(3-hydroxyphenyl)pyridin-3-yl)-1H-pyrrole-1- carboxylate (0.12 g, 0.357 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.07 mL, 0.428 mmol) and n-octyl isocyanate (0.056 g, 0.35 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h. After completion of the reaction (monitored by liquid chromatography-mass spectrometry (LCMS)), the reaction mixture was concentrated to a residue. The residue was purified by automated normal-phase chromatography and eluted with ethyl acetate / petroleum ether to give tert-butyl 2-(5-(3-((octylcarbamoyl)oxy)phenyl)pyridin-3-yl)-1H-pyrrole-1-carboxylate (0.16 g) as an off white solid. MS (ES+APCI) m / z 492.5 (M+1). Synthesis of 3-(5-(1H-pyrrol-2-yl)pyridin-3-yl)phenyl octylcarbamate (Example-35) 63336124\1 To a stirred solution of tert-butyl 2-(5-(3-((octylcarbamoyl)oxy)phenyl)pyridin-3-yl)-1H- pyrrole-1-carboxylate (0.18 g, 0.366 mmol) in DCM (2 mL) was added TFA (0.56 mL, 7.32 mmol) at 0°C under nitrogen atmosphere. Then reaction mixture was stirred at 40 °C for 30 minutes. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with 10% sodium bicarbonate solution and extracted with dichloromethane and washed with water. The organic layer was dried over sodium sulfate then evaporated under reduced pressure. The residue was purified by preparative High-Performance Liquid Chromatography (HPLC) (0.1% FA) to yield the target compound (70 mg) as an off white solid.1HNMR (400 MHz, DMSO-d6): δ 11.45 (s, 1H), 8.88 (d, J = 2.40 Hz, 1H), 8.66 (d, J = 2.40 Hz, 1H), 8.29 (t, J = 2.00 Hz, 1H), 7.82 (t, J = 5.60 Hz, 1H), 7.65 (d, J = 8.40 Hz, 1H), 7.55 - 7.51 (m, 2H), 7.19 - 7.16 (m, 1H), 6.99 - 6.98 (m, 1H), 6.79 - 6.77 (m, 1H), 6.20 - 6.18 (m, 1H), 3.10 - 3.05 (m, 2H), 1.49 (t, J = 6.80 Hz, 2H), 1.29 - 1.27 (m, 10H), 0.87 (t, J = 7.20 Hz, 3H); MS (ES+APCI) m / z 392.5 (M+1). Synthesis of tert-butyl 2-(5-(3-(((cyclohexylmethyl)carbamoyl)oxy)phenyl)pyridin-3-yl)- 1H-pyrrole-1-carboxylate To a stirred solution of tert-butyl 2-(5-(3-hydroxyphenyl)pyridin-3-yl)-1H-pyrrole-1- carboxylate (0.12 g, 0.357 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.074 mL, 0.535 mmol) and cyclohexanemethyl isocyanate (0.06 g, 0.42 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by automated normal-phase chromatography and eluted with ethyl acetate / petroleum ether to give tert-butyl 2-(5-(3- (((cyclohexylmethyl)carbamoyl)oxy)phenyl)pyridin-3-yl)-1H-pyrrole-1-carboxylate (0.15 g, as an off white solid. MS (ES+APCI) m / z 476.3 (M+1). 63336124\1 Synthesis of 3-(5-(1H-pyrrol-2-yl)pyridin-3-yl)phenyl (cyclohexylmethyl)carbamate (Example-36) To a stirred solution of tert-butyl 2-(5-(3-(((cyclohexylmethyl)carbamoyl)oxy)phenyl)pyridin- 3-yl)-1H-pyrrole-1-carboxylate (0.15 g, 0.336 mmol) in DCM (2 mL) was added TFA (0.52 mL, 6.73 mmol) at 0 °C under nitrogen atmosphere. Then reaction mixture was stirred at 40 °C for 30 minutes. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with 10% sodium bicarbonate solution and extracted with dichloromethane and washed with water. The organic layer was dried over sodium sulfate then evaporated under reduced pressure. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (76 mg) as an off white solid.1HNMR (400 MHz, DMSO-d6): δ 11.56 (s, 1H), 8.88 (d, J = 2.00 Hz, 1H), 8.66 (d, J = 2.00 Hz, 1H), 8.29 (t, J = 2.00 Hz, 1H), 7.84 (t, J = 6.00 Hz, 1H), 7.65 (d, J = 8.40 Hz, 1H), 7.54 - 7.50 (m, 2H), 7.19 - 7.16 (m, 1H), 7.00 - 6.98 (m, 1H), 6.80 - 6.77 (m, 1H), 6.18 - 6.20 (m, 1H), 2.94 (t, J = 6.40 Hz, 2H), 1.75 - 0.88 (m, 11H); MS (ES+APCI) m / z 376.2 (M+1). Synthesis of tert-butyl 2-(5-(3-((benzylcarbamoyl)oxy)phenyl)pyridin-3-yl)-1H-pyrrole-1- carboxylate To a stirred solution of tert-butyl 2-(5-(3-hydroxyphenyl)pyridin-3-yl)-1H-pyrrole-1- carboxylate (0.12 g, 0.357 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.075 mL, 0.535 mmol) and benzyl isocyanate (0.043 g, 0.482 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by automated normal-phase chromatography and eluted with ethyl acetate / petroleum ether to give tert-butyl 2-(5-(3-((benzylcarbamoyl)oxy)phenyl)pyridin- 3-yl)-1H-pyrrole-1-carboxylate (160 mg) as an off white solid. MS (ES+APCI) m / z 469.4 (M+1). 63336124\1 Synthesis of 3-(5-(1H-pyrrol-2-yl)pyridin-3-yl)phenyl benzylcarbamate (Example-37) To a stirred solution of tert-butyl 2-(5-(3-((benzylcarbamoyl)oxy)phenyl)pyridin-3-yl)-1H- pyrrole-1-carboxylate (0.15 g, 0.319 mmol) in DCM (2 mL) was added TFA (0.49 mL, 6.39 mmol) at 0°C under nitrogen atmosphere. Then reaction mixture was stirred at 40 °C for 30 minutes. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with 10% sodium bicarbonate solution and extracted with dichloromethane and washed with water. The organic layer was dried over sodium sulfate then evaporated under reduced pressure. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (41 mg) as an off white solid.1HNMR (400 MHz, DMSO-d6): δ 11.54 (s, 1H), 8.88 (d, J = 2.00 Hz, 1H), 8.67 (d, J = 2.00 Hz, 1H), 8.41 (t, J = 6.00 Hz, 1H), 8.30 (t, J = 2.00 Hz, 1H), 7.68 - 7.52 (m, 3H), 7.39 - 7.20 (m, 6H), 6.99 - 6.98 (m, 1H), 6.78 (t, J = 4.00 Hz, 1H), 6.20 - 6.18 (m, 1H), 4.32 (d, J = 6.40 Hz, 2H); MS (ES+APCI) m / z 370.3 (M+1). Synthesis of tert-butyl 2-(5-(3-((cyclopentylcarbamoyl)oxy)phenyl)pyridin-3-yl)-1H- pyrrole-1-carboxylate To a stirred solution of tert-butyl 2-(5-(3-hydroxyphenyl)pyridin-3-yl)-1H-pyrrole-1- carboxylate (0.1 g, 0.297 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.062 mL, 0.45 mmol) and cyclopentyl isocyanate (0.040 g, 0.375 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by automated normal-phase chromatography and eluted with ethyl acetate / petroleum ether to give tert-butyl 2-(5-(3- ((cyclopentylcarbamoyl)oxy)phenyl)pyridin-3-yl)-1H-pyrrole-1-carboxylate (120 mg) as an off white solid. MS (ES+APCI) m / z 448.4 (M+1). Synthesis of 3-(5-(1H-pyrrol-2-yl)pyridin-3-yl)phenyl cyclopentylcarbamate (Example- 63336124\1 38) To a stirred solution of tert-butyl 2-(5-(3-((cyclopentylcarbamoyl)oxy)phenyl)pyridin-3-yl)- 1H-pyrrole-1-carboxylate (0.12 g, 0.268 mmol) in DCM (2mL) was added TFA (0.41 mL, 5.36 mmol) at 0 °C under nitrogen atmosphere. Then reaction mixture was stirred at 40 °C for 30 minutes. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with 10% sodium bicarbonate solution and extracted with dichloromethane and washed with water. The organic layer was dried over sodium sulfate then evaporated under reduced pressure. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (27 mg) as an off white solid.1HNMR (400 MHz, DMSO-d6) δ 11.55 (s, 1H), 8.88 (d, J = 2.40 Hz, 1H), 8.66 (d, J = 2.40 Hz, 1H), 8.29 (t, J = 2.00 Hz, 1H), 7.87 (d, J = 7.20 Hz, 1H), 7.65 (d, J = 8.00 Hz, 1H), 7.54 - 7.51 (m, 2H), 7.19 - 7.17 (m, 1H), 7.00 - 6.98 (m, 1H), 6.79 - 6.77 (m, 1H), 6.20 - 6.18 (m, 1H), 3.90 - 3.85 (m, 1H), 1.89 - 1.19 (m, 8H); MS (ES+APCI) m / z 348.4 (M+1). Synthesis of tert-butyl 2-(5-(3-((cyclohexylcarbamoyl)oxy)phenyl)pyridin-3-yl)-1H- pyrrole-1-carboxylate To a stirred solution of tert-butyl 2-(5-(3-hydroxyphenyl)pyridin-3-yl)-1H-pyrrole-1- carboxylate (0.1 g, 0.297 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.064 mL, 0.47 mmol) and cyclohexyl isocyanate (0.045 g, 0.357 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by automated normal-phase chromatography and eluted with ethyl acetate / petroleum ether to give tert-butyl 2-(5-(3- ((cyclohexylcarbamoyl)oxy)phenyl)pyridin-3-yl)-1H-pyrrole-1-carboxylate (120 mg) as off white solid. MS (ES+APCI) m / z 462.4 (M+1). Synthesis of 3-(5-(1H-pyrrol-2-yl)pyridin-3-yl)phenyl cyclohexylcarbamate (Example-39) 63336124\1 To a stirred solution of tert-butyl 2-(5-(3-((cyclohexylcarbamoyl)oxy)phenyl)pyridin-3-yl)-1H- pyrrole-1-carboxylate (0.08g, 0.173 mmol) in DCM (2 mL) was added TFA (0.27 mL, 3.47 mmol) at 0 °C under nitrogen atmosphere. Then reaction mixture was stirred at 40 °C for 30 minutes. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with 10% sodium bicarbonate solution and extracted with dichloromethane and washed with water. The organic layer was dried over sodium sulfate then evaporated under reduced pressure. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (27 mg) as an off white solid.1H-NMR (400 MHz, DMSO-d6): δ 11.4 (s, 1H), δ 8.88 (d, J = 2.00 Hz, 1H), 8.66 (d, J = 2.40 Hz, 1H), 8.29 (t, J = 2.40 Hz, 1H), 7.80 (d, J = 8.00 Hz, 1H), 7.65 (d, J = 8.40 Hz, 1H), 7.54 - 7.50 (m, 2H), 7.19 - 7.17 (m, 1H), 7.00 - 6.98 (m, 1H), 6.79 - 6.77 (m, 1H), 6.20 - 6.18 (m, 1H), 3.35 (d, J = 17.60 Hz, 1H), 1.94 - 1.56 (m, 5H), 1.36 - 1.08 (m, 5H); MS (ES+APCI) m / z 362.3 (M+1). Synthesis of tert-butyl 2-(5-(3-((cycloheptylcarbamoyl)oxy)phenyl)pyridin-3-yl)-1H- pyrrole-1-carboxylate To a stirred solution of tert-butyl 2-(5-(3-hydroxyphenyl)pyridin-3-yl)-1H-pyrrole-1- carboxylate (0.12 g, 0.357 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.075 mL, 0.54 mmol) and cycloheptyl isocyanate (0.06 g, 0.428 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by automated normal-phase chromatography and eluted with ethyl acetate / petroleum ether to give tert-butyl 2-(5-(3- ((cycloheptylcarbamoyl)oxy)phenyl)pyridin-3-yl)-1H-pyrrole-1-carboxylate (0.15g) as an off white solid. MS (ES+APCI) m / z 476.3 (M+1). Synthesis of 3-(5-(1H-pyrrol-2-yl)pyridin-3-yl)phenyl cycloheptylcarbamate (Example- 40) 63336124\1 To a stirred solution of tert-butyl 2-(5-(3-((cycloheptylcarbamoyl)oxy)phenyl)pyridin-3-yl)- 1H-pyrrole-1-carboxylate (0.12 g, 0.252 mmol) in DCM (2 mL) was added TFA (0.38 mL, 5.05 mmol) at 0 °C under nitrogen atmosphere. Then reaction mixture was stirred at 40 °C for 30 minutes. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with 10% sodium bicarbonate solution and extracted with dichloromethane and washed with water. The organic layer was dried over sodium sulfate then evaporated under reduced pressure. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (14 mg) as an off white solid.1HNMR (400 MHz, DMSO-d6): δ 11.50 (s, 1H), 8.88 (d, J = 2.40 Hz, 1H), 8.66 (d, J = 2.00 Hz, 1H), 8.29 (t, J = 2.00 Hz, 1H), 7.83 (d, J = 7.60 Hz, 1H), 7.65 (d, J = 8.00 Hz, 1H), 7.54 - 7.50 (m, 2H), 7.19 - 7.16 (m, 1H), 6.99 - 6.98 (m, 1H), 6.79 - 6.77 (m, 1H), 6.20 - 6.18 (m, 1H), 3.60 - 3.33 (m, 1H), 1.91 - 1.31 (m, 12H); MS (ES+APCI) m / z 376.3 (M+1). Synthesis of tert-butyl 2-(5-(5-hydroxy-2-methoxyphenyl)pyridin-3-yl)-1H-pyrrole-1- carboxylate To a stirred solution of tert-butyl 2-(5-bromopyridin-3-yl)-1H-pyrrole-1-carboxylate (0.5 g, 1.55 mmol) in 1,4-dioxane (10 mL) and water (1.1 mL) was added (5-hydroxy-2- methoxyphenyl)boronic acid (0.31 g, 1.86 mmol) and K2CO3 (0.64 g, 4.64 mmol) at RT. The reaction mixture was degassed for 15 minutes then Pd(PPh3)4 (0.09 g, 0.08 mmol) was added. The reaction mixture was stirred at 80 °C for 5 h under nitrogen atmosphere. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The residue was dissolved in ethyl acetate, washed with water followed by brine. The organic layer was dried over sodium sulfate then evaporated under reduced pressure. The residue was purified by automated normal-phase chromatography and eluted with ethyl acetate / petroleum ether to give tert-butyl 2-(5-(5-hydroxy-2- methoxyphenyl)pyridin-3-yl)-1H-pyrrole-1-carboxylate (510 mg) as an pale yellow solid.1H- 63336124\1 NMR (400 MHz, DMSO-d6): δ 9.13 (s, 1H), 8.57 - 8.47 (m, 2H), 7.77 (s, 1H), 7.43 - 7.42 (m, 1H), 6.98 (d, J = 12.00 Hz, 1H), 6.81 - 6.76 (m, 2H), 6.43 - 6.41 (m, 1H), 6.34 (t, J = 4.40 Hz, 1H), 3.68 (s, 3H), 1.32 (s, 9H); MS (ES+APCI) m / z 367.2 (M+1). Synthesis of tert-butyl 2-(5-(2-methoxy-5-((octylcarbamoyl)oxy)phenyl)pyridin-3-yl)-1H- pyrrole-1-carboxylate To a stirred solution of tert-butyl 2-(5-(5-hydroxy-2-methoxyphenyl)pyridin-3-yl)-1H-pyrrole- 1-carboxylate (0.1 g, 0.27 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.06 mL, 0.41 mmol) and n-octyl isocyanate (0.05 g, 0.33 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by automated normal-phase chromatography and eluted with ethyl acetate / petroleum ether to give tert-butyl 2-(5-(2-methoxy-5- ((octylcarbamoyl)oxy)phenyl)pyridin-3-yl)-1H-pyrrole-1-carboxylate (0.12 g) as off white solid. MS (ES+APCI) m / z 522.2 (M+1). Synthesis of 3-(5-(1H-pyrrol-2-yl)pyridin-3-yl)-4-methoxyphenyl octylcarbamate (Example-41) To a stirred solution of tert-butyl 2-(5-(2-methoxy-5-((octylcarbamoyl)oxy)phenyl)pyridin-3- yl)-1H-pyrrole-1-carboxylate (0.18 g, 0.37 mmol) in DCM (2 mL) was added TFA (0.56 mL, 7.32 mmol) at 0°C under nitrogen atmosphere. Then reaction mixture was stirred at 40 °C for 30 minutes. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with 10% sodium bicarbonate solution and extracted with dichloromethane and washed with water. The organic layer was dried over sodium sulfate then evaporated under reduced pressure. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound 63336124\1 (64 mg) as gummy solid.1H-NMR (400 MHz, DMSO-d6): δ 11.60 (s, 1H), 8.89 (d, J = 2.00 Hz, 1H), 8.56 (s, 1H), 8.30 (s, 1H), 7.72 (t, J = 5.20 Hz, 1H), 7.20 (d, J = 16.40 Hz, 3H), 7.01 (s, 1H), 6.80 (s, 1H), 6.21 (s, 1H), 3.82 (s, 3H), 3.08 - 3.03 (m, 2H), 1.46 (t, J = 6.40 Hz, 2H), 1.27 (m, 10H), 0.85 (t, J = 6.80 Hz, 3H); MS (ES+APCI) m / z 422.2 (M+1). Synthesis of tert-butyl 2-(5-(5-(((cyclohexylmethyl)carbamoyl)oxy)-2- methoxyphenyl)pyridin-3-yl)-1H-pyrrole-1-carboxylate To a stirred solution of tert-butyl 2-(5-(5-hydroxy-2-methoxyphenyl)pyridin-3-yl)-1H-pyrrole- 1-carboxylate (0.1 g, 0.27 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.06 mL, 0.41 mmol) and cyclohexanemethyl isocyanate (0.05 g, 0.33 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by automated normal-phase chromatography and eluted with ethyl acetate / petroleum ether to give tert-butyl 2-(5-(5- (((cyclohexylmethyl)carbamoyl)oxy)-2-methoxyphenyl)pyridin-3-yl)-1H-pyrrole-1- carboxylate (0.12 g) as off white solid. MS (ES+APCI) m / z 506.3 (M+1). Synthesis of 3-(5-(1H-pyrrol-2-yl)pyridin-3-yl)-4-methoxyphenyl (cyclohexylmethyl)carbamate (Example-42) To a stirred solution of tert-butyl 2-(5-(5-(((cyclohexylmethyl)carbamoyl)oxy)-2- methoxyphenyl)pyridin-3-yl)-1H-pyrrole-1-carboxylate (0.11 g, 0.22 mmol) in DCM (2 mL) was added TFA (0.33 mL, 4.35 mmol) at 0°C under nitrogen atmosphere. Then reaction mixture was stirred at 40 °C for 30 minutes. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with 10% sodium bicarbonate solution and extracted with dichloromethane and washed with water. The organic layer was dried over sodium sulfate then 63336124\1 evaporated under reduced pressure. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (40 mg) as an off white solid.1H-NMR (400 MHz, DMSO-d6): δ 11.49 (s, 1H), 8.83 (d, J = 2.40 Hz, 1H), 8.47 (d, J = 2.00 Hz, 1H), 8.09 (t, J = 2.00 Hz, 1H), 7.73 (t, J = 6.00 Hz, 1H), 7.16 - 7.14 (m, 3H), 6.96 - 6.95 (m, 1H), 6.72 - 6.70 (m, 1H), 6.19 - 6.17 (m, 1H), 3.80 (s, 3H), 2.91 (t, J = 6.40 Hz, 2H), 1.73 - 1.41 (m, 6H), 1.24 - 0.94 (m, 5H); MS (ES+APCI) m / z 406.2 (M+1). Synthesis of tert-butyl 2-(5-(5-((benzylcarbamoyl)oxy)-2-methoxyphenyl)pyridin-3-yl)- 1H-pyrrole-1-carboxylate To a stirred solution of tert-butyl 2-(5-(5-hydroxy-2-methoxyphenyl)pyridin-3-yl)-1H-pyrrole- 1-carboxylate (0.1 g, 0.27 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.06 mL, 0.41 mmol) and benzyl isocyanate (0.04 g, 0.33 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by automated normal-phase chromatography and eluted with ethyl acetate / petroleum ether to give tert-butyl 2-(5-(5-((benzylcarbamoyl)oxy)-2- methoxyphenyl)pyridin-3-yl)-1H-pyrrole-1-carboxylate (120 mg) as off white solid. MS (ES+APCI) m / z 500.2 (M+1). Synthesis of 3-(5-(1H-pyrrol-2-yl)pyridin-3-yl)-4-methoxyphenyl benzylcarbamate (Example-43) To a stirred solution of tert-butyl 2-(5-(5-((benzylcarbamoyl)oxy)-2-methoxyphenyl)pyridin-3- yl)-1H-pyrrole-1-carboxylate (0.12 g, 0.24 mmol) in DCM (2 mL) was added TFA (0.37 mL, 4.80 mmol) at 0°C under nitrogen atmosphere. Then reaction mixture was stirred at 40 °C for 30 minutes. After completion of the reaction (monitored by TLC), the reaction mixture was 63336124\1 diluted with 10% sodium bicarbonate solution and extracted with dichloromethane and washed with water. The organic layer was dried over sodium sulfate then evaporated under reduced pressure. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (4 mg) as an off white solid.1H-NMR (400 MHz, DMSO-d6): δ 11.48 (s, 1H), 8.82 (d, J = 2.00 Hz, 1H), 8.46 (d, J = 2.00 Hz, 1H), 8.29 (t, J = 6.40 Hz, 1H), 8.06 (t, J = 2.00 Hz, 1H), 7.27 - 7.38 (m, 5H), 7.19 - 7.16 (m, 3H), 6.95 - 6.94 (m, 1H), 6.69 (t, J = 3.60 Hz, 1H), 6.18 - 6.16 (m, 1H), 4.29 (d, J = 6.00 Hz, 2H), 3.81 (s, 3H); MS (ES+APCI) m / z 400.2 (M+1). Synthesis of tert-butyl 2-(5-(5-((cyclopentylcarbamoyl)oxy)-2-methoxyphenyl)pyridin-3- yl)-1H-pyrrole-1-carboxylate To a stirred solution of tert-butyl 2-(5-(5-hydroxy-2-methoxyphenyl)pyridin-3-yl)-1H-pyrrole- 1-carboxylate (0.1 g, 0.27 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.06 mL, 0.41 mmol) and cyclopentyl isocyanate (0.04 g, 0.33 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by automated normal-phase chromatography and eluted with ethyl acetate / petroleum ether to give tert-butyl 2-(5-(5-((cyclopentylcarbamoyl)oxy)-2- methoxyphenyl)pyridin-3-yl)-1H-pyrrole-1-carboxylate (110 mg) as off white solid. MS (ES+APCI) m / z 478.3 (M+1). Synthesis of 3-(5-(1H-pyrrol-2-yl)pyridin-3-yl)-4-methoxyphenyl cyclopentylcarbamate (Example-44) To a stirred solution of tert-butyl 2-(5-(5-((cyclopentylcarbamoyl)oxy)-2- methoxyphenyl)pyridin-3-yl)-1H-pyrrole-1-carboxylate (0.11 g, 0.25 mmol) in DCM (2 mL) 63336124\1 was added TFA (0.39 mL, 5.03 mmol) at 0°C under nitrogen atmosphere. Then reaction mixture was stirred at 40 °C for 30 minutes. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with 10% sodium bicarbonate solution and extracted with dichloromethane and washed with water. The organic layer was dried over sodium sulfate then evaporated under reduced pressure. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (17 mg) as an off white solid.1H-NMR (400 MHz, DMSO-d6): δ 11.48 (s, 1H), 8.82 (d, J = 2.40 Hz, 1H), 8.46 (d, J = 2.00 Hz, 1H), 8.06 (t, J = 2.00 Hz, 1H), 7.75 (d, J = 7.20 Hz, 1H), 7.15 (t, J = 3.20 Hz, 3H), 6.95 - 6.94 (m, 1H), 6.69 (s, 1H), 6.18 - 6.16 (m, 1H), 3.87 - 3.80 (m, 4H), 1.85 - 1.85 (m, 8H); MS (ES+APCI) m / z 378.2 (M+1). Synthesis of tert-butyl 2-(5-(5-((cyclohexylcarbamoyl)oxy)-2-methoxyphenyl)pyridin-3- yl)-1H-pyrrole-1-carboxylate To a stirred solution of tert-butyl 2-(5-(5-hydroxy-2-methoxyphenyl)pyridin-3-yl)-1H-pyrrole- 1-carboxylate (0.1 g, 0.27 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.06 mL, 0.41 mmol) and cyclohexyl isocyanate (0.04 g, 0.33 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by automated normal-phase chromatography and eluted with ethyl acetate / petroleum ether to give tert-butyl 2-(5-(5-((cyclohexylcarbamoyl)oxy)-2- methoxyphenyl)pyridin-3-yl)-1H-pyrrole-1-carboxylate (100 mg) as an off white solid. MS (ES+APCI) m / z 492.2 (M+1). Synthesis of 3-(5-(1H-pyrrol-2-yl)pyridin-3-yl)-4-methoxyphenyl cyclohexylcarbamate (Example-45) To a stirred solution of tert-butyl 2-(5-(5-((cyclohexylcarbamoyl)oxy)-2- 63336124\1 methoxyphenyl)pyridin-3-yl)-1H-pyrrole-1-carboxylate (0.1 g, 0.24 mmol) in DCM (2 mL) was added TFA (0.37 mL, 4.88 mmol) at 0°C under nitrogen atmosphere. Then reaction mixture was stirred at 40 °C for 30 minutes. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with 10% sodium bicarbonate solution and extracted with dichloromethane and washed with water. The organic layer was dried over sodium sulfate then evaporated under reduced pressure. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (47 mg) as an off white solid.1H-NMR (400 MHz, DMSO-d6): δ 11.48 (s, 1H), 8.82 (d, J = 2.00 Hz, 1H), 8.46 (d, J = 2.00 Hz, 1H), 8.06 (t, J = 2.00 Hz, 1H), 7.68 (d, J = 8.00 Hz, 1H), 7.15 (d, J = 2.80 Hz, 3H), 6.95 - 6.94 (m, 1H), 6.69 (t, J = 3.60 Hz, 1H), 6.18 - 6.16 (m, 1H), 3.35 (d, J = 17.60 Hz, 1H), 3.80 (s, 3H), 1.84 - 1.55 (m, 5H), 1.29 - 1.06 (m, 5H); MS (ES+APCI) m / z 392.2 (M+1). Synthesis of tert-butyl 2-(5-(5-((cycloheptylcarbamoyl)oxy)-2-methoxyphenyl)pyridin-3- yl)-1H-pyrrole-1-carboxylate To a stirred solution of tert-butyl 2-(5-(5-hydroxy-2-methoxyphenyl)pyridin-3-yl)-1H-pyrrole- 1-carboxylate (0.1 g, 0.27 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.06 mL, 0.41 mmol) and cycloheptyl isocyanate (0.05 g, 0.33 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by automated normal-phase chromatography and eluted with ethyl acetate / petroleum ether to give tert-butyl 2-(5-(5-((cycloheptylcarbamoyl)oxy)-2- methoxyphenyl)pyridin-3-yl)-1H-pyrrole-1-carboxylate (110 mg) as off white solid. MS (ES+APCI) m / z 506.2 (M+1). Synthesis of 3-(5-(1H-pyrrol-2-yl)pyridin-3-yl)-4-methoxyphenyl cycloheptylcarbamate (Example-46) 63336124\1 To a stirred solution of tert-butyl 2-(5-(5-((cycloheptylcarbamoyl)oxy)-2- methoxyphenyl)pyridin-3-yl)-1H-pyrrole-1-carboxylate (0.11 g, 0.22 mmol) in DCM (2 mL) was added TFA (0.33 mL, 4.35 mmol) at 0°C under nitrogen atmosphere. Then reaction mixture was stirred at 40 °C for 30 minutes. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with 10% sodium bicarbonate solution and extracted with dichloromethane and washed with water. The organic layer was dried over sodium sulfate then evaporated under reduced pressure. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (28 mg) as an off-white solid.1H-NMR (400 MHz, DMSO-d6): δ 11.48 (s, 1H), 8.82 (d, J = 2.40 Hz, 1H), 8.82 (d, J = 2.40 Hz, 1H), 8.06 (t, J = 2.00 Hz, 1H), 7.72 (d, J = 8.00 Hz, 1H), 7.14 (t, J = 2.00 Hz, 3H), 6.95 - 6.94 (m, 1H), 6.70 - 6.68 (m, 1H), 6.18 - 6.16 (m, 1H), 3.80 (s, 3H), 3.56 - 3.52 (m, 1H), 1.89 - 1.36 (m, 12H); MS (ES+APCI) m / z 406.2 (M+1). Synthesis of 3-bromo-5-(furan-2-yl)pyridine To a stirred solution of 3,5-dibromopyridine (2 g, 8.44 mmol) in 1,4-dioxane (20 mL) was added furan-2-ylboronic acid (1.20 g, 10.60 mmol) and Cs2CO3(5.5 g, 16.88 mmol) at RT. The reaction mixture was degassed for 15 minutes then Pd(PPh3)4 (0.68 g, 0.60 mmol) was added. The reaction mixture was stirred at 100 °C for 2 h under nitrogen atmosphere. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The residue was purified by automated normal-phase chromatography and eluted with ethyl acetate / petroleum ether to give 3-bromo-5-(furan-2- yl)pyridine (700 mg) as an off white solid.1H-NMR (400 MHz, DMSO-d6): δ 8.93 (d, J = 2.00 Hz, 1H), 8.61 (d, J = 2.40 Hz, 1H), 8.34 (t, J = 2.00 Hz, 1H), 7.88 (d, J = 1.20 Hz, 1H), 7.26 (d, J = 3.60 Hz, 1H), 6.69 - 6.677 (m, 1H); MS (ES+APCI) m / z 226.1(M+2) Synthesis of 3-(5-(furan-2-yl)pyridin-3-yl)phenol 63336124\1 To a stirred solution of 3-bromo-5-(furan-2-yl) pyridine (0.7 g, 3.12 mmol) in 1,4-dioxane (7 mL) and water (0.5 mL) was added (3-hydroxyphenyl)boronic acid (0.47 g, 3.44 mmol) and K2CO3(3.05 g, 9.37 mmol) at RT. The reaction mixture was degassed for 15 minutes then Pd(PPh3)4 (0.18 g, 0.16 mmol) was added. The reaction mixture was stirred at 90 °C for 5 h under nitrogen atmosphere. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The residue was purified by automated normal-phase chromatography and eluted with ethyl acetate / petroleum ether to give 3-(5-(furan-2-yl)pyridin-3-yl)phenol (0.68 g) as an off white solid.1H-NMR (400 MHz, DMSO-d6): δ 9.64 (s, 1H), 8.92 (d, J = 2.80 Hz, 1H), 8.72 (d, J = 2.80 Hz, 1H), 8.23 (t, J = 2.80 Hz, 1H), 7.86 - 7.85 (m, 1H), 7.35 - 7.12 (m, 4H), 6.87 - 6.84 (m, 1H), 6.68 - 6.66 (m, 1H); MS (ES+APCI) m / z 238.1 (M+1). Synthesis of 3-(5-(furan-2-yl)pyridin-3-yl)phenyl octylcarbamate (Example-47) To a stirred solution of 3-(5-(furan-2-yl)pyridin-3-yl)phenol (0.08 g, 0.33 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.07 mL, 0.50 mmol) and n-octyl isocyanate (0.06 g, 0.40 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 5 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (20 mg) as an off white solid.1H-NMR (400 MHz, DMSO-d6): δ 8.95 (d, J = 2.00 Hz, 1H), 8.81 (d, J = 2.00 Hz, 1H), 8.32 (t, J = 2.00 Hz, 1H), 7.88 - 7.87 (m, 1H), 7.82 (t, J = 5.60 Hz, 1H), 7.67 - 7.51 (m, 3H), 7.29 - 7.28 (m, 1H), 7.20 - 7.17 (m, 1H), 6.70 - 6.68 (m, 1H), 3.08 (t, J = 6.0Hz, 2H), 1.49 - 1.48 (m, 2H), 1.29 - 1.26 (m, 10H), 0.86 (t, J = 6.80 Hz, 3H); MS (ES+APCI) m / z 493.3 (M+1). Synthesis of 3-(5-(furan-2-yl)pyridin-3-yl)phenyl (cyclohexylmethyl)carbamate (Example- 48) 63336124\1 To a stirred solution of 3-(5-(furan-2-yl)pyridin-3-yl)phenol (0.08 g, 0.33 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.07 mL, 0.50 mmol) and cyclohexanemethyl isocyanate (0.06 g, 0.40 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 5 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (57 mg) as an off white solid.1H- NMR (400 MHz, DMSO-d6): δ 8.95 (d, J = 2.00 Hz, 1H), 8.81 (d, J = 2.40 Hz, 1H), 8.33 (t, J = 2.00 Hz, 1H), 7.88 - 7.83 (m, 2H), 7.67 - 7.65 (m, 1H), 7.57 - 7.51 (m, 2H), 7.29 - 7.28 (m, 1H), 7.20 - 7.18 (m, 1H), 6.70 - 6.68 (m, 1H), 2.94 (t, J = 6.40 Hz, 2H), 1.75 - 0.87 (m, 11H); MS (ES+APCI) m / z 377.3 (M+1). Synthesis of 3-(5-(furan-2-yl)pyridin-3-yl)phenyl benzylcarbamate (Example-49) To a stirred solution of 3-(5-(furan-2-yl)pyridin-3-yl)phenol (0.08 g, 0.33 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.07 mL, 0.47 mmol) and benzyl isocyanate (0.06 g, 0.40 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 5 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to give the target compound (50 mg) as an off white solid.1H-NMR (400 MHz, DMSO-d6): δ 8.95 (d, J = 2.00 Hz, 1H), 8.82 (d, J = 2.00 Hz, 1H), 8.40 (t, J = 6.00 Hz, 1H), 8.38 - 8.33 (m, 1H), 7.87 (d, J = 1.20 Hz, 1H), 7.68 - 7.52 (m, 3H), 7.39 - 7.34 (m, 4H), 7.30 - 7.21 (m, 3H), 6.70 - 6.69 (m, 1H), 4.32 (d, J = 6.40 Hz, 2H); MS (ES+APCI) m / z 371.3 (M+1). Synthesis of 3-(5-(furan-2-yl)pyridin-3-yl)phenyl cyclopentylcarbamate (Example-50) 63336124\1 To a stirred solution of 3-(5-(furan-2-yl)pyridin-3-yl)phenol (0.08 g, 0.33 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.07 mL, 0.50 mmol) and cyclopentyl isocyanate (0.05 g, 0.40 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 5 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (60 mg) as an off white solid.1H-NMR (400 MHz, DMSO-d6): δ 8.95 (d, J = 2.00 Hz, 1H), 8.81 (d, J = 2.00 Hz, 1H), 8.33 (t, J = 2.00 Hz, 1H), 7.88 - 7.85 (m, 2H), 7.66 (d, J = 8.00 Hz, 1H), 7.57 - 7.51 (m, 2H), 7.29 - 7.28 (m, 1H), 7.20 - 7.18 (m, 1H), 6.70 - 6.68 (m, 1H), 3.90 - 3.85 (m, 1H), 1.88 - 1.50 (m, 8H); MS (ES+APCI) m / z 349.3 (M+1). Synthesis of 3-(5-(furan-2-yl)pyridin-3-yl)phenyl cyclohexylcarbamate (Example-51) To a stirred solution of 3-(5-(furan-2-yl)pyridin-3-yl)phenol (0.08 g, 0.33 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.07 mL, 0.50 mmol) and cyclohexyl isocyanate (0.05 g, 0.40 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 5 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (63 mg) as an off white solid.1H-NMR (400 MHz, DMSO-d6): δ 8.95 (d, J = 2.00 Hz, 1H), 8.81 (d, J = 2.00 Hz, 1H), 8.33 (t, J = 2.40 Hz, 1H), 7.88 - 7.87 (m, 1H), 7.79 (d, J = 8.00 Hz, 1H), 7.66 (d, J = 8.40 Hz, 1H), 7.57 - 7.51 (m, 2H), 7.29 - 7.28 (m, 1H), 7.20 - 7.18 (m, 1H), 6.70 - 6.68 (m, 1H), 3.33 (s, 1H), 1.96 - 1.56 (m, 5H), 1.33 - 1.11 (m, 5H); MS (ES+APCI) m / z 363.4 (M+1). Synthesis of 3-(5-(furan-2-yl)pyridin-3-yl)phenyl cycloheptylcarbamate (Example-52) 63336124\1 To a stirred solution of 3-(5-(furan-2-yl)pyridin-3-yl)phenol (0.08 g, 0.33 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.07 mL, 0.50 mmol) and cycloheptyl isocyanate (0.060 g, 0.40 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 5 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (58 mg) as an off white solid.1H-NMR (400 MHz, DMSO-d6): δ 8.95 (d, J = 2.00 Hz, 1H), 8.81 (d, J = 2.40 Hz, 1H), 8.33 (t, J = 2.00 Hz, 1H), 7.88 - 7.82 (m, 2H), 7.65 (d, J = 8.00 Hz, 1H), 7.57 - 7.50 (m, 2H), 7.29 - 7.28 (m, 1H), 7.29 - 7.19 (3, 1H), 6.70 - 6.68 (m, 1H), 3.60 - 3.53 (m, 1H), 1.91 - 1.86 (m, 2H), 1.68 - 1.42 (m, 10H); MS (ES+APCI) m / z 377.3 (M+1). Synthesis of 3-(5-(furan-2-yl)pyridin-3-yl)-4-methoxyphenol To a stirred solution of 3-bromo-5-(furan-2-yl)pyridine (0.4 g, 1.78 mmol) in 1,4-dioxane (5 mL) and water (0.5 mL) was added (5-hydroxy-2-methoxyphenyl)boronic acid (0.33 g, 1.96 mmol) and K2CO3 (1.8 g, 5.40 mmol) at RT. The reaction mixture was degassed for 15 minutes then Pd(PPh3)4(0.10 g, 0.09 mmol) was added. The reaction mixture was stirred at 90 °C for 5 h under nitrogen atmosphere. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The residue was dissolved in ethyl acetate, washed with water followed by brine. The organic layer was dried over sodium sulfate then evaporated under reduced pressure. The residue was purified by automated normal-phase chromatography and eluted with ethyl acetate / petroleum ether to yield the target compound (440 mg) as an off white solid.1H-NMR (400 MHz, DMSO-d6): δ 9.16 (s, 1H), 8.88 (t, J = 2.80 Hz, 1H), 8.54 (d, J = 2.40 Hz, 1H), 8.09 (t, J = 2.80 Hz, 1H), 7.84 (t, J = 0.80 Hz, 1H), 7.18 (d, J = 4.00 Hz, 1H), 7.01 - 6.98 (m, 1H), 6.83 - 6.78 (m, 2H), 6.67 - 6.65 (m, 1H), 3.70 (s, 3H); MS (ES+APCI) m / z 268.3 (M+1). 63336124\1 Synthesis of 3-(5-(furan-2-yl)pyridin-3-yl)-4-methoxyphenyl octylcarbamate (Example- 53) To a stirred solution of 3-(5-(furan-2-yl)pyridin-3-yl)-4-methoxyphenol (0.07 g, 0.28 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.06 mL, 0.40 mmol) and n-octyl isocyanate (0.05 g, 0.32 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 5 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (47 mg) as an off white solid.1H- NMR (400 MHz, DMSO-d6): δ 8.90 (d, J = 2.40 Hz, 1H), 8.58 (d, J = 2.00 Hz, 1H), 8.13 (t, J = 2.00 Hz, 1H), 7.86 - 7.85 (m, 1H), 7.71 (t, J = 5.60 Hz, 1H), 7.20 - 7.15 (m, 4H), 6.67 - 6.66 (m, 1H), 3.81 (s, 3H), 3.07 - 3.02 (m, 2H), 1.46 (t, J = 7.20 Hz, 2H), 1.26 (d, J = 6.40 Hz, 10H), 0.86 (t, J = 6.80 Hz, 3H); MS (ES+APCI) m / z 423.4 (M+1). Synthesis of 3-(5-(furan-2-yl)pyridin-3-yl)-4-methoxyphenyl (cyclohexylmethyl)carbamate (Example-54) To a stirred solution of 3-(5-(furan-2-yl)pyridin-3-yl)-4-methoxyphenol (0.07 g, 0.28 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.06 mL, 0.40 mmol) and cyclohexanemethyl isocyanate (0.05 g, 0.32 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutesand then stirred at 75 °C for 5 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to give 3-(5-(furan-2-yl)pyridin-3-yl)-4- methoxyphenyl (cyclohexylmethyl)carbamate (32 mg) as an off white solid.1H-NMR (400 MHz, DMSO-d6): δ 8.90 (d, J = 2.00 Hz, 1H), 8.58 (d, J = 2.40 Hz, 1H), 8.13 (t, J = 2.40 Hz, 1H), 7.85 (d, J = 1.20 Hz, 1H), 7.73 (t, J = 6.00 Hz, 1H), 7.20 - 7.15 (m, 4H), 6.68 - 6.66 (m, 1H), 3.80 (s, 3H), 2.91 (t, J = 6.40 Hz, 2H), 1.73 - 1.61 (m, 5H), 1.46 - 1.42 (m, 1H), 1.24 - 1.11 63336124\1 (m, 3H), 0.92 (d, J = 12.00 Hz, 2H); MS (ES+APCI) m / z 407.3 (M+1). Synthesis of 3-(5-(furan-2-yl)pyridin-3-yl)-4-methoxyphenyl benzylcarbamate (Example- 55) To a stirred solution of 3-(5-(furan-2-yl)pyridin-3-yl)-4-methoxyphenol (0.07 g, 0.28 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.06 mL, 0.40 mmol) and benzyl isocyanate (0.05 g, 0.32 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 5 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (34 mg) as an off white solid.1H- NMR (400 MHz, DMSO-d6): δ 8.90 (d, J = 2.40 Hz, 1H), 8.59 (d, J = 2.00 Hz, 1H), 8.30 (t, J = 6.40 Hz, 1H), 8.14 (t, J = 2.40 Hz, 1H), 7.86 (d, J = 1.60 Hz, 1H), 7.38 - 7.31 (m, 4H), 7.29 - 7.25 (m, 1H), 7.22 - 7.15 (m, 4H), 6.67 (d, J = 1.60 Hz, 1H), 4.29 (d, J = 6.00 Hz, 2H), 3.81 (s, 3H); MS (ES+APCI) m / z 401.3 (M+1). Synthesis of 3-(5-(furan-2-yl)pyridin-3-yl)-4-methoxyphenyl cyclopentylcarbamate (Example-56) To a stirred solution of 3-(5-(furan-2-yl)pyridin-3-yl)-4-methoxyphenol (0.07 g, 0.28 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.06 mL, 0.40 mmol) and cyclopentyl isocyanate (0.04 g, 0.32 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 5 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (62 mg) as an off white solid.1H-NMR (400 MHz, DMSO-d6): δ 8.90 (d, J = 2.00 Hz, 1H), 8.59 (d, J = 2.00 Hz, 1H), 8.13 (t, J = 2.00 Hz, 1H), 7.86 - 7.85 (m, 1H), 7.76 (d, J = 7.60 Hz, 1H), 7.20 - 7.15 (m, 4H), 6.68 - 6.66 (m, 1H), 3.87 - 3.81 (m, 4H), 1.85 - 1.80 (m, 2H), 1.69 - 1.65 (m, 2H), 1.53 - 1.46 63336124\1 (m, 4H); MS (ES+APCI) m / z 379.3 (M+1). Synthesis of 3-(5-(furan-2-yl)pyridin-3-yl)-4-methoxyphenyl cyclohexylcarbamate (Example-57) To a stirred solution of 3-(5-(furan-2-yl)pyridin-3-yl)-4-methoxyphenol (0.07 g, 0.26 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.06 mL, 0.40 mmol) and cyclohexyl isocyanate (0.04 g, 0.32 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 5 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (45 mg) as an off white solid.1H- NMR (400 MHz, DMSO-d6): δ 8.90 (d, J = 2.40 Hz, 1H), 8.58 (d, J = 2.00 Hz, 1H), 8.13 (t, J = 2.00 Hz, 1H), 7.86 - 7.85 (m, 1H), 7.69 (d, J = 8.00 Hz, 1H), 7.20 - 7.15 (m, 4H), 6.68 - 6.66 (m, 1H), 3.81 (s, 3H), 3.32 (d, J = 12.00 Hz, 1H), 1.83 (d, J = 8.80 Hz, 2H), 1.72 - 1.69 (m, 2H), 1.56 (d, J = 12.40 Hz, 1H), 1.28 - 1.10 (m, 5H); MS (ES+APCI) m / z 393.4 (M+1). Synthesis of 3-(5-(furan-2-yl)pyridin-3-yl)-4-methoxyphenyl cycloheptylcarbamate (Example-58) To a stirred solution of 3-(5-(furan-2-yl)pyridin-3-yl)-4-methoxyphenol (0.07 g, 0.28 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.06 mL, 0.40 mmol) and cycloheptyl isocyanate (0.05 g, 0.32 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 5 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (35 mg) as an off white solid.1H-NMR (400 MHz, DMSO-d6): δ 8.90 (d, J = 2.40 Hz, 1H), 8.58 (d, J = 2.40 Hz, 1H), 8.13 (t, J = 2.00 Hz, 1H), 7.86 - 7.85 (m, 1H), 7.72 (d, J = 7.60 Hz, 1H), 7.20 - 7.15 (m, 4H), 6.67 - 6.66 (m, 1H), 3.80 (s, 3H), 3.54 (t, J = 4.40 Hz, 1H), 1.89 - 1.83 (m, 2H), 1.66 - 1.37 (m, 63336124\1 10H); MS (ES+APCI) m / z 407.3 (M+1). Synthesis of 3-bromo-5-(thiophen-2-yl)pyridine To a stirred solution of 3,5-dibromopyridine (1 g, 4.22 mmol) in 1,4-dioxane (10 mL) was added thiophen-2-ylboronic acid (1.13 g, 8.86 mmol) and Cs2CO3 (2.27 g, 6.97 mmol) at RT. The reaction mixture was degassed for 15 minutes then Pd(PPh3)4(0.34 g, 0.30 mmol) was added. The reaction mixture was stirred at 100 °C for 2 h under nitrogen atmosphere. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The residue was purified by automated normal-phase chromatography and eluted with ethyl acetate / petroleum ether to give 3-bromo-5-(thiophen-2- yl) pyridine (400 mg) as an off white solid. MS (ES+APCI) m / z 240.1. Synthesis of 3-(5-(thiophen-2-yl)pyridin-3-yl)phenol To a stirred solution of 3-bromo-5-(thiophen-2-yl)pyridine (0.4 g, 1.67 mmol) in 1,4-dioxane (4 mL) and water (0.5 mL) was added (3-hydroxyphenyl)boronic acid (0.35 g, 2.50 mmol) and K2CO3 (0.69 g, 5.00 mmol) at RT. The reaction mixture was degassed for 15 minutes then Pd(PPh3)4(0.1 g, 0.08 mmol) was added. The reaction mixture was stirred at 90 °C for 16 h under nitrogen atmosphere. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The residue was dissolved in minimum amount of DCM and was added petroleum ether slowly. The precipitated solid was filtered and dried to give 3-(5-(thiophen-2-yl)pyridin-3-yl)phenol (320 mg) as an off white solid. MS (ES+APCI) m / z 254.3 (M+1). Synthesis of 3-(5-(thiophen-2-yl)pyridin-3-yl)phenyl octylcarbamate (Example-59) 63336124\1 To a stirred solution of 3-(5-(thiophen-2-yl)pyridin-3-yl)phenol (0.08 g, 0.32 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.07 mL, 0.47 mmol) and n-octyl isocyanate (0.058 g, 0.38 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (12 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 8.89 (d, J = 2.00 Hz, 1H), 8.82 (d, J = 2.00 Hz, 1H), 8.30 - 8.29 (m, 1H), 7.83 - 7.80 (m, 2H), 7.71 - 7.66 (m, 2H), 7.58 - 7.51 (m, 2H), 7.24 - 7.18 (m, 2H), 3.10 - 3.05 (m, 2H), 1.49 (t, J = 6.80 Hz, 2H), 1.29 - 1.25 (m, 10H), 0.86 (t, J = 7.20 Hz, 3H); MS (ES+APCI) m / z 409.3 (M+1). Synthesis of 3-(5-(thiophen-2-yl)pyridin-3-yl)phenyl (cyclohexylmethyl)carbamate (Example-60) To a stirred solution of 3-(5-(thiophen-2-yl)pyridin-3-yl)phenol (0.08 g, 0.32 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.07 mL, 0.47 mmol) and cyclohexanemethyl isocyanate (0.053 g, 0.38 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (28 mg) as an off white solid.1HNMR (400 MHz, DMSO-d6) δ 8.89 (d, J = 2.40 Hz, 1H), 8.82 (d, J = 2.00 Hz, 1H), 8.30 (t, J = 2.00 Hz, 1H), 7.86 - 7.81 (m, 2H), 7.71 - 7.66 (m, 2H), 7.59 - 7.51 (m, 2H), 7.24 - 7.18 (m, 2H), 2.95 - 2.92 (m, 2H), 1.75 - 0.87 (m, 11H); MS (ES+APCI) m / z 393.4 (M+1). Synthesis of 3-(5-(thiophen-2-yl)pyridin-3-yl)phenyl benzylcarbamate (Example-61) 63336124\1 To a stirred solution of 3-(5-(thiophen-2-yl)pyridin-3-yl)phenol (0.08 g, 0.32 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.07 mL, 0.47 mmol) and benzyl isocyanate (0.05 g, 0.38 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (30 mg) as an off white solid.1HNMR (400 MHz, DMSO-d6) δ 8.89 (d, J = 2.00 Hz, 1H), 8.83 (d, J = 2.00 Hz, 1H), 8.40 (t, J = 6.40 Hz, 1H), 8.31 (t, J = 2.40 Hz, 1H), 7.82 - 7.81 (m,1H), 7.71 - 7.68 (m, 2H), 7.62 (t, J = 1.60 Hz, 1H), 7.54 (t, J = 8.00 Hz, 1H), 7.39 - 7.22 (m, 7H), 4.31 (d, J = 6.40 Hz, 2H); MS (ES+APCI) m / z 387.2 (M+1). Synthesis of 3-(5-(thiophen-2-yl)pyridin-3-yl)phenyl cyclopentylcarbamate (Example-62) To a stirred solution of 3-(5-(thiophen-2-yl)pyridin-3-yl)phenol (0.08 g, 0.32 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.07 mL, 0.47 mmol) and cyclopentyl isocyanate (0.042 g, 0.38 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to give yield the target compound (30 mg) as an off white solid.1HNMR (400 MHz, DMSO-d6) δ 8.89 (d, J = 2.40 Hz, 1H), 8.82 (d, J = 2.00 Hz, 1H), 8.30 (t, J = 2.00 Hz, 1H), 7.87 - 7.81 (m, 2H), 7.71 - 7.66 (m, 2H), 7.60 - 7.51 (m, 2H), 7.24 - 7.19 (m, 2H), 3.90 - 3.85 (m, 1H), 1.88 - 1.47 (m, 8H); MS (ES+APCI) m / z 365.3 (M+1). Synthesis of 3-(5-(thiophen-2-yl)pyridin-3-yl)phenyl cyclohexylcarbamate (Example-63) 63336124\1 To a stirred solution of 3-(5-(thiophen-2-yl)pyridin-3-yl)phenol (0.08 g, 0.32 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.07 mL, 0.47 mmol) and cyclohexyl isocyanate (0.05 g, 0.38 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (35 mg) as an off white solid.1HNMR (400 MHz, DMSO-d6) δ 8.89 (d, J = 2.40 Hz, 1H), 8.82 (d, J = 2.00 Hz, 1H), 8.30 (t, J = 2.00 Hz, 1H), 7.82 - 7.78 (m, 2H), 7.71 - 7.66 (m, 2H), 7.59 - 7.51 (m, 2H), 7.24 - 7.18 (m, 2H), 3.36 - 3.36 (m, 1H), 1.90 - 1.08 (m, 10H); MS (ES+APCI) m / z 379.3 (M+1). Synthesis of 3-(5-(thiophen-2-yl)pyridin-3-yl)phenyl cycloheptylcarbamate (Example-64) To a stirred solution of 3-(5-(thiophen-2-yl)pyridin-3-yl)phenol (0.08 g, 0.32 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.07 mL, 0.47 mmol) and cycloheptyl isocyanate (0.053 g, 0.38 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (33 mg) as an off white solid.1HNMR (400 MHz, DMSO-d6) δ 8.89 (d, J = 2.00 Hz, 1H), 8.84 (d, J = 2.40 Hz, 1H), 8.30 (t, J = 2.00 Hz, 1H), 8.29 - 7.81 (m, 2H), 7.71 - 7.65 (m, 2H), 7.59 - 7.50 (m, 2H), 7.24 - 7.18 (m, 2H), 3.60 - 3.53 (m, 1H), 1.91 - 1.86 (m, 2H), 1.67 - 1.39 (m, 10H); MS (ES+APCI) m / z 393.4 (M+1). Synthesis of 4-methoxy-3-(5-(thiophen-2-yl)pyridin-3-yl)phenol 63336124\1 To a stirred solution of 3-bromo-5-(thiophen-2-yl)pyridine (0.5 g, 2.08 mmol) in 1,4-dioxane (5 mL) and water (0.5 mL) was added (5-hydroxy-2-methoxyphenyl)boronic acid (0.53 g, 3.12 mmol) and K2CO3 (0.86 g, 6.25 mmol) at RT. The reaction mixture was degassed for 15 minutes then Pd(PPh3)4 (0.12 g, 0.10 mmol) was added. The reaction mixture was stirred at 90 °C for 16 h under nitrogen atmosphere. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The residue was dissolved in ethyl acetate, washed with water followed by brine. The organic layer was dried over sodium sulfate then evaporated under reduced pressure. The residue was purified by automated normal-phase chromatography and eluted with ethyl acetate / petroleum ether to give 4-methoxy-3-(5-(thiophen-2-yl)pyridin-3-yl)phenol (450 mg) as an off white solid. MS (ES+APCI) m / z 284.1 (M+1). Synthesis of 4-methoxy-3-(5-(thiophen-2-yl)pyridin-3-yl)phenyl octylcarbamate (Example-65) To a stirred solution of 4-methoxy-3-(5-(thiophen-2-yl)pyridin-3-yl)phenol (0.08 g, 0.28 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.06 mL, 0.34 mmol) and octyl isocyanate (0.05 g, 0.34 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (45 mg) as an off white solid.1HNMR (400 MHz, DMSO-d6) δ 8.85 (d, J = 2.40 Hz, 1H), 8.60 (d, J = 2.00 Hz, 1H), 8.10 (t, J = 2.40 Hz, 1H), 7.72-7.67 (m, 3H), 7.22-7.16 (m, 4H), 3.81 (s, 3H), 3.07-3.02 (m, 2H), 1.46 (t, J = 7.20 Hz, 2H), 1.27-1.25 (m, 10H), 0.87-0.84 (m, 3H); MS (ES+APCI) m / z 439.3 (M+1). Synthesis of 4-methoxy-3-(5-(thiophen-2-yl)pyridin-3-yl)phenyl (cyclohexylmethyl)carbamate (Example-66) 63336124\1 To a stirred solution of 4-methoxy-3-(5-(thiophen-2-yl)pyridin-3-yl)phenol (0.08 g, 0.28 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.06 mL, 0.34 mmol) and cyclohexanemethyl isocyanate (0.05 g, 0.34 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (36 mg) as an off white solid.1HNMR (400 MHz, DMSO-d6) δ 8.85 (d, J = 2.00 Hz, 1H), 8.60 (d, J = 2.00 Hz, 1H), 8.10 (t, J = 2.00 Hz, 1H), 7.75 - 7.67 (m, 3H), 7.22 - 7.15 (m, 4H), 3.81 (s, 3H), 2.91 (t, J = 6.40 Hz, 2H), 1.73 - 0.88 (m, 11H); MS (ES+APCI) m / z 423.3 (M+1). Synthesis of 4-methoxy-3-(5-(thiophen-2-yl)pyridin-3-yl)phenyl benzylcarbamate (Example-67) To a stirred solution of 4-methoxy-3-(5-(thiophen-2-yl)pyridin-3-yl)phenol (0.08 g, 0.28 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.06 mL, 0.34 mmol) and benzyl isocyanate (0.05 g, 0.34 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (42 mg) as an off white solid.1HNMR (400 MHz, DMSO-d6) δ 8.85 (d, J = 2.00 Hz, 1H), 8.61 (d, J = 2.00 Hz, 1H), 8.29 (t, J = 6.40 Hz, 1H), 8.11 (t, J = 2.00 Hz, 1H), 7.72-7.67 (m, 2H), 7.38-7.28 (m, 4H), 7.27-7.15 (m, 5H), 4.29 (d, J = 6.00 Hz, 2H), 3.81 (s, 3H); MS (ES+APCI) m / z 417.2 (M+1). Synthesis of 4-methoxy-3-(5-(thiophen-2-yl)pyridin-3-yl)phenyl cyclopentylcarbamate (Example-68) 63336124\1 To a stirred solution of 4-methoxy-3-(5-(thiophen-2-yl)pyridin-3-yl)phenol (0.08 g, 0.28 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.06 mL, 0.34 mmol) and cyclopentyl isocyanate (0.04 g, 0.34 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (55 mg) as an off white solid.1HNMR (400 MHz, DMSO-d6) δ 8.85 (d, J = 2.40 Hz, 1H), 8.60 (d, J = 2.00 Hz, 1H), 8.10 (t, J = 2.40 Hz, 1H), 7.77 - 7.67 (m, 3H), 7.22 - 7.16 (m, 4H), 3.87 - 3.84 (m, 1H), 3.81 (s, 3H), 1.84 - 1.48 (m, 8H); MS (ES+APCI) m / z 395.2 (M+1). Synthesis of 4-methoxy-3-(5-(thiophen-2-yl)pyridin-3-yl)phenyl cyclohexylcarbamate (Example-69) To a stirred solution of 4-methoxy-3-(5-(thiophen-2-yl)pyridin-3-yl)phenol (0.08 g, 0.28 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.06 mL, 0.34 mmol) and cyclohexyl isocyanate (0.04 g, 0.34 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (10 mg) as an off white solid.1HNMR (400 MHz, DMSO-d6) δ 8.85 (d, J = 2.40 Hz, 1H), 8.60 (d, J = 2.00 Hz, 1H), 8.10 (t, J = 2.40 Hz, 1H), 7.67 - 7.72 (m, 3H), 7.22 - 7.20 (m, 2H), 7.16 (d, J = 1.20 Hz, 2H), 3.81 (s, 3H), 1.84 - 1.09 (m, 10H); MS (ES+APCI) m / z 409.3 (M+1). Synthesis of 4-methoxy-3-(5-(thiophen-2-yl)pyridin-3-yl)phenyl cycloheptylcarbamate (Example-70) 63336124\1 To a stirred solution of 4-methoxy-3-(5-(thiophen-2-yl)pyridin-3-yl)phenol (0.08 g, 0.28 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.06 mL, 0.34 mmol) and cycloheptyl isocyanate (0.05 g, 0.34 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (35 mg) as an off white solid.1HNMR (400 MHz, DMSO-d6) δ 8.85 (d, J = 2.40 Hz, 1H), 8.60 (d, J = 2.00 Hz, 1H), 8.10 (t, J = 2.00 Hz, 1H), 7.73 - 7.67 (m, 3H), 7.22 - 7.15 (m, 4H), 3.81 (s, 3H), 3.57 - 3.49 (m, 1H), 1.89 - 1.40 (m, 12H); MS (ES+APCI) m / z 423.2 (M+1) Scheme III: Reagents and conditions: a) Pd(PPh3)4, aq K2CO3, 1,4-dioxane, 90oC, 12 h or Pd(dppf)Cl2, KOAc, 1,4-dioxane, 80oC, 4 h; b) TOSMIC, K2CO3, MeOH, 80oC, 1 h; c) R3-NCO, TEA, ACN, 75oC, 12 h. Synthesis of 3-(5-(oxazol-2-yl)pyridin-3-yl)phenol 63336124\1 To a solution of TOSMIC (0.068 g, 0.35 mmol) in methanol (6 mL) was added K2CO3 (0.14 g, 1.054 mmol) and at RT and stirred for 30 minutes under nitrogen atmosphere. 5-(3- hydroxyphenyl)nicotinaldehyde (0.07 g, 0.35 mmol) was then added to the resulting mixture and stirred at RT for additional 30 minutes. The reaction mixture was heated at 70oC for 1 h under nitrogen atmosphere. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The residue was dissolved in ethyl acetate, washed with water followed by brine. The organic layer was dried over sodium sulfate and then the solvent was evaporated under reduced pressure. The compound was purified by column chromatography on silica gel eluting with hexane / EtOAc (gradient 10-70% EtOAc) to yield the 3-(5-(oxazol-2-yl)pyridin-3-yl)phenol (40 mg) as a white solid.1H NMR (400 MHz, DMSO-d6): δ 9.70 (s, 1H), 8.94 (s, 1H), 8.82 (s, 1H), 8.58 (s, 1H), 8.32 (s, 1H), 7.97 (s, 1H), 7.34 (t, J = 8.1 Hz, 1H), 7.22 (d, J = 8.1 Hz, 1H), 7.15 (s, 1H), 6.87 (dd, J = 8.1 Hz, 1H). Synthesis of 3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl pentylcarbamate (Example-71) To a stirred solution of 3-(5-(oxazol-2-yl)pyridin-3-yl)phenol (0.08 g, 0.33 mmol) in anhydrous acetonitrile (2 mL) under a nitrogen atmosphere was added TEA (0.05 mL, 0.33 mmol) and n- pentyl isocyanate (0.06 g, 0.40 mmol) at RT. The reaction mixture was stirred at RT for 10 minutes and then heated to 75 °C for 12 h, under nitrogen atmosphere. The progress of the reaction was monitored by TLC. Upon completion, the reaction mixture was cooled to RT, and the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel, eluting with hexane / EtOAc (gradient 40–60% EtOAc) to yield the target compound (46 mg) as an off white solid.1H NMR (400 MHz, CDCl3): δ 8.84 (d, J = 2.1 Hz, 1H), 8.73 (d, J = 2.2 Hz, 1H), 8.03 (t, J = 2.2 Hz, 1H), 7.93 (s, 1H), 7.30 – 7.47 (m, 4H), 7.15 (ddd, J = 7.8, 2.4, 1.4 Hz, 1H), 4.99 (s, 1H), 3.03 – 3.41 (m, 2H), 1.54 (t, J = 7.1 Hz, 2H), 1.11 – 1.44 (m, 4H), 0.77 – 0.91 (m, 3H). 63336124\1 Synthesis of 3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl heptylcarbamate (Example-72) To a stirred solution of 3-(5-(oxazol-2-yl)pyridin-3-yl)phenol (0.08 g, 0.33 mmol) in anhydrous acetonitrile (2 mL) under a nitrogen atmosphere was added TEA (0.05 mL, 0.33 mmol) and n- heptyl isocyanate (0.05 g, 0.33 mmol) at RT. The reaction mixture was stirred at RT for 10 minutes and then heated to 75 °C for 12 h, under nitrogen atmosphere. The progress of the reaction was monitored by TLC. Upon completion, the reaction mixture was cooled to RT, and the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel, eluting with hexane / EtOAc (gradient 40–60% EtOAc) to yield the target compound (48 mg) as a as an off white solid.1H NMR (400 MHz, CDCl3): δ 8.84 (d, J = 2.1 Hz, 1H), 8.72 (d, J = 2.2 Hz, 1H), 8.02 (t, J = 2.1 Hz, 1H), 7.93 (s, 1H), 7.93 – 7.49 (m, 4H), 7.30 – 7.15 (m, 1H, J = 7.8, 2.3, 1.4 Hz), 3.22 (td, J = 7.2, 6.0 Hz, 2H), 1.70 – 1.41 (m, 4H), 1.41 – 1.13 (m, 8H), 0.93 – 0.69 (m, 3H) Synthesis of 3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl octylcarbamate (Example-73) To a stirred solution of 3-(5-(oxazol-2-yl)pyridin-3-yl)phenol (0.08 g, 0.33 mmol) in anhydrous acetonitrile (2 mL) under a nitrogen atmosphere, TEA (0.05 mL, 0.33 mmol) and n-octyl isocyanate (0.05 g, 0.33 mmol) were added at RT. The reaction mixture was stirred at RT for 10 minutes and then heated to 75 °C for 12 h, under nitrogen atmosphere. The progress of the reaction was monitored by TLC. Upon completion, the reaction mixture was cooled to RT, and the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel, eluting with hexane / EtOAc (gradient 40-60% EtOAc) to yield the target compound (44 mg) as an off white solid.1H NMR (400 MHz, CDCl3): δ 8.91 (d, J = 2.1 Hz, 1H), 8.79 (d, J = 2.2 Hz, 1H), 8.09 (t, J = 2.2 Hz, 1H), 8.00 (s, 1H), 7.51 (s, 1H), 7.42 – 7.51 (m, 2H), 7.40 (t, J = 2.0 Hz, 1H), 7.22 (ddd, J = 7.8, 2.3, 1.4 Hz, 1H), 5.10 (t, J = 63336124\1 6.0 Hz, 1H), 3.29 (td, J = 7.2, 6.0 Hz, 2H), 1.39 – 2.82 (m, 2H), 1.21 – 1.38 (m, 10H), 0.97 – 0.85 (m, 3H). Synthesis of 3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl (cyclohexylmethyl)carbamate (Example-74) To a stirred solution of 3-(5-(oxazol-2-yl)pyridin-3-yl)phenol (0.08 g, 0.33 mmol) in anhydrous acetonitrile (2 mL) under a nitrogen atmosphere, TEA, (0.05 mL, 0.33 mmol) and cyclohexanemethyl isocyanate (0.05 g, 0.40 mmol) were added at RT. The reaction mixture was stirred at RT for 10 minutes and then heated to 75 °C for 12 h, under nitrogen atmosphere. The progress of the reaction was monitored by TLC. Upon completion, the reaction mixture was cooled to RT, and the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel, eluting with hexane / EtOAc (gradient 40-60% EtOAc) to yield the target compound (43 mg) as an off white solid.1H NMR (400 MHz, CDCl3): δ 8.91 (d, J = 2.1 Hz, 1H), 8.79 (d, J = 2.2 Hz, 1H), 8.09 (t, J = 2.2 Hz, 1H), 8.00 (s, 1H), 7.51 (s, 1H), 7.43 – 7.51 (m, 2H), 7.41 (t, J = 2.0 Hz, 1H), 7.22 (ddd, J = 7.8, 2.3, 1.3 Hz, 1H), 5.14 (t, J = 6.2 Hz, 1H), 3.14 (t, J = 6.5 Hz, 2H), 1.62 – 2.22 (m, 5H), 1.15 – 1.36 (m, 4H), 1.08 – 0.82 (m, 2H) Synthesis of 3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl cyclopentylcarbamate (Example-75) To a stirred solution of 3-(5-(oxazol-2-yl)pyridin-3-yl)phenol (0.08 g, 0.33 mmol) in anhydrous acetonitrile (2 mL) under a nitrogen atmosphere, TEA (0.05 mL, 0.33 mmol) and cyclopentyl isocyanate (0.04 g, 0.40 mmol) were added at RT. The reaction mixture was stirred at RT for 10 minutes and then heated to 75 °C for 12 h, under nitrogen atmosphere. The reaction progress was monitored by TLC. Upon completion, the reaction mixture was cooled to RT and the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel, eluting with hexane / EtOAc (gradient 40-60% EtOAc) to yield the 63336124\1 target compound (42 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.19 – 9.46 (m, 1H), 8.96 – 9.24 (m, 1H), 8.34 (s, 1H), 7.67 – 8.14 (m, 4H), 7.23 – 7.68 (m, 2H), 5.47 (d, J = 7.5 Hz, 1H), 4.41 (q, J = 6.8 Hz, 1H), 2.12 – 2.36 (m, 2H), 1.78 – 2.19 (m, 4H), 1.62 – 1.75 (m, 2H), 8.45 (t, J = 2.1 Hz, 1H). Synthesis of 3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl cyclohexylcarbamate (Example-76) To a stirred suspension of 3-(5-(oxazol-2-yl)pyridin-3-yl)phenol (0.08 g, 0.33 mmol) in anhydrous acetonitrile (2 mL), TEA (0.05 mL, 0.33 mmol) and cyclohexyl isocyanate (0.04 g, 0.39 mmol) were added at RT under a nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated to 75 °C for 12 h, under nitrogen atmosphere. The reaction progress was monitored by TLC. Upon completion, the reaction mixture was cooled to RT, and the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel, eluting with hexane / EtOAc (gradient 40-60% EtOAc) to yield the target compound (44 mg) as an off white solid.1H NMR (400 MHz, CDCl3) δ 8.91 (d, J = 2.1 Hz, 1H), 8.80 (d, J = 2.2 Hz, 1H), 8.10 (t, J = 2.2 Hz, 1H), 7.43 – 7.56 (m, 3H), 7.41 (t, J = 2.0 Hz, 1H), 7.22 (ddd, J = 7.8, 2.3, 1.3 Hz, 1H), 4.97 (d, J = 8.2 Hz, 1H), 4.04 (d, J = 8.0 Hz, 1H), 3.39 – 3.70 (m, 1H), 1.52 – 1.86 (m, 4H), 1.93 (dd, J = 12.6, 3.9 Hz, 2H), 1.00 – 1.43 (m, 2H). Synthesis of 3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl ((1s,3s)-adamantan-1-yl)carbamate (Example-77) To a stirred solution of 3-(5-(oxazol-2-yl)pyridin-3-yl)phenol (0.08 g, 0.33 mmol) in anhydrous acetonitrile (2 mL) under a nitrogen atmosphere, TEA (0.05 mL, 0.33 mmol) and adamantyl isocyanate (0.058 g, 0.39 mmol) were added at RT. The reaction mixture was stirred at RT for 10 minutes and then heated to 75 °C for 12 h, under nitrogen atmosphere. The progress of the 63336124\1 reaction was monitored by TLC. Upon completion, the reaction mixture was cooled to RT and the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel, eluting with hexane / EtOAc (gradient 40-60% EtOAc) to yield the target compound (49 mg) as an off white solid.1H NMR (400 MHz, CDCl3) δ 8.84 (d, J = 2.1 Hz, 1H), 8.72 (d, J = 2.2 Hz, 1H), 8.02 (t, J = 2.1 Hz, 1H), 7.93 (s, 1H), 7.31 – 7.56 (m, 4H), 7.14 (ddd, J = 7.9, 2.3, 1.3 Hz, 1H), 4.89 (s, 1H), 2.05 (q, J = 3.2 Hz, 3H), 1.89 – 2.00 (m, 7H), 1.63 (t, J = 3.1 Hz, 5H). Synthesis of Synthesis of 4-methoxy-3-(5-(oxazol-2-yl)pyridin-3-yl)phenol To a solution of TOSMIC (0.085 g, 0.43 mmol) in methanol (5 mL) was added K2CO3 (0.17 g, 1.29 mmol) and at RT and stirred for 30 minutes under nitrogen atmosphere.5-(5-hydroxy-2- methoxyphenyl)nicotinaldehyde (0.1 g, 0.43 mmol) was then added to the resulting mixture and stirred at RT for additional 30 minutes. The reaction mixture was heated at 70oC for 1 h under nitrogen atmosphere. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The residue was dissolved in ethyl acetate, washed with water followed by brine. The organic layer was dried over sodium sulfate and then the solvent was evaporated under reduced pressure. The compound was purified by column chromatography on silica gel eluting with hexane / EtOAc (gradient 30-70% EtOAc) to yield the 4-methoxy-3-(5-(oxazol-2-yl)pyridin-3- yl)phenol (65 mg) as a pale-yellow solid. Synthesis of 4-methoxy-3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl octylcarbamate (Example- 78) To a stirred solution of 4-methoxy-3-(5-(oxazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.37 mmol) in anhydrous acetonitrile (2 mL), TEA (0.05 mL, 0.37 mmol), and n-octyl isocyanate (0.06 g, 0.44 63336124\1 mmol) were added at RT under a nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes, then heated to 75 °C and stirred for 12 h, under nitrogen atmosphere. The reaction progress was monitored by TLC. Upon completion, the reaction mixture was cooled to RT and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with a hexane / ethyl acetate (EtOAc) gradient (40- 60% EtOAc) to yield the target compound (60 mg) as an off white solid.1H NMR (400 MHz, deuterated methanol (MeOD)) δ 8.76 (d, J = 2.0 Hz, 1H), 8.56 (d, J = 2.0 Hz, 1H), 8.25 (s, 1H), 8.18 (t, J = 2.1 Hz, 1H), 7.64 (s, 1H), 7.06 (dd, J = 6.1, 3.0 Hz, 3H), 3.08 (t, J = 7.0 Hz, 2H), 1.46 (p, J = 7.2 Hz, 2H), 1.21 (dd, J = 14.5, 8.9 Hz, 11H), 0.78 (d, J = 6.9 Hz, 3H). Synthesis of 4-methoxy-3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl (cyclohexylmethyl) carbamate (Example-79) To a stirred solution of 4-methoxy-3-(5-(oxazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.37 mmol) in anhydrous acetonitrile (2 mL), TEA (0.05 mL, 0.37 mmol), and cyclohexanemethyl isocyanate (0.06 g, 0.44 mmol) were added at RT under a nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes, then heated to 75 °C and stirred for 12 h, under nitrogen atmosphere. The reaction progress was monitored by TLC. Upon completion, the reaction mixture was cooled to RT and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with a hexane / ethyl acetate (EtOAc) gradient (40-60% EtOAc) to yield the target compound (55 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 8.94 (d, J = 2.1 Hz, 1H), 8.69 (s, 1H), 8.51 (s, 1H), 8.23 (td, J = 2.1, 1.1 Hz, 1H), 7.88 (s, 1H), 7.78 (t, J = 5.9 Hz, 1H), 7.44 – 7.66 (m, 1H), 7.29 – 7.43 (m, 2H), 7.18 (ddd, J = 8.9, 4.1, 2.9 Hz, 1H), 3.26 (s, 3H), 2.85 (t, J = 6.4 Hz, 2H), 1.62 (td, J = 16.2, 8.8 Hz, 6H), 0.95 – 1.31 (m, 3H), 0.83 (qd, J = 12.7, 3.8 Hz, 2H). Synthesis of 4-methoxy-3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl cyclopentylcarbamate (Example-80) 63336124\1 To a stirred solution of 4-methoxy-3-(5-(oxazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.37 mmol) in anhydrous acetonitrile (2 mL), TEA (0.05 mL, 0.37 mmol), and cyclopentyl isocyanate (0.04 g, 0.44 mmol) were added at RT under a nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes, then heated to 75 °C and stirred for 12 h, under nitrogen atmosphere. The reaction progress was monitored by TLC. Upon completion, the reaction mixture was cooled to RT and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with a hexane / ethyl acetate (EtOAc) gradient (40- 60% EtOAc) to yield the target compound (57 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.01 (d, J = 2.1 Hz, 1H), 8.76 (t, J = 2.0 Hz, 1H), 8.58 (s, 1H), 8.31 (td, J = 2.2, 1.1 Hz, 1H), 7.96 (s, 1H), 7.81 (d, J = 7.9 Hz, 1H), 7.35 – 7.51 (m, 2H), 7.25 (ddd, J = 8.9, 4.2, 2.9 Hz, 1H), 3.26 (s, 3H), 1.78 – 1.91 (m, 2H), 1.71 (t, J = 6.3 Hz, 2H), 1.57 (d, J = 12.6 Hz, 1H), 1.18 – 1.40 (m, 4H). Synthesis of 4-methoxy-3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl cyclohexylcarbamate (Example-81) To a stirred solution of 4-methoxy-3-(5-(oxazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.37 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.05 mL, 0.37 mmol) and cyclohexyl isocyanate (0.05 g, 0.44 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h, under nitrogen atmosphere. The reaction progress was monitored by TLC. Upon completion, the reaction mixture was cooled to RT and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 40-60% EtOAc) to yield the target compound to (59 mg) as an off white solid.1H NMR (400 MHz, MeOD) δ 8.77 (d, J = 2.0 Hz, 1H), 8.56 (d, J = 2.0 Hz, 1H), 8.25 (s, 1H), 8.19 (d, J = 2.2 Hz, 1H), 7.65 (s, 1H), 6.95 – 7.12 (m, 3H), 3.75 (s, 3H), 3.33 (ddt, J = 10.4, 7.5, 3.9 Hz, 1H), 1.85 (dd, J = 10.0, 5.1 Hz, 63336124\1 2H), 1.68 (dt, J = 12.3, 3.6 Hz, 2H), 1.54 (dd, J = 10.5, 6.6 Hz, 1H), 1.04 – 1.37 (m, 5H). Synthesis of 4-methoxy-3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl (4- methylcyclohexyl)carbamate (Example-82) To a stirred solution of 4-methoxy-3-(5-(oxazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.37 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.05 mL, 0.37 mmol) and trans-4- Methylcyclohexyl isocyanate (0.06 g, 0.44 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h, under nitrogen atmosphere. The reaction progress was monitored by TLC. Upon completion, the reaction mixture was cooled to RT and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 40-60% EtOAc) to yield the target compound to (55 mg) as an off white solid.1H NMR (400 MHz, MeOD) δ 8.77 (d, J = 2.0 Hz, 1H), 8.56 (d, J = 2.0 Hz, 1H), 8.25 (s, 1H), 8.18 (d, J = 2.1 Hz, 1H), 7.64 (s, 1H), 6.88 – 7.31 (m, 3H), 3.75 (s, 3H), 3.22 – 3.46 (m, 1H), 1.87 (dd, J = 13.4, 3.7 Hz, 2H), 1.60 – 1.80 (m, 2H), 1.10 – 1.43 (m, 3H), 0.96 (td, J = 12.6, 3.3 Hz, 2H), 0.81 (d, J = 6.5 Hz, 3H). Synthesis of 4-methoxy-3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl cycloheptylcarbamate (Example-83) To a stirred solution of 4-methoxy-3-(5-(oxazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.37 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.05 mL, 0.37 mmol) and cycloheptyl isocyanate (0.06 g, 0.44 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h, under nitrogen atmosphere. The reaction progress was monitored by TLC. Upon completion, the reaction mixture was cooled to RT and the solvent was evaporated under reduced pressure. The residue was purified by flash 63336124\1 column chromatography on silica gel eluting with hexane / EtOAc (gradient 40-60% EtOAc) to yield the target compound (63 mg) as an off white solid.1H NMR (400 MHz, MeOD) δ 8.76 (d, J = 2.1 Hz, 1H), 8.56 (d, J = 2.1 Hz, 1H), 8.25 (s, 1H), 8.17 (t, J = 2.1 Hz, 1H), 7.64 (s, 1H), 6.81 – 7.23 (m, 3H), 3.74 (s, 3H), 3.55 (dp, J = 9.1, 4.4 Hz, 1H), 1.84 – 1.99 (m, 2H), 1.32 – 1.73 (m, 10H). Synthesis of 2-methoxy-5-(5-(oxazol-2-yl)pyridin-3-yl)phenol To a solution of TOSMIC (0.085 g, 0.43 mmol) in methanol (5 mL) was added K2CO3 (0.17 g, 1.29 mmol) and at RT and stirred for 30 minutes under nitrogen atmosphere.5-(3-hydroxy-4- methoxyphenyl)nicotinaldehyde (0.1 g, 0.43 mmol) was then added to the resulting mixture and stirred at RT for additional 30 minutes. The reaction mixture was heated at 70oC for 1 h under nitrogen atmosphere. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The residue was dissolved in ethyl acetate, washed with water followed by brine. The organic layer was dried over sodium sulfate and then the solvent was evaporated under reduced pressure. The compound was purified by column chromatography on silica gel eluting with hexane / EtOAc (gradient 30-70% EtOAc) to yield the 2-methoxy-5-(5-(oxazol-2-yl)pyridin-3- yl)phenol (65 mg) as a pale-yellow solid. Synthesis of 2-methoxy-5-(5-(oxazol-2-yl)pyridin-3-yl)phenyl octylcarbamate (Example- 84) To a stirred solution of 2-methoxy-5-(5-(oxazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.37 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.05 mL, 0.37 mmol) and n-octyl isocyante (0.06 g, 0.44 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h, under nitrogen atmosphere. The reaction 63336124\1 progress was monitored by TLC. Upon completion, the reaction mixture was cooled to RT and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 40-60% EtOAc) to yield the target compound (20 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.20 (s, 1H), 8.85 - 8.68 (m, 2H), 8.50 (d, J = 1.4 Hz, 1H), 8.24 (dt, J = 39.6, 2.1 Hz, 1H), 7.89 (d, J = 4.3 Hz, 1H), 7.75 - 7.47 (m, 2H), 7.26 - 7.05 (m, 2H), 3.76 (d, J = 2.7 Hz, 3H), 1.45 - 1.32 (m, 4H), 1.32 - 1.17 (m, 11H), 0.79 (q, J = 5.3 Hz, 3H). Synthesis of 4-fluoro-3-(5-(oxazol-2-yl)pyridin-3-yl)phenol To a solution of TOSMIC (0.089 g, 0.46 mmol) in methanol (5 mL) was added K2CO3(0.19 g, 1.38 mmol) and at RT and stirred for 30 minutes under nitrogen atmosphere. 5-(2-fluoro-5- hydroxyphenyl)nicotinaldehyde (0.1 g, 0.46 mmol) was then added to the resulting mixture and stirred at RT for additional 30 minutes. The reaction mixture was heated at 70oC for 1 h under nitrogen atmosphere. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The residue was dissolved in ethyl acetate, washed with water followed by brine. The organic layer was dried over sodium sulfate and then the solvent was evaporated under reduced pressure. The compound was purified by column chromatography on silica gel eluting with hexane / EtOAc (gradient 30-60% EtOAc) to yield the 4-fluoro-3-(5-(oxazol-2-yl)pyridin-3- yl)phenol (70 mg) as a pale-yellow solid. Synthesis of 4-fluoro-3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl cyclopentylcarbamate (Example-85) To a stirred solution of 4-fluoro-3-(5-(oxazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.39 mmol) in anhydrous acetonitrile (2 mL), TEA (0.05 mL, 0.39 mmol) and cyclopentyl isocyanate (0.05 g, 63336124\1 0.46 mmol) were added at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated to 75 °C and stirred for 12 h, under a nitrogen atmosphere. The reaction progress was monitored by TLC. Upon completion, the reaction mixture was cooled to RT and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with a hexane / ethyl acetate (EtOAc) gradient (40-60% EtOAc) to yield the target compound (45 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.48 (s, 1H), 9.23 (dd, J = 9.7, 2.0 Hz, 2H), 8.99 (dt, J = 21.8, 1.9 Hz, 2H), 8.76 - 8.31 (m, 2H), 8.24 (td, J = 2.1, 1.1 Hz, 1H), 7.69 - 7.31 (m, 1H), 7.18 - 6.78 (m, 3H), 3.83 (q, J = 6.7 Hz, 1H), 1.91 - 1.40 (m, 6H), 1.36 - 1.19 (m, 2H). Synthesis of 4-fluoro-3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl (4- methylcyclohexyl)carbamate (Example-86) To a stirred solution of 4-fluoro-3-(5-(oxazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.39 mmol) in anhydrous acetonitrile (2 mL), TEA, (0.05 mL, 0.39 mmol) and trans-4-methylcyclohexyl isocyanate (0.06 g, 0.46 mmol) were added at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes, then heated to 75 °C and stirred for 12 h under a nitrogen atmosphere. The reaction progress was monitored by TLC. Upon completion, the reaction mixture was cooled to RT and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with a hexane / ethyl acetate (EtOAc) gradient (40-60% EtOAc) to yield the target compound (45 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.00 (d, J = 2.1 Hz, 1H), 8.75 (t, J = 2.0 Hz, 1H), 8.58 (s, 1H), 8.30 (dt, J = 3.3, 1.6 Hz, 1H), 7.95 (s, 1H), 7.77 (d, J = 7.9 Hz, 1H), 7.68 - 7.53 (m, 1H), 7.50 - 7.34 (m, 2H), 7.24 (ddd, J = 8.9, 4.1, 2.9 Hz, 1H), 3.30 - 3.20 (m, 1H), 1.95 - 1.80 (m, 2H), 1.75 - 1.60 (m, 3H), 1.31 - 1.20 (m, 2H), 1.09 - 0.91 (m, 2H), 0.86 (d, J = 6.6 Hz, 3H). Synthesis of 4-fluoro-3-(5-(oxazol-2-yl)pyridin-3-yl)phenyl cycloheptylcarbamate (Example-87) 63336124\1 To a stirred solution of 4-fluoro-3-(5-(oxazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.39 mmol) in anhydrous acetonitrile (2 mL), TEA, (0.05 mL, 0.39 mmol) and cycloheptyl isocyanate (0.06 g, 0.46 mmol) were added at RT under a nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes, then heated to 75 °C and stirred for 12 h under nitrogen atmosphere. The reaction progress was monitored by TLC. Upon completion, the reaction mixture was cooled to RT and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with a hexane / ethyl acetate (EtOAc) gradient (40- 60% EtOAc) to yield the target compound (46 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.01 (d, J = 2.1 Hz, 1H), 8.76 (t, J = 2.0 Hz, 1H), 8.58 (s, 1H), 8.31 (td, J = 2.2, 1.1 Hz, 1H), 7.95 (s, 1H), 7.84 (d, J = 7.9 Hz, 1H), 7.61 - 7.35 (m, 2H), 7.25 (ddd, J = 8.9, 4.1, 2.9 Hz, 1H), 3.55 (dtd, J = 12.4, 9.0, 4.5 Hz, 1H), 1.87 (ddd, J = 13.5, 7.2, 3.2 Hz, 2H), 1.68 - 1.30 (m, 10H). Synthesis of 3-(5-(oxazol-2-yl)pyridin-3-yl)-4-(trifluoromethoxy)phenol To a solution of TOSMIC (0.068 g, 0.35 mmol) in methanol (5 mL) was added K2CO3 (0.14 g, 1.05 mmol) and at RT and stirred for 30 minutes under nitrogen atmosphere.5-(5-hydroxy-2- (trifluoromethoxy)phenyl)nicotinaldehyde (0.1 g, 0.35 mmol) was then added to the resulting mixture and stirred at RT for additional 30 minutes. The reaction mixture was heated at 70oC for 1 h under nitrogen atmosphere. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The residue was dissolved in ethyl acetate, washed with water followed by brine. The organic layer was dried over sodium sulfate and then the solvent was evaporated under reduced pressure. The compound was purified by column chromatography on silica gel eluting with hexane / EtOAc (gradient 30-70% EtOAc) to yield the 3-(5-(oxazol-2-yl)pyridin-3- yl)-4-(trifluoromethoxy)phenol (60 mg) as a pale-yellow solid. 63336124\1 Synthesis of 3-(5-(oxazol-2-yl)pyridin-3-yl)-4-(trifluoromethoxy)phenyl octylcarbamate (Example-88) To a stirred solution of 3-(5-(oxazol-2-yl)pyridin-3-yl)-4-(trifluoromethoxy)phenol (0.1 g, 0.31 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.04 mL, 0.31 mmol) and n-octyl isocyanate (0.05 g, 0.37 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h, under nitrogen atmosphere. The reaction progress was monitored by TLC. Upon completion, the reaction mixture was cooled to RT and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 40-60% EtOAc) to yield the target compound (55 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 8.96 (d, J = 2.1 Hz, 1H), 8.61 (d, J = 2.1 Hz, 1H), 8.51 (s, 1H), 8.18 (t, J = 2.1 Hz, 1H), 7.86 (d, J = 13.3 Hz, 2H), 7.51 (dq, J = 8.9, 1.5 Hz, 1H), 7.40 (d, J = 2.9 Hz, 1H), 7.28 (dd, J = 9.0, 2.9 Hz, 1H), 3.08 - 2.90 (m, 2H), 1.54 - 1.35 (m, 2H), 1.37 - 1.10 (m, 10H), 0.88 - 0.69 (m, 3H). Synthesis of 3-(5-(oxazol-2-yl)pyridin-3-yl)-4-(trifluoromethoxy)phenyl cyclohexylcarbamate (Example-89) To a stirred solution of 3-(5-(oxazol-2-yl)pyridin-3-yl)-4-(trifluoromethoxy)phenol (0.1 g, 0.31 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.04 mL, 0.31 mmol) and cyclohexyl isocyanate (0.04 g, 0.37 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h, under nitrogen atmosphere. The reaction progress was monitored by TLC. Upon completion, the reaction mixture was cooled to RT and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 40-60% EtOAc) to yield the target compound (49 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.03 (d, J = 2.1 Hz, 1H), 8.68 (d, J = 2.1 Hz, 1H), 8.58 (s, 1H), 8.26 (t, J = 2.1 Hz, 1H), 7.95 (s, 1H), 63336124\1 7.89 (d, J = 7.9 Hz, 1H), 7.58 (dq, J = 8.9, 1.4 Hz, 1H), 7.48 (d, J = 2.9 Hz, 1H), 7.36 (dd, J = 8.9, 2.9 Hz, 1H), 1.92 - 1.78 (m, 2H), 1.71 (dd, J = 9.0, 3.6 Hz, 2H), 1.57 (d, J = 12.6 Hz, 2H), 1.40 - 1.19 (m, 5H). Synthesis of 3-(5-(oxazol-2-yl)pyridin-3-yl)-4-(trifluoromethoxy)phenyl (4- methylcyclohexyl)carbamate (Example-90) To a stirred solution of 3-(5-(oxazol-2-yl)pyridin-3-yl)-4-(trifluoromethoxy)phenol (0.1 g, 0.31 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.04 mL, 0.31 mmol) and trans-4- Methylcyclohexyl isocyanate (0.05 g, 0.37 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h, under nitrogen atmosphere. The reaction progress was monitored by TLC. Upon completion, the reaction mixture was cooled to RT and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 40-60% EtOAc) to yield the target compound (47 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.03 (d, J = 2.1 Hz, 1H), 8.68 (d, J = 2.1 Hz, 1H), 8.58 (s, 1H), 8.25 (t, J = 2.1 Hz, 1H), 7.90 (d, J = 37.9 Hz, 2H), 7.57 (dq, J = 8.9, 1.4 Hz, 1H), 7.47 (d, J = 2.9 Hz, 1H), 7.43 - 7.05 (m, 1H), 3.55 - 3.37 (m, 1H), 1.92 - 1.83 (m, 2H), 1.75 - 1.64 (m, 2H), 1.37 - 1.15 (m, 3H), 1.15 (td, J = 12.7, 3.5 Hz, 2H), 0.99 (td, J = 12.7, 3.5 Hz, 2H), 0.87 (d, J = 6.5 Hz, 3H). Synthesis of 3-(5-(oxazol-2-yl)pyridin-3-yl)-4-(trifluoromethoxy)phenyl cycloheptylcarbamate (Example-91) To a stirred solution of 3-(5-(oxazol-2-yl)pyridin-3-yl)-4-(trifluoromethoxy)phenol (0.1 g, 0.31 mmol) in anhydrous acetonitrile (2 mL), TEA (0.04 mL, 0.31 mmol), and cycloheptyl isocyanate (0.05 g, 0.37 mmol) were added at RT under a nitrogen atmosphere. The reaction 63336124\1 mixture was stirred at RT for 10 minutes, then heated to 75 °C and stirred for 12 h, under nitrogen atmosphere. The reaction progress was monitored by TLC. Upon completion, the reaction mixture was cooled to RT and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with a hexane / ethyl acetate (EtOAc) gradient (40-60% EtOAc) to yield the target compound (48 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 8.96 (d, J = 2.1 Hz, 1H), 8.61 (d, J = 2.1 Hz, 1H), 8.51 (s, 1H), 8.18 (t, J = 2.1 Hz, 1H), 7.86 (d, J = 11.2 Hz, 2H), 7.50 (dq, J = 8.9, 1.5 Hz, 1H), 7.41 (d, J = 2.9 Hz, 1H), 7.28 (dd, J = 9.0, 2.9 Hz, 1H), 3.48 (qt, J = 8.9, 4.5 Hz, 1H), 1.80 (dtd, J = 13.9, 7.5, 4.6 Hz, 2H), 1.69 - 1.26 (m, 11H). Synthesis of 2-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenol To a solution of TOSMIC (0.089 g, 0.46 mmol) in methanol (5 mL) was added K2CO3(0.19 g, 1.38 mmol) and at RT and stirred for 30 minutes under nitrogen atmosphere.5-(3-hydroxy-4- methylphenyl)nicotinaldehyde (0.1 g, 0.46 mmol) was then added to the resulting mixture and stirred at RT for additional 30 minutes. The reaction mixture was heated at 70oC for 1 h under nitrogen atmosphere. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The residue was dissolved in ethyl acetate, washed with water followed by brine. The organic layer was dried over sodium sulfate and then the solvent was evaporated under reduced pressure. The compound was purified by column chromatography on silica gel eluting with hexane / EtOAc (gradient 30-50% EtOAc) to yield the 2-methyl-5-(5-(oxazol-2-yl)pyridin-3- yl)phenol (64 mg) as a pale-yellow solid. Synthesis of 2-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenyl octylcarbamate (Example-92) To a stirred solution of 2-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.39 mmol) in anhydrous acetonitrile (2 mL), TEA (0.05 mL, 0.39 mmol), and n-octyl isocyanate (0.07 g, 0.47 63336124\1 mmol) were added at RT under a nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes, then heated to 75 °C and stirred for 12 h, under nitrogen atmosphere. After completion of the reaction, monitored by TLC, the reaction mixture was concentrated to a residue. The residue was purified by flash column chromatography on silica gel, eluting with a hexane / ethyl acetate (EtOAc) gradient (40-60% EtOAc) to yield the target compound (50 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 8.92 (dd, J = 16.9, 2.1 Hz, 2H), 8.58 (s, 1H), 8.39 (t, J = 2.2 Hz, 1H), 7.98 (s, 1H), 7.83 (t, J = 5.7 Hz, 1H), 7.62 (dd, J = 7.8, 2.0 Hz, 1H), 7.54 (d, J = 2.0 Hz, 1H), 7.24 - 7.51 (m, 1H), 3.16 - 2.94 (m, 2H), 2.20 (s, 3H), 1.48 (q, J = 6.7 Hz, 2H), 1.43 - 1.15 (m, 10H), 1.06 - 0.65 (m, 3H). Synthesis of 2-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenyl (cyclohexylmethyl)carbamate (Example-93) To a stirred solution of 2-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.39 mmol) in anhydrous acetonitrile (2 mL), TEA (0.05 mL, 0.39 mmol), and cyclohexanemethyl isocyanate (0.06 g, 0.47 mmol) were added at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes, then heated to 75 °C and stirred for 12 h, under nitrogen atmosphere. After completion of the reaction, monitored by TLC, the reaction mixture was concentrated to a residue. The residue was purified by flash column chromatography on silica gel, eluting with a hexane / ethyl acetate (EtOAc) gradient (40-60% EtOAc) to yield the target compound (52 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 8.92 (dd, J = 15.3, 2.1 Hz, 2H), 8.58 (s, 1H), 8.39 (t, J = 2.2 Hz, 1H), 7.98 (s, 1H), 7.86 (t, J = 6.0 Hz, 1H), 7.62 (dd, J = 7.8, 1.9 Hz, 1H), 7.55 (d, J = 1.9 Hz, 1H), 7.29 - 7.48 (m, 1H), 3.00 - 2.86 (m, 2H), 2.20 (s, 3H), 1.70 (td, J = 17.0, 9.0 Hz, 4H), 1.55 - 1.45 (m, 1H), 1.19 (qt, J = 11.9, 9.4 Hz, 4H), 0.92 (qd, J = 13.1, 3.9 Hz, 2H). Synthesis of 2-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenyl benzylcarbamate (Example- 94) 63336124\1 To a stirred solution of 2-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.39 mmol) in anhydrous acetonitrile (2 mL), TEA (0.05 mL, 0.39 mmol), and benzyl isocyanate (0.06 g, 0.47 mmol) were added at RT under nitrogen atmosphere. The reaction mixture was stirred at 75 °C for 12 h, under nitrogen atmosphere. After completion of the reaction, monitored by TLC and the reaction mixture was concentrated to a residue. The residue was purified by flash column chromatography on silica gel, eluting with a hexane / ethyl acetate (EtOAc) gradient (40-60% EtOAc) to yield the target compound (49 mg) as an off white solid.1H NMR (400 MHz, DMSO- d6) δ 8.92 (dd, J = 13.2, 2.1 Hz, 2H), 8.58 (s, 1H), 8.49 - 8.22 (m, 2H), 7.98 (s, 1H), 7.74 - 7.49 (m, 2H), 7.49 - 7.19 (m, 6H), 4.32 (d, J = 6.1 Hz, 2H), 2.21 (s, 3H). Synthesis of 2-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenyl cyclohexylcarbamate (Example-95) To a stirred solution of 2-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.39 mmol) in anhydrous acetonitrile (2 mL), TEA (0.05 mL, 0.39 mmol), and cyclohexyl isocyanate (0.05 g, 0.47 mmol) were added at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes, then heated to 75 °C and stirred for 12 h, under nitrogen atmosphere. After completion of the reaction, monitored by TLC, the reaction mixture was concentrated to a residue. The residue was purified by flash column chromatography on silica gel, eluting with a hexane / ethyl acetate (EtOAc) gradient (40-60% EtOAc) to yield the target compound (49 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 8.92 (dd, J = 14.3, 2.1 Hz, 2H), 8.58 (s, 1H), 8.39 (t, J = 2.2 Hz, 1H), 7.98 (s, 1H), 7.80 (d, J = 8.0 Hz, 1H), 7.62 (dd, J = 7.9, 2.0 Hz, 1H), 7.55 (d, J = 1.9 Hz, 1H), 7.48 - 7.36 (m, 1H), 3.31 (m, 1H), 2.20 (s, 3H), 1.85 (dd, J = 8.9, 4.4 Hz, 2H), 1.72 (t, J = 5.7 Hz, 2H), 1.57 (d, J = 12.5 Hz, 1H), 1.39 - 1.17 (m, 4H), 1.12 (d, J = 10.9 Hz, 1H). Synthesis of 2-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenyl (4- 63336124\1 methylcyclohexyl)carbamate (Example-96) To a stirred solution of 2-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.39 mmol) in anhydrous acetonitrile (2 mL), TEA (0.05 mL, 0.39 mmol), and trans-4-methylcyclohexyl isocyanate (0.06 g, 0.47 mmol) were added at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes, then heated to 75 °C and stirred for 12 h, under nitrogen atmosphere. After completion of the reaction, monitored by TLC, the reaction mixture was concentrated to a residue. The residue was purified by flash column chromatography on silica gel, eluting with a hexane / ethyl acetate (EtOAc) gradient (40-60% EtOAc) to yield the target compound (36 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 8.92 (dd, J = 15.1, 2.1 Hz, 2H), 8.58 (s, 1H), 8.39 (t, J = 2.2 Hz, 1H), 7.98 (s, 1H), 7.77 (d, J = 8.0 Hz, 1H), 7.72 - 7.51 (m, 2H), 7.51 - 7.36 (m, 1H), 3.26 (ddt, J = 11.7, 8.1, 3.1 Hz, 1H), 2.19 (s, 3H), 2.01 - 1.85 (m, 2H), 1.85 - 1.52 (m, 3H), 1.28 (qd, J = 12.4, 2.8 Hz, 3H), 0.99 (td, J = 12.5, 3.3 Hz, 2H), 0.94 - 0.79 (m, 3H). Synthesis of 2-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenyl cycloheptylcarbamate (Example-97) To a stirred solution of 2-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.39 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.05 mL, 0.39 mmol) and cycloheptyl isocyanate (0.06 g, 0.47 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes, then heated to 75 °C and stirred for 12 h, under nitrogen atmosphere. The reaction progress was monitored by TLC. After completion of the reaction, the mixture was concentrated to a residue. The residue was purified by flash column chromatography on silica gel, eluting with a hexane / EtOAc gradient (40-60% EtOAc) to yield the target compound (37 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 8.92 (dd, J = 14.5, 2.1 Hz, 2H), 8.58 (s, 1H), 8.39 (t, J = 2.1 Hz, 1H), 7.98 (s, 1H), 7.85 (d, J = 8.0 Hz, 63336124\1 1H), 7.68 - 7.50 (m, 2H), 7.50 - 7.28 (m, 1H), 3.54 (ddd, J = 9.3, 7.8, 4.6 Hz, 1H), 2.19 (s, 3H), 1.98 - 1.75 (m, 2H), 1.71 - 1.42 (m, 10H). Synthesis of 2-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenyl cyclooctylcarbamate (Example-98) To a stirred solution of 2-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.39 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.05 mL, 0.39 mmol) and cyclooctyl isocyanate (0.07 g, 0.47 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated to 75 °C and stirred for 12 h, under nitrogen atmosphere. The reaction progress was monitored by TLC. After completion of the reaction, the reaction mixture was concentrated to a residue. The residue was purified by flash column chromatography on silica gel, eluting with a hexane / EtOAc gradient (40-60% EtOAc) to yield the target compound (36 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 8.97 (dd, J = 15.5, 2.1 Hz, 2H), 8.63 (s, 1H), 8.45 (t, J = 2.2 Hz, 1H), 7.97 (d, J = 50.3 Hz, 2H), 7.89 (s, 1H), 7.56 - 7.79 (m, 2H), 7.40 - 7.56 (m, 1H), 3.64 (td, J = 8.3, 3.9 Hz, 1H), 2.25 (s, 3H), 1.97 - 1.32 (m, 10H). Synthesis of 3-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenol To a solution of TOSMIC (0.089 g, 0.46 mmol) in methanol (5 mL) was added K2CO3(0.19 g, 1.38 mmol) and at RT and stirred for 30 minutes under nitrogen atmosphere.5-(3-hydroxy-5- methylphenyl)nicotinaldehyde (0.1 g, 0.46 mmol) was then added to the resulting mixture and stirred at RT for additional 30 minutes. The reaction mixture was heated at 70oC for 1 h under nitrogen atmosphere. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The residue was dissolved in ethyl acetate, washed with water followed by brine. The organic 63336124\1 layer was dried over sodium sulfate and then the solvent was evaporated under reduced pressure. The compound was purified by column chromatography on silica gel eluting with hexane / EtOAc (gradient 30-50% EtOAc) to yield the 3-methyl-5-(5-(oxazol-2-yl)pyridin-3- yl)phenol (64 mg) as a pale-yellow solid. Synthesis of 3-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenyl (cyclohexylmethyl)carbamate (Example-99) To a stirred solution of 3-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.37 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.05 mL, 0.37 mmol) and cyclohexanemethyl isocyanate (0.06 g, 0.44 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h, under nitrogen atmosphere. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated to a residue. The residue was purified by flash column chromatography on silica gel, eluting with a hexane / EtOAc gradient (40-60% EtOAc) to yield the target compound (40 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 8.92 (dd, J = 28.2, 2.1 Hz, 1H), 8.38 (t, J = 2.1 Hz, 1H), 7.97 (s, 0H), 7.82 (t, J = 5.9 Hz, 0H), 7.45 - 7.72 (m, 1H), 7.36 (t, J = 2.1 Hz, 1H), 7.02 (ddd, J = 2.3, 1.5, 0.8 Hz, 1H), 2.92 (t, J = 6.4 Hz, 1H), 1.52 - 1.83 (m, 3H), 1.44 (ddp, J = 10.6, 6.9, 3.6 Hz, 0H), 1.10 - 1.34 (m, 2H), 0.82 - 1.00 (m, 1H). Synthesis of 3-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenyl benzylcarbamate (Example- 100) To a stirred solution of 3-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.37 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.05 mL, 0.37 mmol) and benzyl isocyanate (0.05 g, 0.44 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT 63336124\1 for 10 minutes and then heated to 75 °C and stirred for 12 h, under nitrogen atmosphere. The reaction progress was monitored by TLC. After completion of the reaction, the reaction mixture was concentrated to a residue. The residue was purified by flash column chromatography on silica gel, eluting with a hexane / EtOAc gradient (40-60% EtOAc) to yield the target compound (41 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6): δ 9.35 – 8.73 (m, 2H), 8.60 (s, 1H), J = 2.2 Hz, 8.35 (t, 1H), 7.97 (s, 1H), 7.83 – 7.59 (m, 1H), 7.55 – 7.13 (m, 8H), 5.09 (s, 2H), 2.40 (s, 3H). Synthesis of 3-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenyl cyclohexylcarbamate (Example-101) To a stirred solution of 3-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.37 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.05 mL, 0.37 mmol) and cyclohexyl isocyanate (0.05 g, 0.44 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes, and then heated to 75 °C and stirred for 12 h, under nitrogen atmosphere. The reaction progress was monitored by TLC. After completion of the reaction, the reaction mixture was concentrated to a residue. The residue was purified by flash column chromatography on silica gel, eluting with a hexane / EtOAc gradient (40-60% EtOAc) to yield the target compound (38 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6): δ 8.92 (dd, J = 28.1, 2.1 Hz, 2H), 8.58 (s, 1H), 8.58 (s, 1H), 7.98 (s, 1H), 7.77 (d, J = 8.0 Hz, 1H), 7.37 – 7.56 (m, 1H), 7.36 (d, J = 2.2 Hz, 1H), 7.02 (d, J = 2.1 Hz, 1H), 3.32 (m, 1H), 1.84 (d, J = 9.2 Hz, 2H), 1.71 (t, J = 6.8 Hz, 2H), 1.57 (d, J = 12.7 Hz, 1H), 1.26 (td, J = 11.7, 5.8 Hz, 5H), 2.41 (s, 3H). Synthesis of 3-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenyl (4- methylcyclohexyl)carbamate (Example-102) 63336124\1 To a stirred solution of 3-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.37 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.05 mL, 0.37 mmol) and trans-4- Methylcyclohexyl isocyanate (0.06 g, 0.44 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes, then heated to 75 °C and stirred for 12 h under nitrogen atmosphere. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated to a residue. The residue was purified by flash column chromatography on silica gel, eluting with a hexane / EtOAc gradient (40-60% EtOAc) to yield the target compound (40 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6): δ 8.95 (d, J = 2.0 Hz, 1H), 8.88 (d, J = 2.2 Hz, 1H), 8.58 (s, 1H), 8.38 (t, J = 2.1 Hz, 1H), 7.98 (s, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.54 – 7.68 (m, 1H), 7.50 (d, J = 1.9 Hz, 1H), 7.32 – 7.43 (m, 1H), 7.02 (d, J = 2.0 Hz, 1H), 2.40 (s, 3H), 1.86 (d, J = 12.4 Hz, 2H), 1.70 (tt, J = 25.4, 11.5 Hz, 3H), 1.20 – 1.46 (m, 4H), 0.82 – 0.94 (m, 4H). Synthesis of 3-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenyl cycloheptylcarbamate (Example-103) To a stirred solution of 3-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.37 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.05 mL, 0.37 mmol) and cycloheptyl isocyanate (0.06 g, 0.44 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated to 75 °C and stirred for 12 h, under nitrogen atmosphere. The reaction progress was monitored by TLC. After completion of the reaction, the reaction mixture was concentrated to a residue. The residue was purified by flash column chromatography on silica gel, eluting with a hexane / EtOAc gradient (40-60% EtOAc) to yield the target compound (45 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6): δ 8.98 (dd, J = 28.0, 2.1 Hz, 2H), 8.64 (s, 1H), 8.44 (t, J = 2.1 Hz, 1H), 8.04 (s, 1H), 7.87 (d, J = 8.0 Hz, 1H), 7.56 (d, J = 1.9 Hz, 1H), 7.43 (d, J = 2.0 Hz, 1H), 7.02 – 7.18 (m, 1H), 3.62 (dd, J = 8.6, 4.3 Hz, 1H), 2.47 (s, 3H), 1.93 (ddd, J = 13.7, 7.6, 4.3 Hz, 2H), 1.40 – 1.76 (m, 10H). Synthesis of 3-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenyl cyclooctylcarbamate (Example-104) 63336124\1 To a stirred solution of 3-methyl-5-(5-(oxazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.37 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.05 mL, 0.37 mmol) and cyclooctyl isocyanate (0.06 g, 0.44 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 12 h under nitrogen atmosphere. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated to a residue. The residue was purified by flash column chromatography on silica gel, eluting with a hexane / EtOAc gradient (40-60% EtOAc) to yield the target compound (45 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6): δ 8.85 (dd, J = 28.1, 2.1 Hz, 2H), 8.51 (s, 1H), 8.31 (t, J = 2.2 Hz, 1H), 7.83 (d, J = 63.6 Hz, 2H), 7.73 (s, 1H), 7.43 (d, J = 1.8 Hz, 1H), 7.29 (t, J = 2.0 Hz, 1H), 6.95 (d, J = 2.0 Hz, 1H), 3.51 (td, J = 8.5, 4.0 Hz, 1H), 2.34 (s, 3H), 1.32 – 1.68 (m, 12H). Scheme IV: Reagents and conditions: a) N,N-dimethylformamide dimethyl acetal (DMF-DMA),100oC, 5 h; b) NH2-OH, MeOH, 60oC, 6 h; c) Pd(PPh3)4Na2CO3,toluene / ethanol (EtOH), 90oC, 4-8 h; d) R3-NCO, TEA, ACN:EtOH (1:1), RT,16 h. 63336124\1 Synthesis of (E)-1-(5-bromopyridin-3-yl)-3-(dimethylamino)prop-2-en-1-one To a stirred solution of 1-(5-bromopyridin-3-yl)ethan-1-one (10 g, 50 mmol) in DMF-DMA (200 mL) and stirred the reaction mixture at 100 °C for 5 h. After completion of the reaction (monitored by TLC), the resulting mixture was concentrated to a residue. The residue was triturated with petroleum ether and filtered the precipitated solid and dried to give (E)-1-(5- bromopyridin-3-yl)-3-(dimethylamino)prop-2-en-1-one (10 g) which was used for next step without further purification. MS (ES+APCI) m / z 257.0 (M+2) Synthesis of 5-(5-bromopyridin-3-yl)isoxazole To a stirred solution of (E)-1-(5-bromopyridin-3-yl)-3-(dimethylamino)prop-2-en-1-one (4 g, 15.68 mmol) in MeOH (40 mL) was added hydroxylamine hydrochloride (1.63 g, 23.52 mmol) stirred at 60 °C for 6 h under nitrogen atmosphere. After completion of the reaction (monitored by TLC), the reaction mixture was evaporated under reduced pressure. The residue was purified by automated normal-phase chromatography and eluted with ethyl acetate / petroleum ether to give 5-(5-bromopyridin-3-yl)isoxazole (2 g, 57 % yield) as an off white solid.1HNMR (400 MHz, DMSO-d6) δ 9.09 (d, J = 1.80 Hz, 1H), 8.82 (d, J = 2.10 Hz, 1H), 8.76 (d, J = 1.80 Hz, 1H), 8.58 (t, J = 1.80 Hz, 1H), 7.29 (d, J = 2.10 Hz, 1H); MS (ES+APCI) m / z 227.1.0 (M+1). Synthesis of 3-(5-(isoxazol-5-yl)pyridin-3-yl)phenol To a stirred solution of 5-(5-bromopyridin-3-yl)isoxazole (0.6 g, 2.67 mmol) in toluene (6 mL) and EtOH (0.6 mL) was added (3-hydroxyphenyl)boronic acid (0.44 g, 3.20 mmol) and Na2CO3 63336124\1 (0.57 g, 5.33 mmol) at RT. The reaction mixture was degassed for 15 minutes then Pd(PPh3)4 (0.22 g, 0.19 mmol) was added. The reaction mixture was stirred at 90 °C for 4 h under nitrogen atmosphere. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The residue was quenched with water and precipitated solid was filtered and dried to give a residue. The residue was purified by automated normal-phase chromatography and eluted with ethyl acetate / petroleum ether to give 3-(5-(isoxazol-5-yl)pyridin-3-yl)phenol (0.19 g) as pale yellow solid.1HNMR (400 MHz, DMSO-d6) δ 9.69 (s, 1H), 9.08 (d, J = 2.00 Hz, 1H), 8.94 (d, J = 2.00 Hz, 1H), 8.76 (d, J = 2.00 Hz, 1H), 8.46 (t, J = 2.00 Hz, 1H), 7.37 - 7.33 (m, 2H), 7.26 - 7.24 (m, 1H), 7.18 (t, J = 2.00 Hz, 1H), 6.90 - 6.89 (m, 1H); MS (ES+APCI) m / z 239.2 (M+1). Synthesis of 3-(5-(isoxazol-5-yl)pyridin-3-yl)phenyl octylcarbamate (Example-105) To a stirred solution of 3-(5-(isoxazol-5-yl)pyridin-3-yl)phenol (0.08 g, 0.34 mmol) in anhydrous acetonitrile (1 mL) and EtOH (1 mL) was added TEA (0.05 mL, 0.34 mmol) and n- octyl isocyanate (0.06 g, 0.40 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (40 mg) as an off white solid.1HNMR (400 MHz, DMSO-d6) δ 9.11 (d, J = 2.00 Hz, 1H), 9.02 (d, J = 2.00 Hz, 1H), 8.77 (d, J = 2.00 Hz, 1H), 8.55 (t, J = 2.00 Hz, 1H), 7.82 (t, J = 5.60 Hz, 1H), 7.72 - 7.70 (m, 1H), 7.61 (t, J = 2.00 Hz, 1H), 7.55 (t, J = 7.60 Hz, 1H), 7.34 (d, J = 2.00 Hz, 1H), 7.22 - 7.20 (m, 1H), 3.10 - 3.05 (m, 2H), 1.49 (t, J = 7.20 Hz, 2H), 1.29 - 1.27 (m, 10H), 0.86 (t, J = 7.20 Hz, 3H); MS (ES+APCI) m / z 394.3 (M+1). Synthesis of 3-(5-(isoxazol-5-yl)pyridin-3-yl)phenyl cyclopentylcarbamate (Example-106) To a stirred solution of 3-(5-(isoxazol-5-yl)pyridin-3-yl)phenol (0.05 g, 0.21 mmol) in anhydrous acetonitrile (1 mL) and EtOH (1 mL) was added TEA (0.03 mL, 0.21 mmol) and 63336124\1 cyclopentyl isocyanate (0.28 g, 0.25 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (26 mg) as an off white solid.1HNMR (400 MHz, DMSO-d6) δ 9.11 (d, J = 2.00 Hz, 1H), 9.03 (d, J = 2.00 Hz, 1H), 8.77 (d, J = 2.00 Hz, 1H), 8.56 (t, J = 2.00 Hz, 1H), 7.87 (d, J = 7.20 Hz, 1H), 7.71 (t, J = 7.60 Hz, 1H), 7.63 (t, J = 2.00 Hz, 1H), 7.54 (t, J = 7.60 Hz, 1H), 7.34 (d, J = 2.00 Hz, 1H), 7.23 - 7.20 (m, 1H), 3.90 - 3.85 (m, 1H), 1.89 - 1.47 (m, 8H); MS (ES+APCI) m / z 350.3 (M+1). Synthesis of 3-(5-(isoxazol-5-yl)pyridin-3-yl)phenyl cyclohexylcarbamate (Example-107) To a stirred solution of 3-(5-(isoxazol-5-yl)pyridin-3-yl)phenol (0.05 g, 0.21 mmol) in anhydrous acetonitrile (1 mL) and EtOH (1 mL) was added TEA (0.03 mL, 0.21 mmol) and cyclohexyl isocyanate (0.03 g, 0.25 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (25 mg) as an off white solid.1HNMR (400 MHz, DMSO-d6) δ 9.11 (d, J = 1.60 Hz, 1H), 9.03 (d, J = 2.00 Hz, 1H), 8.77 (d, J = 1.60 Hz, 1H), 8.56 (t, J = 2.00 Hz, 1H), 7.80 (d, J = 8.00 Hz, 1H), 7.70 (d, J = 8.00 Hz, 1H), 7.62 (d, J = 2.00 Hz, 1H), 7.54 (t, J = 8.00 Hz, 1H), 7.34 (d, J = 2.00 Hz, 1H), 7.21 (dd, J = 1.60, 8.20 Hz, 1H), 1.87 - 1.11 (m, 10H); MS (ES+APCI) m / z 364.3 (M+1). Synthesis of 3-(5-(isoxazol-5-yl)pyridin-3-yl)phenyl cycloheptylcarbamate (Example-108) To a stirred solution of 3-(5-(isoxazol-5-yl)pyridin-3-yl)phenol (0.08 g, 0.34 mmol) in anhydrous acetonitrile (1 mL) and EtOH (1 mL) was added TEA (0.05 mL, 0.34 mmol) and cycloheptyl isocyanate (0.05 g, 0.40 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 16 h. After completion of the reaction (monitored by TLC), the 63336124\1 reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (50 mg) as an off white solid.1HNMR (400 MHz, DMSO-d6) δ 9.11 (d, J = 2.00 Hz, 1H), 9.03 (d, J = 2.00 Hz, 1H), 8.77 (d, J = 2.00 Hz, 1H), 8.56 (t, J = 2.00 Hz, 1H), 7.84 (d, J = 8.00 Hz, 1H), 7.70 (d, J = 8.00 Hz, 1H), 7.62 (t, J = 2.00 Hz, 1H), 7.54 (t, J = 7.60 Hz, 1H), 7.34 (d, J = 1.60 Hz, 1H), 7.21 (dd, J = 1.60, 8.00 Hz, 1H), 3.58 - 3.54 (m, 1H), 1.91 - 1.45 (m, 12H); MS (ES+APCI) m / z 378.4 (M+1). Synthesis of 3-(5-(isoxazol-5-yl)pyridin-3-yl)-4-methoxyphenol To a stirred solution of 5-(5-bromopyridin-3-yl)isoxazole (0.5 g, 2.22 mmol) in 1,4-dioxane (5 mL) and water (0.5 mL) was added (5-hydroxy-2-methoxyphenyl)boronic acid (0.45 g, 2.67 mmol) and Cs2CO3 (1.45 g, 4.44 mmol) at RT. The reaction mixture was degassed for 15 minutes then Pd(dppf)Cl2(0.11 g, 0.16 mmol) was added. The reaction mixture was stirred at 80 °C for 1 h under nitrogen atmosphere. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The residue was quenched with water and extracted with ethyl acetate, and the combined organic layers were washed with water, brine and concentrated to give a residue. The residue was purified by automated normal-phase chromatography and eluted with ethyl acetate / petroleum ether to give 3-(5-(isoxazol-5-yl)pyridin-3-yl)-4-methoxyphenol (0.4 g) as pale yellow solid.1HNMR (400 MHz, DMSO-d6) δ 9.19 (s, 1H), 9.03 (d, J = 2.10 Hz, 1H), 8.74 (t, J = 1.80 Hz, 2H), 8.31 (t, J = 2.10 Hz, 1H), 7.26 (d, J = 1.80 Hz, 1H), 7.01 (d, J = 9.30 Hz, 1H), 6.84 - 6.81 (m, 2H), 3.71 (s, 3H); MS (ES+APCI) m / z 269.1 (M+1). Synthesis of 3-(5-(isoxazol-5-yl) pyridin-3-yl)-4-methoxyphenyl octylcarbamate (Example- 109) To a stirred solution of 3-(5-(isoxazol-5-yl)pyridin-3-yl)-4-methoxyphenol (0.08 g, 0.30 mmol) in anhydrous acetonitrile (1 mL) and EtOH (1 mL) was added TEA (0.04 mL, 0.30 mmol) and 63336124\1 octyl isocyanate (0.05 g, 0.36 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (55 mg) as an off white solid.1HNMR (400 MHz, DMSO-d6) δ 9.06 (d, J = 2.00 Hz, 1H), 8.80 (d, J = 2.00 Hz, 1H), 8.75 (d, J = 2.00 Hz, 1H), 8.35 (t, J = 2.00 Hz, 1H), 7.72 (t, J = 5.60 Hz, 1H), 7.27 (d, J = 2.00 Hz, 1H), 7.23 (d, J = 1.60 Hz, 1H), 7.17 (d, J = 1.20 Hz, 2H), 3.82 (s, 3H), 3.08 - 3.03 (m, 2H), 1.46 (t, J = 6.80 Hz, 2H), 1.27 - 1.26 (m, 10H), 0.85 (t, J = 6.80 Hz, 3H); MS (ES+APCI) m / z 424.3 (M+1). Synthesis 3-(5-(isoxazol-5-yl)pyridin-3-yl)-4-methoxyphenyl (cyclohexylmethyl)carbamate (Example-110) To a stirred solution of 3-(5-(isoxazol-5-yl)pyridin-3-yl)-4-methoxyphenol (0.08 g, 0.30 mmol) in anhydrous acetonitrile (1 mL) and EtOH (1 mL) was added TEA (0.04 mL, 0.30 mmol) and cyclohexylmethyl isocyanate (0.05 g, 0.36 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (25 mg) as an off white solid.1HNMR (400 MHz, DMSO-d6) δ 9.06 (d, J = 2.00 Hz, 1H), 8.80 (d, J = 2.00 Hz, 1H), 8.75 (d, J = 1.60 Hz, 1H), 8.35 (t, J = 2.00 Hz, 1H), 7.74 (t, J = 6.00 Hz, 1H), 7.27 (d, J = 2.00 Hz, 1H), 7.23 (t, J = 1.60 Hz, 1H), 7.17 (d, J = 1.60 Hz, 2H), 3.82 (s, 3H), 2.91 (t, J = 6.40 Hz, 2H), 1.73- 0.88 (m, 11H); MS (ES+APCI) m / z 408.2 (M+1). Synthesis of 3-(5-(isoxazol-5-yl)pyridin-3-yl)-4-methoxyphenyl benzylcarbamate (Example-111) To a stirred solution of 3-(5-(isoxazol-5-yl)pyridin-3-yl)-4-methoxyphenol (0.08 g, 0.30 mmol) in anhydrous acetonitrile (1 mL) and EtOH (1 mL) was added TEA (0.04 mL, 0.30 mmol) and 63336124\1 benzyl isocyanate (0.04 g, 0.36 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (25 mg) as pale-yellow solid.1HNMR (400 MHz, DMSO-d6) δ 9.06 (d, J = 2.00 Hz, 1H), 8.80 (d, J = 2.00 Hz, 1H), 8.75 (d, J = 2.00 Hz, 1H), 8.35 (t, J = 2.00 Hz, 1H), 8.32 - 8.29 (m, 1H), 7.38 - 7.32 (m, 4H), 7.28 - 7.22 (m, 3H), 7.21 - 7.17 (m, 2H), 4.29 (d, J = 6.00 Hz, 2H), 3.82 (s, 3H); MS (ES+APCI) m / z 402.4 (M+1). Synthesis of 3-(5-(isoxazol-5-yl)pyridin-3-yl)-4-methoxyphenyl cyclopentylcarbamate (Example-112) To a stirred solution of 3-(5-(isoxazol-5-yl)pyridin-3-yl)-4-methoxyphenol (0.08 g, 0.30 mmol) in anhydrous acetonitrile (1 mL) and EtOH (1 mL) was added TEA (0.04 mL, 0.30 mmol) and cyclopentyl isocyanate (0.04 g, 0.36 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (39 mg) as an off white solid.1HNMR (400 MHz, DMSO-d6) δ 9.06 (d, J = 2.40 Hz, 1H), 8.80 (d, J = 2.00 Hz, 1H), 8.75 (d, J = 2.00 Hz, 1H), 8.35 (t, J = 2.00 Hz, 1H), 7.76 (d, J = 7.60 Hz, 1H), 7.27 (d, J = 2.00 Hz, 1H), 7.24 (s, 1H), 7.18 (d, J = 1.20 Hz, 2H), 3.89 - 3.84 (m, 1H), 3.82 (s, 3H), 1.85 - 1.46 (m, 8H); MS (ES+APCI) m / z 380.1 (M+1). Synthesis of 3-(5-(isoxazol-5-yl)pyridin-3-yl)-4-methoxyphenyl cyclohexylcarbamate (Example-113) To a stirred solution of 3-(5-(isoxazol-5-yl)pyridin-3-yl)-4-methoxyphenol (0.08 g, 0.30 mmol) in anhydrous acetonitrile (1 mL) and EtOH (1 mL) was added TEA (0.04 mL, 0.30 mmol) and cyclohexyl isocyanate (0.04 g, 0.36 mmol) at RT under nitrogen atmosphere. The reaction 63336124\1 mixture was stirred at RT for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (60 mg) as an off white solid.1HNMR (400 MHz, DMSO-d6) δ 9.06 (d, J = 2.00 Hz, 1H), 8.80 (d, J = 2.00 Hz, 1H), 8.75 (d, J = 2.00 Hz, 1H), 8.35 (t, J = 2.00 Hz, 1H), 7.69 (d, J = 7.60 Hz, 1H), 7.27 (d, J = 2.00 Hz, 1H), 7.24 (s, 1H), 7.17 (d, J = 1.60 Hz, 2H), 3.82 (s, 3H), 1.84 - 1.10 (m, 10H); MS (ES+APCI) m / z 394.1 (M+1). Synthesis of (3-(5-(isoxazol-5-yl)pyridin-3-yl)-4-methoxyphenyl cycloheptylcarbamate (Example-114) To a stirred solution of 3-(5-(isoxazol-5-yl)pyridin-3-yl)-4-methoxyphenol (0.08 g, 0.30 mmol) in anhydrous acetonitrile (1 mL) and EtOH (1 mL) was added TEA (0.04 mL, 0.30 mmol) and cycloheptyl isocyanate (0.05 g, 0.36 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (35 mg) as an off white solid.1HNMR (400 MHz, DMSO-d6) δ 9.06 (d, J = 2.00 Hz, 1H), 8.80 (d, J = 2.00 Hz, 1H), 8.75 (d, J = 1.60 Hz, 1H), 8.35 (t, J = 2.00 Hz, 1H), 7.73 (d, J = 8.00 Hz, 1H), 7.27 (d, J = 2.00 Hz, 1H), 7.23 (d, J = 1.20 Hz, 1H), 7.17 (d, J = 1.60 Hz, 2H), 3.82 (s, 3H), 3.58 - 3.51 (m, 1H), 1.89 - 1.35 (m, 12H); MS (ES+APCI) m / z 408.2 (M+1). Scheme V: 63336124\1 Reagents and conditions: a) Pd(PPh3)4, Cs2CO3, 1,4-dioxane, 100oC, 5 h; b) Pd(PPh3)4, K2CO3, 1,4-dioxane, H2O, 90oC, 5 h; c) R3-isocyanate (R3-NCO), TEA, ACN, 75oC, 5 h. Synthesis of 2-(5-bromopyridin-3-yl)thiazole To a stirred solution of 2-bromothiazole (12 g, 73.17 mmol) in 1,4-dioxane (120 mL) was added (5-bromopyridin-3-yl)boronic acid (18 g, 87.80 mmol) and Cs2CO3(35.8 g, 109.8 mmol) at RT. The reaction mixture was degassed for 15 minutes then Pd(PPh3)4 (5.1 g, 4.40 mmol) was added. The reaction mixture was stirred at 100 °C for 5 h under nitrogen atmosphere. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The residue was purified by automated normal-phase chromatography and eluted with ethyl acetate / petroleum ether to give 2-(5- bromopyridin-3-yl)thiazole (4.5 g) as an off white solid.1H-NMR (400 MHz, DMSO-d6): δ 9.13 (d, J = 2.80 Hz, 1H), 8.81 (d, J = 3.20 Hz, 1H), 8.53 (t, J = 2.80 Hz, 1H), 8.04 (d, J = 4.40 Hz, 1H), 7.96 (d, J = 4.40 Hz, 1H); MS (ES+APCI) m / z 243.1(M+2). Synthesis of 3-(5-(thiazol-2-yl)pyridin-3-yl)phenol To a stirred solution of 2-(5-bromopyridin-3-yl)thiazole (4.5 g, 18.66 mmol) in 1,4-dioxane (50 mL) and water (5 mL) was added (3-hydroxyphenyl)boronic acid (2.9 g, 20.53 mmol) and K2CO3(18.3 g, 56.0 mmol) at RT. The reaction mixture was degassed for 15 minutes then Pd(PPh3)4 (1.1 g, 0.95 mmol) was added. The reaction mixture was stirred at 90 °C for 5 h under nitrogen atmosphere. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The residue was purified by automated normal-phase chromatography and eluted with ethyl acetate / petroleum ether to give 3-(5-(thiazol-2-yl)pyridin-3-yl)phenol (2.2 g) as an off white solid.1H-NMR (400 MHz, DMSO-d6): δ 9.69 (s, 1H), 9.13 (d, J = 2.00 Hz, 1H), 8.92 (d, J = 2.00 Hz, 1H), 8.43 (t, J = 2.40 Hz, 1H), 8.05 (d, J = 3.20 Hz, 1H), 7.94 (d, J = 3.20 Hz, 1H), 7.35 (t, J = 8.00 Hz, 1H), 63336124\1 7.24 (d, J = 8.00 Hz, 1H), 7.16 (t, J = 2.00 Hz, 1H), 6.89 - 6.87 (m, 1H); MS (ES+APCI) m / z 255.2 (M+1). Synthesis of 3-(5-(furan-2-yl)pyridin-3-yl)phenyl octylcarbamate (Example-115) To a stirred solution of 3-(5-(thiazol-2-yl)pyridin-3-yl)phenol (0.07 g, 0.28 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.06 mL, 0.42 mmol) and n-octyl isocyanate (0.05 g, 0.33 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 5 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (70 mg) as an off white solid.1H-NMR (400 MHz, DMSO-d6): δ 9.16 (d, J = 2.00 Hz, 1H), 8.99 (d, J = 2.00 Hz, 1H), 8.50 (t, J = 2.00 Hz, 1H), 8.05 (d, J = 3.20 Hz, 1H), 7.95 (d, J = 3.20 Hz, 1H), 7.82 (t, J = 5.60 Hz, 1H), 7.68 (d, J = 8.00 Hz, 1H), 7.59 (t, J = 2.00 Hz, 1H), 7.54 (t, J = 8.00 Hz, 1H), 7.22 - 7.19 (m, 1H), 3.09 (t, J = 6.40 Hz, 2H), 1.50 - 1.45 (m, 2H), 1.29 - 1.27 (m, 10H), 0.86 (t, J = 6.80 Hz, 3H); MS (ES+APCI) m / z 410.3 (M+1). Synthesis of 3-(5-(thiazol-2-yl)pyridin-3-yl)phenyl (cyclohexylmethyl)carbamate (Example-116) To a stirred solution of 3-(5-(thiazol-2-yl)pyridin-3-yl)phenol (0.07 g, 0.28 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.06 mL, 0.42 mmol) and cyclohexanemethyl isocyanate (0.050 g, 0.33 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 5 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (58 mg) as an off white solid.1H- NMR (400 MHz, DMSO-d6): δ 9.16 (d, J = 2.00 Hz, 1H), 8.99 (d, J = 2.00 Hz, 1H), 8.50 (t, J = 2.00 Hz, 1H), 8.05 (d, J = 3.20 Hz, 1H), 7.96 (d, J = 3.20 Hz, 1H), 7.96 (d, J = 3.20 Hz, 1H), 63336124\1 7.85 (t, J = 6.00 Hz, 1H), 7.69 - 7.67 (m, 1H), 7.60 (t, J = 2.00 Hz, 1H), 7.54 (t, J = 8.00 Hz, 1H), 7.22 - 7.20 (m, 1H), 2.94 (t, J = 6.40 Hz, 2H), 1.75 - 1.62 (m, 5H), 1.48 - 1.43 (m, 1H), 1.26 - 1.13 (m, 3H), 0.96 - 0.88 (m, 2H); MS (ES+APCI) m / z 394.3 (M+1). Synthesis of 3-(5-(thiazol-2-yl)pyridin-3-yl)phenyl benzylcarbamate (Example-117) To a stirred solution of 3-(5-(thiazol-2-yl)pyridin-3-yl)phenol (0.07 g, 0.275 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.06 mL, 0.42 mmol) and benzyl isocyanate (0.05 g, 0.33 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 5 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (46 mg) as an off white solid.1H- NMR (400 MHz, DMSO-d6): δ 9.16 (d, J = 2.00 Hz, 1H), 9.00 (d, J = 2.40 Hz, 1H), 8.51 (t, J = 2.00 Hz, 1H), 8.41 (t, J = 6.00 Hz, 1H), 8.05 (d, J = 3.20 Hz, 1H), 7.96 (d, J = 3.20 Hz, 1H), 7.70 (d, J = 8.00 Hz, 1H), 7.64 (t, J = 2.00 Hz, 1H), 7.56 (t, J = 8.00 Hz, 1H), 7.41 - 7.34 (m, 4H), 7.30 - 7.25 (m, 2H), 4.43 - 4.31 (m, 2H); MS (ES+APCI) m / z 388.3 (M+1). Synthesis of 3-(5-(thiazol-2-yl)pyridin-3-yl)phenyl cyclopentylcarbamate (Example-118) To a stirred solution of 3-(5-(thiazol-2-yl)pyridin-3-yl)phenol (0.07 g, 0.28 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.06 mL, 0.42 mmol) and cyclopentyl isocyanate (0.04 g, 0.33 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 5 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (24 mg) as an off white solid.1H-NMR (400 MHz, DMSO-d6): δ 9.16 (d, J = 2.00 Hz, 1H), 8.99 (d, J = 2.00 Hz, 1H), 8.50 (t, J = 2.40 Hz, 1H), 8.05 (d, J = 3.20 Hz, 1H), 7.95 (d, J = 3.20 Hz, 1H), 7.87 (d, J = 7.60 Hz, 1H), 7.68 (d, J = 7.60 Hz, 1H), 7.61 (t, J = 1.60 Hz, 1H), 7.54 (t, J = 8.00 Hz, 1H), 7.22 - 7.20 (m, 1H), 3.90 - 63336124\1 3.85 (m, 1H), 1.89 - 1.85 (m, 2H), 1.67 (d, J = 12.00 Hz, 2H), 1.54 - 1.51 (m, 4H); MS (ES+APCI) m / z 366.3 (M+1). Synthesis of 3-(5-(thiazol-2-yl)pyridin-3-yl)phenyl cyclohexylcarbamate (Example-119) To a stirred solution of 3-(5-(thiazol-2-yl)pyridin-3-yl)phenol (0.07 g, 0.28 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.06 mL, 0.42 mmol) and cyclohexyl isocyanate (0.04 g, 0.33 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 5 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (44 mg) as an off white solid.1H-NMR (400 MHz, DMSO-d6): δ 9.16 (d, J = 2.00 Hz, 1H), 8.99 (d, J = 2.40 Hz, 1H), 8.50 (t, J = 2.00 Hz, 1H), 8.05 (t, J = 1.60 Hz, 1H), 7.95 (d, J = 3.20 Hz, 1H), 7.80 (d, J = 8.00 Hz, 1H), 7.68 (d, J = 8.00 Hz, 1H), 7.60 (t, J = 1.60 Hz, 1H), 7.54 (t, J = 8.00 Hz, 1H), 7.22 - 7.20 (m, 1H), 3.33 (s, 1H), 1.86 (d, J = 8.40 Hz, 2H), 1.73 (t, J = 4.80 Hz, 2H), 1.58 (d, J = 12.00 Hz, 1H), 1.34 - 1.20 (m, 4H), 1.16 - 1.11 (m, 1H); MS (ES+APCI) m / z 380.3 (M+1). Synthesis of 3-(5-(thiazol-2-yl)pyridin-3-yl)phenyl cycloheptylcarbamate (Example-120) To a stirred solution of 3-(5-(thiazol-2-yl)pyridin-3-yl)phenol (0.07 g, 0.28 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.06 mL, 0.42 mmol) and cycloheptyl isocyanate (0.05 g, 0.33 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 5 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (65 mg) as an off white solid.1H-NMR (400 MHz, DMSO-d6): δ 9.16 (d, J = 2.40 Hz, 1H), 8.99 (d, J = 2.00 Hz, 1H), 8.50 (t, J = 2.00 Hz, 1H), 8.05 (t, J = 1.60 Hz, 1H), 7.95 (d, J = 3.20 Hz, 1H), 7.84 (d, J = 8.00 Hz, 1H), 7.68 (d, J = 8.00 Hz, 1H), 7.60 (t, J = 2.00 Hz, 1H), 7.54 (t, J = 8.00 Hz, 1H), 7.22 - 7.20 (m, 1H), 3.61 - 63336124\1 3.52 (m, 1H), 1.91 - 1.86 (m, 2H), 1.68 - 1.48 (m, 10H); MS (ES+APCI) m / z 394.3 (M+1). Synthesis of 4-methoxy-3-(5-(thiazol-2-yl)pyridin-3-yl)phenol To a stirred solution of 2-(5-bromopyridin-3-yl)thiazole (0.6 g, 2.48 mmol) in 1,4-dioxane (5 mL) and water (0.5 mL) was added (5-hydroxy-2-methoxyphenyl)boronic acid (0.50 g, 2.74 mmol) and K2CO3 (2.5 g, 7.47 mmol) at RT. The reaction mixture was degassed for 15 minutes then Pd(PPh3)4(0.150 g, 0.125 mmol) was added. The reaction mixture was stirred at 90 °C for 5 h under nitrogen atmosphere. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The residue was dissolved in ethyl acetate, washed with water followed by brine. The organic layer was dried over sodium sulfate then evaporated under reduced pressure. The residue was purified by automated normal-phase chromatography and eluted with ethyl acetate / petroleum ether to give 4-methoxy-3-(5-(thiazol-2-yl)pyridin-3-yl)phenol (600 mg) as an off white solid.1H-NMR (400 MHz, DMSO-d6): δ 9.19 (s, 1H), 9.07 (d, J = 2.80 Hz, 1H), 8.73 (d, J = 2.80 Hz, 1H), 8.33 (t, J = 2.80 Hz, 1H), 8.02 (t, J = 2.00 Hz, 1H), 7.91 (d, J = 4.40 Hz, 1H), 7.01 (d, J = 12.00 Hz, 1H), 6.85 - 6.81 (m, 2H), 3.71 (s, 3H); MS (ES+APCI) m / z 285.0 (M+1). Synthesis of 4-methoxy-3-(5-(thiazol-2-yl)pyridin-3-yl)phenyl octylcarbamate (Example- 121) To a stirred solution of 4-methoxy-3-(5-(thiazol-2-yl)pyridin-3-yl)phenol (0.07 g, 0.24 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.05 mL, 0.37 mmol) and octyl isocyanate (0.05 g, 0.30 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 5 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (80 mg) as an off white solid.1H- 63336124\1 NMR (400 MHz, DMSO-d6): δ 9.10 (d, J = 2.40 Hz, 1H), 8.77 (d, J = 2.00 Hz, 1H), 8.37 (t, J = 2.00 Hz, 1H), 8.03 (d, J = 3.20 Hz, 1H), 7.93 (d, J = 3.20 Hz, 1H), 7.72 (t, J = 5.60 Hz, 1H), 7.23 (d, J = 1.20 Hz, 1H), 7.17 (s, 2H), 3.82 (s, 3H), 3.06 (t, J = 6.40 Hz, 2H), 1.48 - 1.43 (m, 2H), 1.27 - 1.26 (m, 10H), 0.85 (t, J = 7.20 Hz, 3H); MS (ES+APCI) m / z 440.2 (M+1). Synthesis of 4-methoxy-3-(5-(thiazol-2-yl)pyridin-3-yl)phenyl (cyclohexylmethyl)carbamate (Example-122) To a stirred solution of 4-methoxy-3-(5-(thiazol-2-yl)pyridin-3-yl)phenol (0.07 g, 0.24 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.05 mL, 0.37 mmol) and cyclohexanemethyl isocyanate (0.04 g, 0.30 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 5 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (63 mg) as an off white solid.1H-NMR (400 MHz, DMSO-d6): δ 9.10 (d, J = 2.00 Hz, 1H), 8.77 (d, J = 2.40 Hz, 1H), 8.37 (t, J = 2.00 Hz, 1H), 8.03 (d, J = 3.20 Hz, 1H), 7.93 (d, J = 3.20 Hz, 1H), 7.74 (t, J = 6.00 Hz, 1H), 7.24 (t, J = 1.60 Hz, 1H), 7.17 (d, J = 1.60 Hz, 2H), 3.82 (s, 3H), 2.91 (t, J = 6.40 Hz, 2H), 1.73 - 1.61 (m, 5H), 1.46 - 1.41 (m, 1H), 1.21 - 1.12 (m, 3H), 0.92 (d, J = 11.60 Hz, 2H); MS (ES+APCI) m / z 424.2 (M+1). Synthesis of 4-methoxy-3-(5-(thiazol-2-yl)pyridin-3-yl)phenyl benzylcarbamate (Example-123) To a stirred solution of 4-methoxy-3-(5-(thiazol-2-yl)pyridin-3-yl)phenol (0.07 g, 0.24 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.05 mL, 0.37 mmol) and benzyl isocyanate (0.04 g, 0.30 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 5 h. After completion of the reaction (monitored by 63336124\1 LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (40 mg) as an off white solid.1H- NMR (400 MHz, DMSO-d6): δ 9.10 (d, J = 2.00 Hz, 1H), 8.78 (d, J = 2.00 Hz, 1H), 8.38 (t, J = 2.00 Hz, 1H), 8.30 (t, J = 6.00 Hz, 1H), 8.03 (d, J = 3.20 Hz, 1H), 7.93 (d, J = 3.20 Hz, 1H), 7.38 - 7.32 (m, 4H), 7.28 - 7.25 (m, 2H), 7.23 - 7.17 (m, 2H), 4.39 - 4.28 (m, 2H), 3.82 (s, 3H); MS (ES+APCI) m / z 418.1 (M+1). Synthesis of 4-methoxy-3-(5-(thiazol-2-yl)pyridin-3-yl)phenyl cyclopentylcarbamate (Example-124) To a stirred solution of 4-methoxy-3-(5-(thiazol-2-yl)pyridin-3-yl)phenol (0.07 g, 0.24 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.05 mL, 0.37 mmol) and cyclopentyl isocyanate (0.04 g, 0.30 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 5 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (58 mg) as an off white solid.1H-NMR (400 MHz, DMSO-d6): δ 9.10 (d, J = 2.00 Hz, 1H), 8.77 (d, J = 2.00 Hz, 1H), 8.37 (t, J = 2.00 Hz, 1H), 8.03 (d, J = 3.20 Hz, 1H), 7.93 (d, J = 3.20 Hz, 1H), 7.76 (d, J = 7.20 Hz, 1H), 7.24 (s, 1H), 7.18 (d, J = 1.60 Hz, 2H), 3.87 - 3.82 (m, 4H), 1.85 - 1.80 (m, 2H), 1.68 - 1.63 (m, 2H), 1.53 - 1.46 (m, 4H); MS (ES+APCI) m / z 396.1 (M+1). Synthesis of 4-methoxy-3-(5-(thiazol-2-yl)pyridin-3-yl)phenyl cyclohexylcarbamate (Example-125) To a stirred solution of 4-methoxy-3-(5-(thiazol-2-yl)pyridin-3-yl)phenol (0.07 g, 0.24 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.05 mL, 0.37 mmol) and cyclohexyl isocyanate (0.04 g, 0.30 mmol) at RT under nitrogen atmosphere. The reaction mixture was 63336124\1 stirred at RT for 10 minutes and then stirred at 75 °C for 5 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (30 mg) as an off white solid.1H-NMR (400 MHz, DMSO-d6): δ 9.10 (d, J = 2.00 Hz, 1H), 8.77 (d, J = 2.00 Hz, 1H), 8.37 (t, J = 2.00 Hz, 1H), 8.03 (d, J = 3.20 Hz, 1H), 7.93 (d, J = 3.20 Hz, 1H), 7.69 (d, J = 8.00 Hz, 1H), 7.24 (d, J = 1.20 Hz, 1H), 7.17 (d, J = 1.60 Hz, 2H), 3.82 (s, 3H), 3.33 (s, 1H), 1.84 - 1.69 (m, 4H), 1.57 (d, J = 12.00 Hz, 1H), 1.29 - 1.21 (m, 4H), 1.18 - 1.10 (m, 1H); MS (ES+APCI) m / z 410.1 (M+1). Synthesis of 4-methoxy-3-(5-(thiazol-2-yl)pyridin-3-yl)phenyl cycloheptylcarbamate (Example-126) To a stirred solution of 4-methoxy-3-(5-(thiazol-2-yl)pyridin-3-yl)phenol (0.07 g, 0.24 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.05 mL, 0.37 mmol) and cycloheptyl isocyanate (0.04 g, 0.30 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then stirred at 75 °C for 5 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (54 mg) as an off white solid.1H-NMR (400 MHz, DMSO-d6): δ 9.10 (d, J = 2.00 Hz, 1H), 8.77 (d, J = 2.00 Hz, 1H), 8.37 (t, J = 2.00 Hz, 1H), 8.03 (d, J = 3.20 Hz, 1H), 7.93 (d, J = 3.20 Hz, 1H), 7.73 (d, J = 8.00 Hz, 1H), 7.24 (d, J = 1.60 Hz, 1H), 7.17 (d, J = 1.20 Hz, 2H), 3.82 (s, 3H), 3.56 - 3.52 (m, 1H), 1.89 - 1.84 (m, 2H), 1.66 - 1.61 (m, 2H), 1.59 - 1.52 (m, 6H), 1.50 - 1.47 (m, 2H); MS (ES+APCI) m / z 424.2 (M+1). 63336124\1 Scheme VI: Reagents and conditions: a) Pd(PPh3)4, K2CO3, 1,4-dioxane, H2O, 90oC, 12 h or Pd(dppf)Cl2, KOAc, 1,4-Dioxane, 90oC, 12 h; b) NH2-NH2.H2O, EtOH, 60oC, 12 h; c) CH(OC2H5)3, 120-130oC, 5 h d) R3-NCO, TEA, ACN, 75oC, 2-6 h; e) Pd / C, Pd(OH)2, H2gas (balloon), tetrahydrofuran (THF), isopropanol (IPA), RT,16 h; f) R3COCl, TEA, ACN, 75oC, 6-12 h. Synthesis of 5-(3-hydroxyphenyl)nicotinohydrazide To a solution of ethyl 5-(3-hydroxyphenyl)nicotinate (0.25 g, 1.028 mmol) in ethanol (6 mL) was added hydrazine hydrate (0.61 g, 6.16 mmol) at RT. The reaction mixture was heated at 90 °C for 15 h. The reaction progress was monitored by TLC, after completion the reaction was cooled to RT. The precipitated product was collected by filtrations and washed by ethanol. The filtrate was evaporated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with DCM / MeOH (gradient 2-20% MeOH) to yield the 5- (3-hydroxyphenyl)nicotinohydrazide (180 mg) as a pale yellow solid.1H NMR (400 MHz, 63336124\1 DMSO-d6) δ 10.06 (s, 1H), 9.67 (s, 1H), 8.94 (m, 2H), 8.35 (m, 1H), 7.32 (m, 1H), 7.20 (d, J = 7.7 Hz, 1H), 7.14 (s, 1H), 6.86 (dd, J = 7.8, 1.7 Hz, 1H), 4.60 (s, 2H). Synthesis of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenol A suspension of 5-(3-hydroxyphenyl)nicotinohydrazide (0.22 g, 0.92 mmol) in triethyl orthoformate (6 mL) was heated to 130 °C for 5 h under nitrogen atmosphere. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The compound was purified by column chromatography on silica gel eluting with DCM / MeOH (gradient 2-20% MeOH) to yield the 3- (5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenol (120 mg) as a yellowish solid.1H NMR (400 MHz, DMSO-d6): δ 9.73 (s, 1H), 9.49 (s, 1H), 9.17 (d, J = 1.8 Hz, 1H), 9.07 (d, J = 2.0 Hz, 1H), 8.49 (m, 1H), 7.35 (m, 1H), 7.24 (d, J = 7.7 Hz, 1H), 7.16 (s, 1H), 6.89 (dd, J = 7.8, 1.5 Hz, 1H). Synthesis of 3-(5-(1,3,4-oxadiazol-2-yl pyridin-3-yl)phenyl pentylcarbamate (Example- 127) To a suspension of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenol (0.08 g, 0.33 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.04 g, 0.4 mmol) and n-pentyl isocyanate (0.05 g, 0.42 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated at 75 °C for 3 h under nitrogen atmosphere. An additional amount of n-pentyl isocyanate (0.016 g, 0.11 mmol) was added to the reaction mixture and the reaction was heated for an additional 3 h. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 10-50% EtOAc) to yield the target compound (40 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6): δ 9.51 (s, 1H), 9.21 (d, J = 2.0 Hz, 1H), 9.16 (d, 63336124\1 J = 2.3 Hz, 1H), 8.61 (t, J = 2.2 Hz, 1H), 7.85 (t, J = 5.7 Hz, 1H), 7.70 (d, J = 7.8 Hz, 1H), 7.63 (t, J = 2.1 Hz, 1H), 7.56 (t, J = 7.9 Hz, 1H), 7.22 (dd, J = 7.9, 2.3 Hz, 1H), 3.08 (q, J = 6.6 Hz, 2H), 0.88 – 1.37 (m, 9H). Synthesis of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl hexylcarbamate (Example- 128) To a suspension of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.42 mmol) in anhydrous acetonitrile (3 mL) was added TEA (0.07 mL, 0.5 mmol) and n-hexyl isocyanate (0.053 g, 0.42 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated at 75 °C for 3 h under nitrogen atmosphere. An additional amount of n-hexyl isocyanate (0.018 g, 0.14 mmol) was added to the reaction mixture and the reaction was heated for an additional 3 h. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 10-55% EtOAc) to yield the target compound (42 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.50 (d, J = 4.5 Hz, 1H), 9.13 – 9.24 (m, 2H), 8.60 (t, J = 2.1 Hz, 1H), 7.85 (t, J = 5.7 Hz, 1H), 7.70 (d, J = 7.7 Hz, 1H), 7.62 (t, J = 2.0 Hz, 1H), 7.56 (t, J = 7.9 Hz, 1H), 7.15 – 7.28 (m, 1H), 3.08 (q, J = 6.6 Hz, 2H), 0.87 – 1.38 (m, 11H) Synthesis of 3-(5-(1,3,4-oxadiazol-2-yl)134 pyridine-3-yl)phenyl heptylcarbamate (Example-129) To a suspension of 3-(5-(1,3,4-oxadiazol-2-yl)pyridine-3-yl)phenol (0.08 g, 0.33 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.04 g, 0.4 mmol) and n-heptyl isocyanate (0.047 g, 0.33 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated at 75 °C for 3 h under nitrogen atmosphere. An additional amount 63336124\1 of n-heptyl isocyanate (0.016 g, 0.11 mmol) was added to the reaction mixture and the reaction was heated for additional 3 h. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 10-55% EtOAc) to yield the target compound (45 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.49 (d, J = 1.8 Hz, 1H), 9.21 (d, J = 2.1 Hz, 1H), 9.15 (d, J = 2.3 Hz, 1H), 8.60 (q, J = 2.3 Hz, 1H), 7.81 (t, J = 5.7 Hz, 1H), 7.70 (d, J = 7.7 Hz, 1H), 7.61 (d, J = 2.2 Hz, 1H), 7.55 (td, J = 7.9, 1.7 Hz, 1H), 7.22 (d, J = 8.1 Hz, 1H), 3.08 (q, J = 6.6 Hz, 2H), 0.83 – 1.34 (m, 13H). Synthesis of 3-(5-(1,3,4-oxadiazol-2-yl)pyridine-3-yl)phenyl octylcarbamate (Example- 130) To a suspension of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenol (0.08 g, 0.33 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.04 g, 0.4 mmol) and n-octyl isocyanate (0.05 g, 0.33 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated at 75 °C for 3 h under nitrogen atmosphere. An additional amount of n-octyl isocyanate (0.017 g, 0.11 mmol) was added to the reaction mixture and the reaction was heated for an additional 3 h. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 10-55% EtOAc) to yield the target compound (43 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.50 (s, 1H), 9.21 (d, J = 2.0 Hz, 1H), 9.15 (d, J = 2.2 Hz, 1H), 8.60 (t, J = 2.3 Hz, 1H), 7.82 (t, J = 5.7 Hz, 1H), 7.67 – 7.73 (m, 1H), 7.61 (t, J = 2.1 Hz, 1H), 7.55 (t, J = 7.9 Hz, 1H), 7.22 (dd, J = 8.0, 2.3 Hz, 1H), 3.08 (q, J = 6.6 Hz, 2H), 0.82 – 1.48 (m, 15H). Synthesis of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl dodecylcarbamate (Example- 131) 63336124\1 To a suspension of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenol (0.08 g, 0.33 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.04 g, 0.4 mmol) and n-dodecyl isocyanate (0.07 g, 0.33 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated at 75 °C for 3 h under nitrogen atmosphere. An additional amount of n-dodecyl isocyanate (0.023 g, 0.11 mmol) was added to the reaction mixture and the reaction was heated for an additional 3 h. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 10-55% EtOAc) to yield the target compound (45 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.50 (s, 1H), 9.21 (d, J = 2.0 Hz, 1H), 9.15 (d, J = 2.2 Hz, 1H), 8.60 (t, J = 2.3 Hz, 1H), 7.82 (t, J = 5.7 Hz, 1H), 7.67 – 7.73 (m, 1H), 7.61 (t, J = 2.1 Hz, 1H), 7.55 (t, J = 7.9 Hz, 1H), 7.22 (dd, J = 8.0, 2.3 Hz, 1H), 3.08 (q, J = 6.6 Hz, 2H), 0.82 – 1.38 (m, 23H). Synthesis of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl tetradecylcarbamate (Example-132) To a suspension of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenol (0.08 g, 0.33 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.04 g, 0.4 mmol) and tetradecyl isocyanate (0.08 g, 0.33 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated at 75 °C for 3 h under nitrogen atmosphere. An additional amount of tetradecyl isocyanate (0.026 g, 0.11 mmol) was added to the reaction mixture and the reaction was heated for an additional 3 h. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 10-50% EtOAc) to yield the target compound (33 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 0.85 – 1.47 (m, 27H), 3.08 (q, J = 6.6 Hz, 2H), 63336124\1 7.19 – 7.26 (m, 1H), 7.55 (t, J = 7.9 Hz, 1H), 7.62 (t, J = 2.1 Hz, 1H), 7.70 (d, J = 7.7 Hz, 1H), 7.84 (t, J = 5.8 Hz, 1H), 8.60 (t, J = 2.1 Hz, 1H), 9.15 (d, J = 2.2 Hz, 1H), 9.21 (d, J = 2.0 Hz, 1H), 9.51 (s, 1H).1H NMR (400 MHz, DMSO-d6) δ 9.51 (s, 1H), 9.21 (d, J = 2.0 Hz, 1H), 9.15 (d, J = 2.2 Hz, 1H), 8.60 (t, J = 2.1 Hz, 1H), 7.84 (t, J = 5.8 Hz, 1H), 7.70 (d, J = 7.7 Hz, 1H), 7.62 (t, J = 2.1 Hz, 1H), 7.55 (t, J = 7.9 Hz, 1H), 7.19 – 7.26 (m, 1H), 3.08 (q, J = 6.6 Hz, 2H), 0.85 – 1.47 (m, 27H). Synthesis of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl octadecylcarbamate (Example- 133) To a suspension of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenol (0.08 g, 0.33 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.04 g, 0.4 mmol) and n-octadecyl isocyanate (0.1 g, 0.33 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated at 75 °C for 3 h under nitrogen atmosphere. An additional amount of n-octadecyl isocyanate (0.032 g, 0.11 mmol) was added to the reaction mixture and the reaction was heated for an additional 3 h. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 10-50% EtOAc) to yield the target compound (45 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.51 (s, 1H), 9.21 (d, J = 2.0 Hz, 1H), 9.15 (s, 1H), 8.60 (s, 1H), 7.83 (d, J = 5.7 Hz, 1H), 7.71 (d, J = 7.7 Hz, 1H), 7.62 (s, 1H), 7.55 (t, J = 7.9 Hz, 1H), 7.22 (d, J = 8.1 Hz, 1H), 3.08 (d, J = 6.8 Hz, 2H), 0.81 – 1.48 (m, 35H). Synthesis of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl (cyclohexylmethyl)carbamate (Example-134) To a suspension of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.42 mmol) in anhydrous acetonitrile (3 mL) was added TEA (0.07 mL, 0.5 mmol) and cyclohexanemethyl 63336124\1 isocyanate (0.06 g, 0.42 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated at 75 °C for 3 h under nitrogen atmosphere. An additional amount of cyclohexanemethyl isocyanate (0.02 mL, 0.14 mmol) was added to the reaction mixture and the reaction was heated for an additional 3 h. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 10-60% EtOAc) to yield the target compound (60 mg) as an off white solid.1H-NMR (400 MHz, DMSO-d6) δ 9.51 (d, J = 1.1 Hz, 1H), 9.21 (d, J = 2.0 Hz, 1H), 9.16 (d, J = 2.2 Hz, 1H), 8.61 (t, J = 2.1 Hz, 1H), 7.86 (t, J = 6.0 Hz, 1H), 7.70 (d, J = 7.6 Hz, 1H), 7.63 (d, J = 2.0 Hz, 1H), 7.55 (t, J = 7.9 Hz, 1H), 7.19 – 7.26 (m, 1H), 2.94 (t, J = 6.4 Hz, 2H), 1.99 (s, 1H), 1.11-1.86 (m, 10H) Synthesis of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl benzylcarbamate (Example- 135) To a suspension of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.42 mmol) in anhydrous acetonitrile (3 mL) was added TEA (0.07 mL, 0.5 mmol) and benzyl isocyanate (0.056 g, 0.42 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated at 75 °C for 3 h under nitrogen atmosphere. An additional amount of benzyl isocyanate (0.02 g, 0.14 mmol) was added to the reaction mixture and the reaction was heated for additional 9 h. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 10-60% EtOAc) to yield the target compound (52 mg) as an off white solid.1H-NMR (400 MHz, DMSO-d6) δ 9.53 (s, 1H), 9.22 (d, J = 2.1 Hz, 1H), 9.18 (d, J = 2.2 Hz, 1H), 8.61 (t, J = 2.1 Hz, 1H), 7.93 (t, J = 5.7 Hz, 1H), 7.73 (d, J = 7.7 Hz, 1H), 7.68 (t, J = 2.1 Hz, 1H), 7.58 (t, J = 7.7 Hz, 1H), 7.12 – 7.38 (m, 5H), 3.82 (s, 2H). 63336124\1 Synthesis of 3-(5-(1,3,4-oxadiazol-2-yl)pyridine-3-yl)phenyl (3-phenylpropyl)carbamate (Example-136) To a suspension of 3-(5-(1,3,4-oxadiazol-2-yl)pyridine-3-yl)phenol (0.08 g, 0.33 mmol) in anhydrous acetonitrile (2 mL) was added TEA (0.04 g, 0.4 mmol) and 3-phenylpropyl isocyanate (0.053 g, 0.42 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated at 75 °C for 3 h under nitrogen atmosphere. An additional amount of 3-phenylpropyl isocyanate (0.018 g, 0.11 mmol) was added to the reaction mixture and the reaction was heated for an additional 3 h. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 20-50% EtOAc) to yield the target compound (45 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.51 (s, 1H), 9.21 (d, J = 2.0 Hz, 1H), 9.16 (d, J = 2.2 Hz, 1H), 8.61 (t, J = 2.1 Hz, 1H), 7.93 (t, J = 5.7 Hz, 1H), 7.71 (d, J = 7.7 Hz, 1H), 7.64 (t, J = 2.0 Hz, 1H), 7.56 (t, J = 7.9 Hz, 1H), 7.34 – 7.13 (m, 5H), 3.12 (q, J = 6.6 Hz, 2H), 2.65 (t, J = 7.7 Hz, 2H), 1.80 (p, J = 7.4 Hz, 2H) Synthesis of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl cycloheptylcarbamate (Example-137) To a suspension of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.42 mmol) in anhydrous acetonitrile (6 mL) was added TEA (0.07 mL, 0.5 mmol) and cycloheptyl isocyanate (0.05 g, 0.40 mmol) at RT under a nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated at 75 °C for 3 h under a nitrogen atmosphere. An additional amount of cycloheptyl isocyanate (0.01 g, 0.14 mmol)was added to the reaction mixture and the reaction was heated for an additional 3 h. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was 63336124\1 evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 10-60% EtOAc) to yield a target compound (72% yield) as a white solid. Synthesis of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl cyclopentylcarbamate (Example-138) To a suspension of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.42 mmol) in anhydrous acetonitrile (3 mL) was added TEA (0.07 mL, 0.5 mmol) and cyclopentyl isocyanate (0.046 mL, 0.42 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated at 75 °C for 3 h under nitrogen atmosphere. An additional amount of cyclopentyl isocyanate (0.015 mL, 0.14 mmol) was added to the reaction mixture and the reaction was heated for an additional 3 h. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 10-50% EtOAc) to yield the target compound (45 mg) as an off white solid.1H-NMR (400 MHz, DMSO-d6): δ 9.51 (s, 1H), 9.21 (s, 1H), 9.15 (s, 1H), 8.61 (t, J = 2.1 Hz, 1H), 7.88 (d, J = 8.1 Hz, 1H), 7.70 (d, J = 8.1 Hz, 1H), 7.64 (s, 1H), 7.55 (t, J = 8.1 Hz, 1H), 7.24 (d, J = 8.1 Hz, 1H), 3.18 (s, 1H), 1.86 – 1.11 (m, 8H). Synthesis of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl cyclohexylcarbamate (Example-139) To a suspension of 3-(5-(1,3,4-oxadiazol-2-yl)yridine-3-yl)phenol (0.11 g, 0.46 mmol) in anhydrous acetonitrile (3 mL) was added TEA (0.076 mL, 0.55 mmol) and cyclohexyl isocyanate (0.06 mL, 0.46 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated at 75 °C for 3 h under nitrogen atmosphere. An 63336124\1 additional amount of cyclohexyl isocyanate (0.02 mL, 0.15 mmol) was added to the reaction mixture and the reaction was heated for an additional 3 h. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 10-60% EtOAc) to yield the target compound (66 mg) as an off white solid.1H-NMR (400 MHz, DMSO-d6) δ 9.51 (s, 1H), 9.21 (s, 1H), 9.15 (s, 1H), 8.60 (t, J = 2.1 Hz, 1H), 7.82 (d, J = 8.1 Hz, 1H), 7.70 (d, J = 8.1 Hz, 1H), 7.63 (s, 1H), 7.55 (t, J = 8.1 Hz, 1H), 7.22 (d, J = 8.1 Hz, 1H), 3.3 (s, 1H), 1.86 – 1.11 (m, 10H) Synthesis of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl naphthalen-1-ylcarbamate (Example-140) To a suspension of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.42 mmol) in anhydrous acetonitrile (3 mL) was added TEA (0.07 mL, 0.5 mmol) and 1-naphthyl isocyanate (0.07 g, 0.42 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 10 minutes and then heated at 75 °C for 3 h under nitrogen atmosphere. An additional amount of 1-naphthyl isocyanate (0.023 g, 0.14 mmol) was added to the reaction mixture and the reaction was heated for an additional 12 h. The reaction progress was monitored by TLC, after completion the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with DCM / MeOH (gradient 2-8% MeOH) to yield the target compound (55 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.74 (s, 1H), 9.50 (d, J = 1.2 Hz, 1H), 9.19 (d, J = 2.0 Hz, 1H), 9.08 (d, J = 2.2 Hz, 1H), 8.51 (t, J = 2.1 Hz, 1H), 8.05 (d, J = 8.2 Hz, 1H), 7.78 – 7.69 (m, 1H), 7.44 – 7.32 (m, 3H), 7.23 – 7.15 (m, 2H), 7.07 (d, J = 8.1 Hz, 1H), 6.94 – 6.86 (m, 1H), 6.70 – 6.63 (m, 1H). Synthesis of piperidine-1-carbonyl chloride 63336124\1 To a stirred solution of Diphosgene (0.47 g, 2.4 mmol) in DCM (2 mL) at 0-5 °C under nitrogen atmosphere was added the solution of cyclohexanamine (0.2 g, 2.0 mmol) in DCM dropwise. N,N-diisopropylethylamine (DIPEA) (0.62 mL, 3.53 mmol) was added, and the resulting mixture was stirred at 0-5 °C for 20 minutes. and then stirred at RT for 20 minutes. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with aq. 1.5N hydrochloric acid solution and extracted with dichloromethane. The combined organic layers were washed with water, brine and concentrated to give piperidine-1-carbonyl chloride which was used for the next step without further purification. Synthesis of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl piperidine-1-carboxylate (Example-141) To a stirred solution of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.42 mmol) in acetonitrile (2 mL) at 0-5 °C under nitrogen atmosphere was added piperidine-1-carbonyl chloride (0.074 g, 0.50 mmol) and TEA (0.07 mL, 0.54 mmol). The resulting mixture was stirred at 75 °C for 16 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (68 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.51 (s, 1H), 9.21 (d, J = 2.00 Hz, 1H), 9.16 (d, J = 2.40 Hz, 1H), 8.62 (t, J = 2.00 Hz, 1H), 7.74 - 7.72 (m, 1H), 7.67 (t, J = 2.00 Hz, 1H), 7.56 (t, J = 8.00 Hz, 1H), 7.27 - 7.24 (m, 1H), 3.6 (bs, 2H), 3.43 (bs, 2H) 1.61 - 1.57 (m, 6H); MS (ES+APCI) m / z 351.4 (M+1). Synthesis of 2-methylpiperidine-1-carbonyl chloride To a stirred solution of diphosgene (0.48 g, 2.42 mmol) in DCM (2 mL) at 0-5 °C under nitrogen 63336124\1 atmosphere was added the solution of 2-methylpiperidine (0.2 g, 2.02 mmol) in DCM dropwise. DIPEA (0.7 ml, 4.03 mmol) was added, and the resulting mixture was stirred at 0-5 °C for 20 minutes. and then stirred at RT for 20 minutes. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with aq.1.5N hydrochloric acid solution and extracted with dichloromethane. The combined organic layers were washed with water, brine and concentrated to give 2-methylpiperidine-1-carbonyl chloride which was used for the next step without further purification. Synthesis of cyclohexyl(methyl)carbamic chloride To a stirred solution of Diphosgene (0.42 g, 2.12 mmol) in DCM (2 mL) at 0-5 °C under nitrogen atmosphere was added the solution of N-methylcyclohexanamine (0.2 g, 1.77 mmol) in DCM dropwise. DIPEA (0.62 mL, 3.53 mmol) was added, and the resulting mixture was stirred at 0- 5 °C for 20 minutes. and then stirred at RT for 20 minutes. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with aq. 1.5N hydrochloric acid solution and extracted with dichloromethane. The combined organic layers were washed with water, brine and concentrated to give cyclohexyl(methyl)carbamic chloride which was used for the next step without further purification. Synthesis of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl cyclohexyl(methyl)carbamate (Example-142) To a stirred solution of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.42 mmol) in acetonitrile (2 mL) at 0-5 °C under nitrogen atmosphere was added cyclohexyl(methyl)carbamic chloride (0.15 g, 0.84 mmol) and TEA (0.2 mL, 1.05 mmol). The resulting mixture was stirred at 75 °C for 16 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (49 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.51 63336124\1 (s, 1H), 9.21 (d, J = 2.00 Hz, 1H), 9.16 (d, J = 2.40 Hz, 1H), 8.62 (t, J = 2.40 Hz, 1H), 7.74 - 7.66 (m, 2H), 7.56 (t, J = 8.00 Hz, 1H), 7.25 (d, J = 8.00 Hz, 1H), 3.99 - 3.87 (m, 1H), 2.96 - 2.84 (m, 3H), 1.81 - 1.79 (m, 3H), 1.69 - 1.49 (m, 4H), 1.36 - 1.30 (m, 2H), 1.17 - 1.03 (m, 1H); MS (ES+APCI) m / z 379.3 (M+1). Synthesis of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl 2-methylpiperidine-1- carboxylate (Example-143) To a stirred solution of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenol (0.12 g, 0.50 mmol) in acetonitrile (2 mL) at 0-5 °C under nitrogen atmosphere was added azepane-1-carbonyl chloride (0.16 g, 1.00 mmol) and TEA (0.09 mL, 0.65 mmol). The resulting mixture was stirred at 75 °C for 16 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (45 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.51 (s, 1H), 9.21 (d, J = 2.00 Hz, 1H), 9.16 (d, J = 2.40 Hz, 1H), 8.62 (t, J = 2.00 Hz, 1H), 7.76 - 7.74 (m, 1H), 7.71 (t, J = 2.00 Hz, 1H), 7.58 (t, J = 7.60 Hz, 1H), 7.30 - 7.27 (m, 1H), 3.68 - 3.64 (m, 6H); MS (ES+APCI) m / z 365.3 (M+1). Synthesis of cycloheptyl(methyl)carbamic chloride To a stirred solution of diphosgene (0.37 g, 1.89 mmol) in DCM (2 mL) at 0-5 °C under nitrogen atmosphere was added the solution of N-methylcycloheptanamine (0.2 g, 1.57 mmol) in DCM dropwise. DIPEA (0.55 mL, 3.14 mmol) was added, and the resulting mixture was stirred at 0- 5 °C for 20 minutes. and then stirred at RT for 20 minutes. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with aq. 1.5N hydrochloric acid solution and extracted with dichloromethane. The combined organic layers were washed with water, brine and concentrated to give cycloheptyl(methyl)carbamic chloride which was used for next step without further purification. 63336124\1 Synthesis of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl cycloheptyl(methyl)carbamate (Example-144) To a stirred solution of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenol (0.09 g, 0.38 mmol) in acetonitrile (2 mL) at 0-5 °C under nitrogen atmosphere was added cycloheptyl(methyl)carbamic chloride (0.14 g, 0.75 mmol) and TEA (0.06 mL, 0.49 mmol). The resulting mixture was stirred at 75 °C for 16 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (85 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.51 (s, 1H), 9.21 (d, J = 2.00 Hz, 1H), 9.16 (d, J = 2.40 Hz, 1H), 8.62 (t, J = 2.00 Hz, 1H), 7.72 (d, J = 8.00 Hz, 1H), 7.66 (s, 1H), 7.56 (t, J = 8.00 Hz, 1H), 7.25 (d, J = 8.00 Hz, 1H), 4.14 - 4.01 (m, 1H), 2.96 - 2.83 (m, 3H), 1.88 - 1.70 (m, 6H), 1.57 - 1.43 (m, 6H); MS (ES+APCI) m / z 379.3 (M+1). Synthesis of cycloheptylcarbamic chloride To a stirred solution of Diphosgene (0.41 g, 2.12 mmol) in DCM (2 mL) at 0-5 °C under nitrogen atmosphere was added the solution of cycloheptanamine (0.2 g, 1.76 mmol) in DCM dropwise. DIPEA (0.55 mL, 3.14 mmol) was added, and the resulting mixture was stirred at 0-5 °C for 20 minutes. and then stirred at RT for 20 minutes. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with aq.1.5N hydrochloric acid solution and extracted with dichloromethane. The combined organic layers were washed with water, brine and concentrated to give cycloheptylcarbamic chloride which was used for next step without further purification. 63336124\1 Synthesis of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl azepane-1-carboxylate (Example-145) To a stirred solution of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.42 mmol) in acetonitrile (2 mL) at 0-5 °C under nitrogen atmosphere was added azepane-1-carbonyl chloride (0.08 g, 0.50 mmol) and TEA (0.07 mL, 0.54 mmol). The resulting mixture was stirred at 75 °C for 16 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (22 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.51 (s, 1H), 9.21 (d, J = 2.00 Hz, 1H), 9.16 (d, J = 2.40 Hz, 1H), 8.62 (t, J = 2.00 Hz, 1H), 7.73 (t, J = 7.60 Hz, 1H), 7.66 (t, J = 2.00 Hz, 1H), 7.57 (t, J = 7.60 Hz, 1H), 7.27 - 7.24 (m, 1H), 3.59 (t, J = 6.00 Hz, 2H), 3.45 (t, J = 6.00 Hz, 2H), 1.78 (t, J = 5.60 Hz, 2H), 1.70 (t, J = 5.60 Hz, 2H), 1.61 - 1.57 (m, 4H); MS (ES+APCI) m / z 365.3 (M+1). Synthesis of 2-azaspiro[3.3]heptane-2-carbonyl chloride To a stirred solution of diphosgene (0.40 g, 2.01 mmol) in DCM (2 mL) at 0-5 °C under nitrogen atmosphere was added the solution of 2-azaspiro[3.3]heptane (0.16 g, 1.67 mmol) in DCM dropwise. DIPEA (0.58 mL, 3.34 mmol) was added, and the resulting mixture was stirred at 0- 5 °C for 20 minutes. and then stirred at RT for 20 minutes. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with aq. 1.5N hydrochloric acid solution and extracted with dichloromethane. The combined organic layers were washed with water, brine and concentrated to give 2-azaspiro[3.3]heptane-2-carbonyl chloride which was used for the next step without further purification. Synthesis of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl 2-azaspiro[3.3]heptane-2- carboxylate (Example-146) 63336124\1 To a stirred solution of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.42 mmol) in acetonitrile (2 mL) at 0-5 °C under nitrogen atmosphere was added 2-azaspiro[3.3]heptane-2- carbonyl chloride (0.13 g, 0.84 mmol) and TEA (0.07 mL, 0.54 mmol). The resulting mixture was stirred at 75 °C for 16 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (60 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.51 (s, 1H), 9.21 (d, J = 2.00 Hz, 1H), 9.16 (d, J = 2.40 Hz, 1H), 8.61 (t, J = 2.00 Hz, 1H), 7.74 - 7.72 (m, 1H), 7.66 (t, J = 2.00 Hz, 1H), 7.56 (t, J = 8.00 Hz, 1H), 7.26 - 7.23 (m, 1H), 4.17 (bs, 2H), 3.98 (bs, 2H), 2.20 (t, J = 7.60 Hz, 4H), 1.84 - 1.77 (m, 2H); MS (ES+APCI) m / z 363.2 (M+1). Synthesis of 2-isocyanatospiro[3.3]heptane To a stirred solution of spiro[3.3]heptan-2-amine hydrochloride (0.12 g, 0.81 mmol) in DCM (2 mL) at 0-5 °C under nitrogen atmosphere was added sodium bicarbonate (0.7 g, 8.33 mmol) and triphosgene (0.024 g, 0.08 mmol). The resulting mixture was stirred at 0-5 °C for 20 minutes. and then stirred at RT for 20 minutes. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with aq.1.5N hydrochloric acid solution and extracted with dichloromethane. The combined organic layers were washed with water, brine and concentrated to give 2-isocyanatospiro[3.3]heptane which was used for the next step without further purification. Synthesis of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl spiro[3.3]heptan-2- ylcarbamate (Example-147) 63336124\1 To a stirred solution of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.42 mmol) in acetonitrile (2 mL) at 0-5 °C under nitrogen atmosphere was added 2- isocyanatospiro[3.3]heptane (0.11 g, 0.84 mmol) and TEA (0.07 mL, 0.54 mmol). The resulting mixture was stirred at 75 °C for 16 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (13 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.51 (s, 1H), 9.21 (d, J = 2.00 Hz, 1H), 9.15 (d, J = 2.40 Hz, 1H), 8.60 (t, J = 2.00 Hz, 1H), 8.08 (d, J = 8.00 Hz, 1H), 7.70 (d, J = 7.60 Hz, 1H), 7.63 (t, J = 2.00 Hz, 1H), 1.00 (t, J = 8.00 Hz, 1H), 7.23 - 7.20 (m, 1H), 3.89 (q, J = 8.40 Hz, 1H), 2.34 - 2.29 (m, 2H), 2.03 - 1.91 (m, 6H), 1.89 - 1.83 (m, 2H); MS (ES+APCI) m / z 377.3 (M+1). Synthesis of 3-azabicyclo[3.1.0]hexane-3-carbonyl chloride To a stirred solution of diphosgene (0.24 mL, 2.01 mmol) in DCM (2 mL) at 0-5 °C under nitrogen atmosphere was added 3-azabicyclo[3.1.0]hexane (0.2 g, 1.67 mmol) and DIPEA (0.58 mL, 3.34 mmol). The resulting mixture was stirred at 0-5 °C for 20 minutes. and then stirred at RT for 20 minutes. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with aq. 1.5N hydrochloric acid solution and extracted with dichloromethane. The combined organic layers were washed with water, brine and concentrated to give 3- azabicyclo[3.1.0]hexane-3-carbonyl chloride which was used for the next step without further purification. 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl 3-azabicyclo[3.1.0]hexane-3-carboxylate (Example-148) To a stirred solution of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.42 mmol) in acetonitrile (2 mL) at 0-5 °C under nitrogen atmosphere was added 3-azabicyclo[3.1.0]hexane- 3-carbonyl chloride (0.12 g, 0.84 mmol) and TEA (0.07 mL, 0.54 mmol). The resulting mixture 63336124\1 was stirred at 75 °C for 16 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (12 mg) as gummy solid.1H NMR (400 MHz, DMSO- d6) δ 9.51 (s, 1H), 9.21 (d, J = 2.00 Hz, 1H), 9.16 (d, J = 2.40 Hz, 1H), 8.61 (t, J = 2.00 Hz, 1H), 7.74 - 7.72 (m, 1H), 7.67 (t, J = 2.00 Hz, 1H), 7.56 (t, J = 8.00 Hz, 1H), 7.27 - 7.24 (m, 1H), 3.75 - 3.72 (m, 2H), 3.52 (m, 2H), 1.67 - 1.59 (m, 2H), 0.80 - 0.75 (m, 1H), 0.28 - 0.25 (m, 1H); MS (ES+APCI) m / z 349.3 (M+1). Synthesis of hexahydrocyclopenta[c]pyrrole-2(1H)-carbonyl chloride To a stirred solution of Triphosgene (0.40 g, 1.34 mmol) in DCM (2 mL) at 0-5 °C under nitrogen atmosphere was added DIPEA (0.58 mL, 3.34 mmol) and octahydrocyclopenta[c]pyrrole (0.19 g, 1.67 mmol) was added, and the resulting mixture was stirred at 0-5 °C for 20 minutes. and then stirred at RT for 20 minutes. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with aq. 1.5N hydrochloric acid solution and extracted with dichloromethane. The combined organic layers were washed with water, brine and concentrated to give hexahydrocyclopenta[c]pyrrole-2(1H)-carbonyl chloride which was used for the next step without further purification. Synthesis 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate (Example-149) To a stirred solution of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.42 mmol) in acetonitrile (2 mL) at 0-5 °C under nitrogen atmosphere was added hexahydrocyclopenta[c]pyrrole-2(1H)-carbonyl chloride (0.15 g, 0.84 mmol) and TEA (0.07 mL, 0.54 mmol). The resulting mixture was stirred at 75 °C for 16 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue 63336124\1 was purified by preparative HPLC (0.1% FA) to yield the target compound (55 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.51 (s, 1H), 9.21 (d, J = 2.00 Hz, 1H), 9.16 (d, J = 2.40 Hz, 1H), 8.61 (t, J = 2.00 Hz, 1H), 7.73 (t, J = 8.00 Hz, 1H), 7.67 (t, J = 2.00 Hz, 1H), 7.56 (t, J = 8.00 Hz, 1H), 7.27 - 7.25 (m, 1H), 3.79 (t, J = 8.00 Hz, 1H), 3.61 (q, J = 8.40 Hz, 1H), 3.53 (m, 1H), 3.16 (q, J = 4.40 Hz, 1H), 2.73 - 2.68 (m, 2H), 1.84 - 1.73 (m, 3H), 1.62 - 1.47 (m, 3H); MS (ES+APCI) m / z 377.3 (M+1). Synthesis of 8-azabicyclo[3.2.1]octane-8-carbonyl chloride To a stirred solution of triphosgene (0.40 g, 1.35 mmol) in DCM (2 mL) at 0-5 °C under nitrogen atmosphere was added DIPEA (1.18 mL, 6.77 mmol) and 8-azabicyclo[3.2.1]octane hydrochloride (0.25 g, 1.70 mmol) was added and the resulting mixture was stirred at 0-5 °C for 20 minutes. and then stirred at RT for 20 minutes. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with aq. 1.5N hydrochloric acid solution and extracted with dichloromethane. The combined organic layers were washed with water, brine and concentrated to give 8-azabicyclo[3.2.1]octane-8-carbonyl chloride which was used for the next step without further purification. Synthesis of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl 8-azabicyclo[3.2.1]octane-8- carboxylate (Example-150) To a stirred solution of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.42 mmol) in acetonitrile (2 mL) at 0-5 °C under nitrogen atmosphere was added 8-azabicyclo[3.2.1]octane- 8-carbonyl chloride (0.15 g, 0.84 mmol) and TEA (0.07 mL, 0.54 mmol). The resulting mixture was stirred at 75 °C for 16 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (55 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.51 (s, 1H), 9.21 (d, J = 2.00 Hz, 1H), 9.16 (d, J = 2.40 Hz, 1H), 8.61 (t, J = 2.00 Hz, 1H), 7.74 - 7.72 (m, 1H), 7.67 (t, J = 2.00 Hz, 1H), 7.56 (t, J = 8.00 Hz, 1H), 7.29 - 7.26 63336124\1 (m, 1H), 4.39 (d, J = 4.80 Hz, 1H), 4.18 (d, J = 6.40 Hz, 1H), 2.08 - 1.93 (m, 2H), 1.85 - 1.73 (m, 5H), 1.57 - 1.47 (m, 3H); MS (ES+APCI) m / z 377.3 (M+1). Synthesis of morpholine-4-carbonyl chloride To a stirred solution of Phosgene (1.0 mL, 2.39 mmol, 20% in toluene) in DCM (2 mL) at 0-5 °C under nitrogen atmosphere was added DIPEA (0.60 mL, 3.43 mmol) and morpholine (0.19 g, 1.71 mmol) was added and the resulting mixture was stirred at 0-5 °C for 20 minutes. and then stirred at RT for 20 minutes. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with aq. 1.5N hydrochloric acid solution and extracted with dichloromethane. The combined organic layers were washed with water, brine and concentrated to give morpholine-4-carbonyl chloride which was used for the next step without further purification. Synthesis of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl morpholine-4-carboxylate (Example-151) To a stirred solution of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.42 mmol) in acetonitrile (2 mL) at 0-5 °C under nitrogen atmosphere was added morpholine-4-carbonyl chloride (0.08 g, 0.50 mmol) and TEA (0.07 mL, 0.54 mmol). The resulting mixture was stirred at 75 °C for 16 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (65 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.51 (s, 1H), 9.21 (d, J = 2.00 Hz, 1H), 9.16 (d, J = 2.40 Hz, 1H), 8.62 (t, J = 2.00 Hz, 1H), 7.74 -7 .72 (m, 1H), 7.67 (t, J = 2.00 Hz, 1H), 7.56 (t, J = 8.00 Hz, 1H), 7.27 - 7.24 (m, 1H), 1.61 - 1.57 (m, 6H); MS (ES+APCI) m / z 353.3 (M+1). 63336124\1 Synthesis of 2-oxa-6-azaspiro[3.3]heptane-6-carbonyl chloride To a stirred solution of phosgene (1.0 mL, 2.57 mmol, 20% in toluene) in DCM (2 mL) at 0-5 °C under nitrogen atmosphere was added DIPEA (0.60 mL, 3.43 mmol) and 2-oxa-6- azaspiro[3.3]heptane (0.17 g, 1.71 mmol) was added and the resulting mixture was stirred at 0- 5 °C for 20 minutes. and then stirred at RT for 20 minutes. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with aq. 1.5N hydrochloric acid solution and extracted with dichloromethane. The combined organic layers were washed with water, brine and concentrated to give 2-oxa-6-azaspiro[3.3]heptane-6-carbonyl chloride which was used for the next step without further purification. Synthesis of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl 2-oxa-6-azaspiro[3.3]heptane- 6-carboxylate (Example-152) To a stirred solution of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.42 mmol) in acetonitrile (2 mL) at 0-5 °C under nitrogen atmosphere was added 2-oxa-6- azaspiro[3.3]heptane-6-carbonyl chloride (0.14 g, 0.84 mmol) and TEA (0.07 mL, 0.54 mmol). The resulting mixture was stirred at 75 °C for 16 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (69 mg) as yellow solid.1H NMR (400 MHz, DMSO-d6) δ 9.51 (s, 1H), 9.21 (d, J = 2.00 Hz, 1H), 9.15 (d, J = 2.40 Hz, 1H), 8.60 (t, J = 2.00 Hz, 1H), 7.73 (d, J = 8.00 Hz, 1H), 7.64 (t, J = 1.60 Hz, 1H), 7.56 (t, J = 8.00 Hz, 1H), 7.24 (dd, J = 1.60, 8.00 Hz, 1H), 4.72 (s, 4H), 4.38 (bs, 2H), 4.19 (bs, 2H); MS (ES+APCI) m / z 365.3 (M+1). Synthesis of 2-oxa-7-azaspiro[3.5]nonane-7-carbonyl chloride 63336124\1 To a stirred solution of diphosgene (0.40 g, 2.01 mmol) in DCM (2 mL) at 0-5 °C under nitrogen atmosphere was added 2-oxa-7-azaspiro[3.5]nonane (0.21 g, 1.67 mmol) and DIPEA (0.58 mL, 3.34 mmol). The resulting mixture was stirred at 0-5 °C for 20 minutes. and then stirred at RT for 20 minutes. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with aq. 1.5N hydrochloric acid solution and extracted with dichloromethane. The combined organic layers were washed with water, brine and concentrated to give 2-oxa-7- azaspiro[3.5]nonane-7-carbonyl chloride which was used for the next step without further purification. Synthesis of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl 2-oxa-7-azaspiro[3.5]nonane- 7-carboxylate (Example-153) To a stirred solution of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.42 mmol) in acetonitrile (2 mL) at 0-5 °C under nitrogen atmosphere was added 2-oxa-7- azaspiro[3.5]nonane-7-carbonyl chloride (0.16 g, 0.84 mmol) and TEA (0.07 mL, 0.54 mmol). The resulting mixture was stirred at 75 °C for 16 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The residue was purified by preparative HPLC (0.1% FA) to yield the target compound (16 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.51 (s, 1H), 9.21 (d, J = 2.00 Hz, 1H), 9.16 (d, J = 2.40 Hz, 1H), 8.61 (t, J = 2.00 Hz, 1H), 7.73 (d, J = 8.00 Hz, 1H), 7.67 (t, J = 1.60 Hz, 1H), 7.56 (t, J = 8.00 Hz, 1H), 7.27 - 7.24 (m, 1H), 4.37 (s, 4H), 3.56 (bs, 2H), 3.39 (bs, 2H), 1.89 - 1.86 (m, 4H); MS (ES+APCI) m / z 393.4 (M+1). Synthesis of methyl(octyl)carbamic chloride To a stirred solution of triphosgene (0.40 g, 1.35 mmol) in DCM (2 mL) at 0-5 °C under nitrogen atmosphere was added DIPEA (1.18 mL, 6.77 mmol) and N-methyloctan-1-amine (0.24 g, 1.70 mmol) was added, and the resulting mixture was stirred at 0-5 °C for 20 minutes. and then stirred 63336124\1 at RT for 20 minutes. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with aq. 1.5N hydrochloric acid solution and extracted with dichloromethane. The combined organic layers were washed with water, brine and concentrated to give dibutylcarbamic chloride which was used for the next step without further purification. Synthesis of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl heptyl(methyl)carbamate (Example-154) To a stirred solution of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.42 mmol) in acetonitrile (2 mL) at 0-5 °C under nitrogen atmosphere was added methyl(octyl)carbamic chloride (0.17 g, 0.84 mmol) and TEA (0.07 mL, 0.54 mmol). The resulting mixture was stirred at 75 °C for 16 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The crude product was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 40-60% EtOAc) to yield the target compound (52 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.50 (s, 1H), 9.21 (d, J = 2.0 Hz, 1H), 9.15 (d, J = 2.2 Hz, 1H), 8.60 (t, J = 2.3 Hz, 1H), 7.82 (t, J = 5.7 Hz, 1H), 7.73 – 7.67 (m, 1H), 7.61 (t, J = 2.1 Hz, 1H), 7.55 (t, J = 7.9 Hz, 1H), 7.22 (dd, J = 8.0, 2.3 Hz, 1H), 3.54 (s, 3H), 3.08 (q, J = 6.6 Hz, 2H), 1.48 – 0.82 (m, 15H) Synthesis of dibutylcarbamic chloride To a stirred solution of triphosgene (0.40 g, 1.35 mmol) in DCM (2 mL) at 0-5 °C under nitrogen atmosphere was added DIPEA (1.18 mL, 6.77 mmol) and dibutylamine (0.23 g, 1.70 mmol) was added and the resulting mixture was stirred at 0-5 °C for 20 minutes. and then stirred at RT for 20 minutes. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with aq. 1.5N hydrochloric acid solution and extracted with dichloromethane. The combined organic layers were washed with water, brine and concentrated to give dibutylcarbamic chloride which was used for the next step without further purification. 63336124\1 Synthesis of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenyl dibutylcarbamate (Example- 155) To a stirred solution of 3-(5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl)phenol (0.1 g, 0.42 mmol) in acetonitrile (2 mL) at 0-5 °C under nitrogen atmosphere was added dibutylcarbamic chloride (0.16 g, 0.84 mmol) and TEA (0.07 mL, 0.54 mmol). The resulting mixture was stirred at 75 °C for 16 h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated to a residue. The crude product was purified by flash column chromatography on silica gel eluting with hexane / EtOAc (gradient 40-60% EtOAc) to yield the target compound (55 mg) as an off white solid.1H NMR (400 MHz, DMSO-d6) δ 9.50 (s, 1H), 9.19 (dd, J = 21.1, 2.1 Hz, 2H), 8.61 (t, J = 2.2 Hz, 1H), 7.72 (ddd, J = 7.8, 1.8, 1.0 Hz, 1H), 7.63 (t, J = 2.0 Hz, 1H), 7.56 (t, J = 7.9 Hz, 1H), 7.23 (ddd, J = 8.1, 2.3, 1.0 Hz, 1H), 1.60 (dt, J = 37.3, 7.4 Hz, 5H), 1.48 – 1.23 (m, 4H), 0.93 (dt, J = 10.9, 7.3 Hz, 9H). Synthesis of ethyl ethyl 5-(2-(benzyloxy)-5-hydroxyphenyl)nicotinate To a stirred solution of ethyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinate (0.99 g, 3.58 mmol) in 1,4-dioxane (36 mL) and water (4 mL) was added 4-(benzyloxy)-3-bromophenol (1 g, 3.58 mmol) and K2CO3 (1.57 g, 14.78 mmol) at RT. The reaction mixture was degassed for 15 minutes then Pd(PPh3)4 (0.57 g, 0.493 mmol) was added. The reaction mixture was stirred at 80 °C for 5 h under nitrogen atmosphere. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to RT and then the solvent was evaporated under reduced pressure. The residue was dissolved in ethyl acetate, washed with water followed by brine. The organic layer was dried over sodium sulfate then evaporated under reduced pressure. The residue was purified by automated normal-phase chromatography and eluted with ethyl acetate / petroleum ether to give ethyl 5-(2-(benzyloxy)-5-hydroxyphenyl)nicotinate (1.1 g) as an off white solid. MS (ES+APCI) m / z 350.3 (M+1). 63336124\1 Synthesis of 5-(2-(benzyloxy)-5-hydroxyphenyl)nicotinohydrazide To a stirred solution of ethyl 5-(2-(benzyloxy)-5-hydroxyphenyl)nicotinate (0.6 g, 1.72 mmol) in ethanol (12 mL) was added hydrazine hydrate (1.3 mL, 1.72 mmol) at RT. The reaction mixture was stirred at 60 °C for 15 h. After completion of the reaction (monitored by TLC), t...

Claims

WHAT IS CLAIMED IS:

1. A compound of Formula I:a prodrug thereof, a or a pharmaceutically active metabolite thereof; wherein W is NH, N(CH3), or none, wherein when W is none R3is directly attached to C(O) by a single bond; X is CH or N; Y is CH or N; Z is CH or N; wherein X, Y and Z cannot all be CH or N; R1is independently -C(O)OR4, -C(O)NHOH, -C(O)NHNH2, CF3, CHO, CN or heteroaryl; wherein R4 may be independently C1-C5 alkyl; R2 is independently hydrogen, halogen, alkyl, alkoxy, thioalkyl, haloalkoxy, wherein R2may be linked via any position on the phenyl ring; R3is independently C5-C20alkyl, C3-C8cycloalkyl, C4-C8heterocycloalkyl, C6-12fused heterocycloakyl, C6-12 spirocycloalkyl, or aryl, wherein R3 may be unsubstituted or substituted at a carbon ring member with halogen or alkyl group.

2. The compound of claim 1, wherein R1 is monocycles: 2-pyrrolyl, 2-furanyl, 2-thienyl, 2-oxazolyl, 5-isoxazolyl, 2-thiazolyl, 1,3,4-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4- thiadiazolyl, 1,2,4-triazolyl, or 1,2,3,4-tetrazolyl.

3. The compound of claim 1 or 2, wherein R2 is H, OH, OCH3, SCH3, F, OCF3, CN, or N(CH3)2.

4. The compound of claim 1, wherein W is NH; X is N; 63336124\1Y is CH; Z is CH; R1 is oxadiazole, oxazole, thiazole, pyrazole or imidazole; R2 is halogen, hydroxy, C1-C4 alkoxy, cyano, or fluoroalkyl; and R3is C1-C8alkyl or C3-C8cycloalkyl.

5. The compound of claim 1, wherein W is NH; X is N; Y is CH; Z is CH; R1 is oxadiazole; R2 is halogen, hydroxy, C1-C4 alkoxy, cyano, or fluoroalkyl; and R3 is C1-C8 alkyl or C3-C8 cycloalkyl.

6. The compound of any one of claims 1 to 3, wherein the compound has the formula of any one of Example 1- Example 268.

7. The compound of claim 1, wherein the compound has the formula of any one of Examples 4, 9, 10, 24, 47, 51, 64, 72, 73, 87, 105, 109, 115, 128, 129, 130, 131, 132, 134, 137, 156, 157, 160, 165, 167, 174, 194, 195, 207, 213, 219, 226, 256 and 263.

8. The IIa prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically active metabolite thereof; wherein R1 is independently -C(O)OR4, -C(O)NHOH, -C(O)NHNH2, CF3, CHO, CN; wherein R4 is independently C1-C5alkyl; R3is independently C5-C18alkyl, C3-C8cycloalkyl, C6-12fused heterocycloakyl, or aryl. 63336124\19. The compound of claim 8, wherein R1 is oxadiazole, oxazole, thiazole, pyrazole or imidazole; and R3is C1-C8alkyl or C3-C8cycloalkyl.

10. The compound of claim 8, wherein R1 is oxadiazole; and R3 is C1-C8 alkyl or C3-C8 cycloalkyl.

11. The compound of claim 8, wherein the compound has the formula of any one of Examples 1-34.

12. The compound of claim 8, wherein the compound has the formula of any one of Examples 1-5, 8-12, 14-18, 26, 27, 30-32, and 34.

13. The compound of claim 8, wherein the compound has the formula of any one of Examples 4, 9, 10 and 24.

14. The compound of claim 1, having Formula IIIa prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically active metabolite thereof; wherein W is NH, N(CH3), or none, wherein when W is none R3is directly attached to C(O) by a single bond; A is O, S, or NH; B is CH or N; C is CH or N; D is CH or N; R2is independently hydrogen, halogen, alkyl, alkoxy, thioalkyl, or haloalkoxy; wherein R2may be linked via any position on the phenyl ring; 63336124\1R3 is independently C5-C20 alkyl, C3-C8 cycloalkyl, C4-C8 heterocycloalkyl, C6-12 fused heterocycloakyl, C6-12 spirocycloalkyl, aryl, wherein R3 may be unsubstituted or substituted at a carbon ring member with halogen or alkyl group.

15. The compound of claim 14, wherein R2 is H, OH, OCH3, SCH3, F, OCF3, CN or N(CH3)2.

16. The compound of claim 14, wherein A is O; B is CH; C is N; D is N; R2is halogen, hydroxy, C1-C4alkoxy, cyano, or fluoroalkyl; and R3 is C1-C8 alkyl or C3-C8 cycloalkyl.

17. The compound of claim 14, wherein A is S; B is CH; C is N; D is N; R2is halogen, hydroxy, C1-C4alkoxy, cyano, or fluoroalkyl; and R3 is C1-C8 alkyl or C3-C8 cycloalkyl.

18. The compound of claim 14, wherein A is O; B is CH; C is CH; D is N; R2is halogen, hydroxy, C1-C4alkoxy, cyano, or fluoroalkyl; and R3 is C1-C8 alkyl or C3-C8 cycloalkyl.

19. The compound of claim 14, wherein A is O; 63336124\1B is CH; C is N; D is CH; R2 is halogen, hydroxy, C1-C4 alkoxy, cyano, or fluoroalkyl; and R3 is C1-C8 alkyl or and C3-C8 cycloalkyl.

20. The compound of claim 14, wherein the compound has the formula of any one of Examples 35-255.

21. The compound of claim 14, wherein the compound has the formula of any one of Examples 35, 40, 41, 47, 48, 50-53, 59, 60, 62-65, 72-74, 78, 80, 81, 83, 85-88, 105-110, 115- 117, 119-121, 127, 128, 130-139, 147, 149, 156, 157, 159-161, 163-167, 169, 174, 179, 180, 186,192-195,204-208, 212-214, 218, 219, 220, 222, 229, 226, 232, and 238.

22. The compound of claim 14, wherein the compound has the formula of any one of Examples 47, 51, 64, 72, 73, 87, 105,109, 115, 128, 129, 130-134, 137,156, 157, 160, 165, 167, 174, 194, 195, 207, 213, 219, and 226.

23. The compound of claim 1, having Formula IV:a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically active metabolite thereof; wherein X is CH or N; Y is CH or N; Z is CH or N; wherein X, Y and Z cannot all be CH or N; R2is H, OH, or OCH3; R3 is independently C5-C20 alkyl, or C3-C8 cycloalkyl; wherein R3 may be unsubstituted or substituted at a carbon ring member with halogen or alkyl group. 63336124\124. The compound of claim 23, wherein X is N; Y is CH; Z is CH; R2 is halogen, hydroxy, C1-C4 alkoxy, cyano, or fluoroalkyl; and R3 is C1-C8 alkyl or C3-C8 cycloalkyl.

25. The compound of claim 23, wherein X is N; Y is CH; Z is CH; R2 is hydroxy or C1-C4 alkoxy; and R3is C1-C8alkyl or C3-C8cycloalkyl.

26. The compound of claim 23, wherein X is N; Y is CH; Z is CH; R2is C1-C4alkoxy; and R3 is C1-C8 alkyl or C3-C8 cycloalkyl.

27. The compound of claim 23, wherein the compound has the formula of any one of Examples 256-268.

28. The compound of claim 23, wherein the compound has the formula of any one of Examples 256, 257, 262-264, and 266-268.

29. The compound of claim 23, wherein the compound has the formula of Example 256 or 263.

30. A pharmaceutical composition comprising at least one compound of any one of claims 1-29 and optionally one or more pharmaceutically acceptable excipients or adjuvants. 63336124\131. The pharmaceutical composition of claim 30, comprising an effective amount of at least one compound of a compound of any one of claim 1-29, wherein the effective amount is between about 0.0001 to about 1,000 mg.

32. The pharmaceutical composition of claim 30 or 31, further comprising one or more additional therapeutic agent.

33. The pharmaceutical composition of claim 33, wherein the one or more additional therapeutic agent is selected from the group consisting of non-steroidal anti-inflammatory drugs (NSAIDs), anti-anxiety agents, antidepressants, antiepileptic drugs, anti-Alzheimer's agents, antipsychotic drugs, antihemorrhagic agents, benzodiazepines, acetylcholinesterase inhibitors, alpha-adrenoreceptor antagonists, alpha-adrenergic receptor agonists, β-blockers, angiotensin-converting enzymes inhibitors (ACEI), serotonin (5-HT) reuptake inhibitors, serotonin and noradrenaline reuptake inhibitors (SNRIs), antirheumatic drug, and anticancer medications.

34. The compound of any one of claims 1 to 29 or the pharmaceutical composition of any one of claims 30 to 33, for use in inhibiting or modulating the activity of fatty acid amide hydrolase (FAAH).

35. The compound of any one of claims 1 to 29, or the pharmaceutical composition of any one of claims 30 to 33, for use in treating a disease, disorder or condition which benefits from the inhibition or modulation of fatty acid amide hydrolase (FAAH) activity.

36. The compound or the pharmaceutical composition of claim 35, wherein the disease, disorder or condition is selected from the group consisting of pain, inflammation, anxiety, mood disorders, metabolic diseases, cardiovascular diseases, autoimmune diseases, central nervous system (CNS) diseases, liver diseases, respiratory diseases, and kidney diseases.

37. A method of treating a disease, disorder or condition which benefits from the inhibition or modulation of fatty acid amide hydrolase (FAAH) activity by administering to a subject in need thereof a compound of any one of claims 1 to 29 or a pharmaceutical composition of any one of claims 30 to 34. 63336124\138. The method of claim 37, wherein the disease, disorder or condition is selected from the group consisting of pain (including but not limited to acute pain, chronic pain, nociceptive pain, and non-nociceptive pain), inflammatory diseases (including but not limited to inflammatory bowel disease, neuroinflammation, neuropathy), anxiety and mood disorder, sleep disorder, eating disorders, obesity, cardiovascular diseases (including but not limited to hypertension, coronary heart disease, ischemia, congestive heart failure, atherosclerosis, myocardial infarction, and peripheral vascular disease), dyslipidemia (including but not limited to hyperlipidemia, hypoalphalipoproteinemia, hypertriglyceridemia, hypercholesterolemia, and low high-density lipoprotein (HDL)), diabetes (type 1 and type 2), allergic airway disease (including but not limited to cough, asthma, and chronic obstructive diseases), cerebrovascular disorders (including stroke, cerebral vasospasm, and learning and memory disorders), drug or alcohol withdrawal, addiction, liver diseases (including but not limited to non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and hepatitis), cancer, chemotherapy- induced nausea and vomiting (CINV), neurodegenerative disease (including but not limited to Alzheimer and Parkinson diseases), central nervous system (CNS) disorders (including but not limited to depression, post- traumatic stress disorder, schizophrenia, seizures, and cognitive disorders), autoimmune diseases (including but not limited to psoriasis, rheumatoid arthritis, Crohn's disease, systemic lupus erythematosis, Sjogren's syndrome, Huntington's chorea, and multiple sclerosis), skin disorders (including but not limited to itching, eczema, pruritis, dermatitis, impaired wound healing), gastrointestinal disorders (including but not limited to nausea, gastrointestinal motility disorder, and paralytic ileus), eye diseases (including but not limited to cataract, and glaucoma). 63336124\1

Images